JP4361545B2 - ＰｒｏｇｒａｍｍｅｄＤｅａｔｈ１（ＰＤ−１）に対するヒトモノクローナル抗体および抗ＰＤ−１抗体単独または他の免疫療法と併用した癌治療方法 - Google Patents

ＰｒｏｇｒａｍｍｅｄＤｅａｔｈ１（ＰＤ−１）に対するヒトモノクローナル抗体および抗ＰＤ−１抗体単独または他の免疫療法と併用した癌治療方法 Download PDF

Info

Publication number
JP4361545B2
JP4361545B2 JP2006128058A JP2006128058A JP4361545B2 JP 4361545 B2 JP4361545 B2 JP 4361545B2 JP 2006128058 A JP2006128058 A JP 2006128058A JP 2006128058 A JP2006128058 A JP 2006128058A JP 4361545 B2 JP4361545 B2 JP 4361545B2
Authority
JP
Japan
Prior art keywords
antibody
human
seq
antibodies
variable region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2006128058A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006340714A (ja
JP2006340714A5 (show.php
Inventor
アラン ジェイ コーマン
モハン スリニバサン
チャンギュ ウォン
マーク ジェイ セルビー
ビング チェン
ジョセフィーヌ エム カルダレッリ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ER Squibb and Sons LLC
Original Assignee
Medarex LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37396674&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP4361545(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Medarex LLC filed Critical Medarex LLC
Publication of JP2006340714A publication Critical patent/JP2006340714A/ja
Publication of JP2006340714A5 publication Critical patent/JP2006340714A5/ja
Application granted granted Critical
Publication of JP4361545B2 publication Critical patent/JP4361545B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2006128058A 2005-05-09 2006-05-02 ＰｒｏｇｒａｍｍｅｄＤｅａｔｈ１（ＰＤ−１）に対するヒトモノクローナル抗体および抗ＰＤ−１抗体単独または他の免疫療法と併用した癌治療方法 Active JP4361545B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US67946605P 2005-05-09 2005-05-09
US73843405P 2005-11-21 2005-11-21
US74891905P 2005-12-08 2005-12-08

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009086400A Division JP5028700B2 (ja) 2005-05-09 2009-03-31 ＰｒｏｇｒａｍｍｅｄＤｅａｔｈ１（ＰＤ−１）に対するヒトモノクローナル抗体および抗ＰＤ−１抗体単独または他の免疫療法と併用した癌治療方法

Publications (3)

Publication Number Publication Date
JP2006340714A JP2006340714A (ja) 2006-12-21
JP2006340714A5 JP2006340714A5 (show.php) 2009-05-14
JP4361545B2 true JP4361545B2 (ja) 2009-11-11

Family

ID=37396674

Family Applications (9)

Application Number Title Priority Date Filing Date
JP2006128058A Active JP4361545B2 (ja) 2005-05-09 2006-05-02 ＰｒｏｇｒａｍｍｅｄＤｅａｔｈ１（ＰＤ−１）に対するヒトモノクローナル抗体および抗ＰＤ−１抗体単独または他の免疫療法と併用した癌治療方法
JP2009086400A Active JP5028700B2 (ja) 2005-05-09 2009-03-31 ＰｒｏｇｒａｍｍｅｄＤｅａｔｈ１（ＰＤ−１）に対するヒトモノクローナル抗体および抗ＰＤ−１抗体単独または他の免疫療法と併用した癌治療方法
JP2012106662A Active JP5872377B2 (ja) 2005-05-09 2012-05-08 ＰｒｏｇｒａｍｍｅｄＤｅａｔｈ１（ＰＤ−１）に対するヒトモノクローナル抗体および抗ＰＤ−１抗体単独または他の免疫療法と併用した癌治療方法
JP2014010140A Pending JP2014077015A (ja) 2005-05-09 2014-01-23 ＰｒｏｇｒａｍｍｅｄＤｅａｔｈ１（ＰＤ−１）に対するヒトモノクローナル抗体および抗ＰＤ−１抗体単独または他の免疫療法と併用した癌治療方法
JP2015213586A Active JP6185971B2 (ja) 2005-05-09 2015-10-30 ＰｒｏｇｒａｍｍｅｄＤｅａｔｈ１（ＰＤ−１）に対するヒトモノクローナル抗体および抗ＰＤ−１抗体単独または他の免疫療法と併用した癌治療方法
JP2016220640A Pending JP2017052784A (ja) 2005-05-09 2016-11-11 Ｐｒｏｇｒａｍｍｅｄ Ｄｅａｔｈ １（ＰＤ−１）に対するヒトモノクローナル抗体および抗ＰＤ−１抗体単独または他の免疫療法と併用した癌治療方法
JP2019018345A Active JP6975733B2 (ja) 2005-05-09 2019-02-05 Ｐｒｏｇｒａｍｍｅｄ Ｄｅａｔｈ １（ＰＤ−１）に対するヒトモノクローナル抗体および抗ＰＤ−１抗体単独または他の免疫療法と併用した癌治療方法
JP2021149019A Active JP7443302B2 (ja) 2005-05-09 2021-09-14 Ｐｒｏｇｒａｍｍｅｄ Ｄｅａｔｈ １（ＰＤ－１）に対するヒトモノクローナル抗体および抗ＰＤ－１抗体単独または他の免疫療法と併用した癌治療方法
JP2023205124A Pending JP2024023539A (ja) 2005-05-09 2023-12-05 Ｐｒｏｇｒａｍｍｅｄ Ｄｅａｔｈ １（ＰＤ－１）に対するヒトモノクローナル抗体および抗ＰＤ－１抗体単独または他の免疫療法と併用した癌治療方法

Family Applications After (8)

Application Number Title Priority Date Filing Date
JP2009086400A Active JP5028700B2 (ja) 2005-05-09 2009-03-31 ＰｒｏｇｒａｍｍｅｄＤｅａｔｈ１（ＰＤ−１）に対するヒトモノクローナル抗体および抗ＰＤ−１抗体単独または他の免疫療法と併用した癌治療方法
JP2012106662A Active JP5872377B2 (ja) 2005-05-09 2012-05-08 ＰｒｏｇｒａｍｍｅｄＤｅａｔｈ１（ＰＤ−１）に対するヒトモノクローナル抗体および抗ＰＤ−１抗体単独または他の免疫療法と併用した癌治療方法
JP2014010140A Pending JP2014077015A (ja) 2005-05-09 2014-01-23 ＰｒｏｇｒａｍｍｅｄＤｅａｔｈ１（ＰＤ−１）に対するヒトモノクローナル抗体および抗ＰＤ−１抗体単独または他の免疫療法と併用した癌治療方法
JP2015213586A Active JP6185971B2 (ja) 2005-05-09 2015-10-30 ＰｒｏｇｒａｍｍｅｄＤｅａｔｈ１（ＰＤ−１）に対するヒトモノクローナル抗体および抗ＰＤ−１抗体単独または他の免疫療法と併用した癌治療方法
JP2016220640A Pending JP2017052784A (ja) 2005-05-09 2016-11-11 Ｐｒｏｇｒａｍｍｅｄ Ｄｅａｔｈ １（ＰＤ−１）に対するヒトモノクローナル抗体および抗ＰＤ−１抗体単独または他の免疫療法と併用した癌治療方法
JP2019018345A Active JP6975733B2 (ja) 2005-05-09 2019-02-05 Ｐｒｏｇｒａｍｍｅｄ Ｄｅａｔｈ １（ＰＤ−１）に対するヒトモノクローナル抗体および抗ＰＤ−１抗体単独または他の免疫療法と併用した癌治療方法
JP2021149019A Active JP7443302B2 (ja) 2005-05-09 2021-09-14 Ｐｒｏｇｒａｍｍｅｄ Ｄｅａｔｈ １（ＰＤ－１）に対するヒトモノクローナル抗体および抗ＰＤ－１抗体単独または他の免疫療法と併用した癌治療方法
JP2023205124A Pending JP2024023539A (ja) 2005-05-09 2023-12-05 Ｐｒｏｇｒａｍｍｅｄ Ｄｅａｔｈ １（ＰＤ－１）に対するヒトモノクローナル抗体および抗ＰＤ－１抗体単独または他の免疫療法と併用した癌治療方法

Country Status (27)

Country Link
US (10) US8008449B2 (show.php)
EP (6) EP2161336B2 (show.php)
JP (9) JP4361545B2 (show.php)
KR (3) KR101498834B1 (show.php)
CN (5) CN101213297B (show.php)
AU (1) AU2006244885B2 (show.php)
BE (1) BE2015C074I2 (show.php)
BR (1) BRPI0610235B8 (show.php)
CA (3) CA2970873C (show.php)
CY (2) CY2015057I2 (show.php)
DK (2) DK2161336T4 (show.php)
ES (2) ES2427646T5 (show.php)
FR (1) FR15C0087I2 (show.php)
HU (2) HUE044719T2 (show.php)
IL (2) IL187108A (show.php)
LT (2) LT2439273T (show.php)
LU (1) LU92904I2 (show.php)
MX (1) MX2007013978A (show.php)
NL (1) NL300782I2 (show.php)
NO (6) NO341219B1 (show.php)
NZ (1) NZ563193A (show.php)
PL (2) PL2161336T5 (show.php)
PT (2) PT2161336E (show.php)
RU (4) RU2406760C3 (show.php)
SI (2) SI2439273T1 (show.php)
TW (1) TWI379898B (show.php)
WO (1) WO2006121168A1 (show.php)

Families Citing this family (2206)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
US7030219B2 (en) 2000-04-28 2006-04-18 Johns Hopkins University B7-DC, Dendritic cell co-stimulatory molecules
PT1503794E (pt) * 2002-04-12 2012-06-21 Medarex Inc Métodos de tratamento usando anticorpos contra ctla-4
DE10161767T1 (de) * 2002-07-03 2018-06-07 Honjo Tasuku Immunopotenzierende Zusammensetzungen, die einen Anti-PD-L1 Antikörper enthalten
US20040121370A1 (en) 2002-09-11 2004-06-24 Genentech, Inc. Novel composition and methods for the treatment of immune related diseases
DE10347710B4 (de) 2003-10-14 2006-03-30 Johannes-Gutenberg-Universität Mainz Rekombinante Impfstoffe und deren Verwendung
EP2161336B2 (en) 2005-05-09 2017-03-29 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
SG10201809390QA (en) 2005-05-10 2018-11-29 Incyte Holdings Corp Modulators of indoleamine 2,3-dioxygenase and methods of using the same
NZ590308A (en) 2005-06-08 2012-02-24 Dana Farber Cancer Inst Inc Methods and compositions for the treatment of cancer by inhibiting the programmed cell death 1 (pd-1) pathway
AU2006265108C1 (en) 2005-07-01 2013-01-17 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to programmed death ligand 1 (PD-L1)
DE102005046490A1 (de) 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
US7700567B2 (en) 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
NZ568016A (en) 2005-12-07 2011-12-22 Medarex Inc CTLA-4 antibody dosage escalation regimens
EP2889309B1 (en) 2006-03-03 2017-12-27 Ono Pharmaceutical Co., Ltd. Multimer of extracellular domain of pd-1 or pd-l1
AU2007342338A1 (en) * 2006-09-20 2008-07-17 The Johns Hopkins University Combinatorial therapy of cancer and infectious diseases with anti-B7-H1 antibodies
NZ600281A (en) 2006-12-27 2013-03-28 Harvard College Compositions and methods for the treatment of infections and tumors
AU2013200388B2 (en) * 2006-12-27 2014-10-23 Dana-Farber Cancer Institute, Inc. Compositions and methods for the treatment of infections and tumors
US20100055111A1 (en) * 2007-02-14 2010-03-04 Med. College Of Georgia Research Institute, Inc. Indoleamine 2,3-dioxygenase, pd-1/pd-l pathways, and ctla4 pathways in the activation of regulatory t cells
EP2185589B1 (en) 2007-06-01 2016-01-06 University of Maryland, Baltimore Immunoglobulin constant region fc receptor binding agents
AU2008266951C1 (en) 2007-06-18 2025-06-19 Merck Sharp & Dohme B.V. Antibodies to human programmed death receptor PD-1
AU2014201367B2 (en) * 2007-06-18 2016-01-28 Merck Sharp & Dohme B.V. Antibodies to human programmed death receptor pd-1
US20090028857A1 (en) 2007-07-23 2009-01-29 Cell Genesys, Inc. Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
US9243052B2 (en) 2007-08-17 2016-01-26 Daniel Olive Method for treating and diagnosing hematologic malignancies
AU2008329530A1 (en) 2007-11-28 2009-06-04 Universite De Montreal PD-1 modulation and uses thereof
ES2618292T3 (es) 2008-01-31 2017-06-21 Inserm - Institut National De La Sante Et De La Recherche Medicale Anticuerpos contra CD39 humano y uso de los mismos para inhibir la actividad de las células T reguladoras
EP2262837A4 (en) * 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
EP2279412B1 (en) 2008-04-09 2017-07-26 Genentech, Inc. Novel compositions and methods for the treatment of immune related diseases
ES2741730T3 (es) 2008-05-19 2020-02-12 Advaxis Inc Sistema de administración doble para antígenos heterólogos que comprende una cepa de Listeria recombinante atenuada por la mutación de dal/dat y la deleción de ActA que comprende una molécula de ácido nucleico que codifica una proteína de fusión de listeriolisina O - antígeno prostático específico
US9017660B2 (en) 2009-11-11 2015-04-28 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors
US9650639B2 (en) 2008-05-19 2017-05-16 Advaxis, Inc. Dual delivery system for heterologous antigens
US8460886B2 (en) 2008-07-04 2013-06-11 Ono Pharmaceutical Co., Ltd. Use of an efficacy marker for optimizing therapeutic efficacy of an anti-human PD-1 antibody on cancers
RS57132B1 (sr) * 2008-07-08 2018-07-31 Incyte Holdings Corp 1,2,5-oksadiazoli kao inhibitori indolamin 2,3-dioksigenaze
WO2010014784A2 (en) 2008-08-01 2010-02-04 Bristol-Myers Squibb Company Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
WO2010027827A2 (en) * 2008-08-25 2010-03-11 Amplimmune, Inc. Targeted costimulatory polypeptides and methods of use to treat cancer
WO2010027423A2 (en) 2008-08-25 2010-03-11 Amplimmune, Inc. Compositions of pd-1 antagonists and methods of use
JP5794917B2 (ja) 2008-09-12 2015-10-14 アイシス・イノベーション・リミテッドＩｓｉｓ Ｉｎｎｏｖａｔｉｏｎｌｉｍｉｔｅｄ Ｐｄ−１特異抗体およびその使用
US8927697B2 (en) 2008-09-12 2015-01-06 Isis Innovation Limited PD-1 specific antibodies and uses thereof
ES2592216T3 (es) * 2008-09-26 2016-11-28 Dana-Farber Cancer Institute, Inc. Anticuerpos anti-PD-1, PD-L1 y PD-L2 humanos y sus usos
CA2743775A1 (en) * 2008-11-12 2010-05-20 Schering Corporation .beta.gi-igg intron for enhanced anti-igf1r expression
US11542328B2 (en) 2008-11-14 2023-01-03 The Brigham And Women's Hospital, Inc. Therapeutic and diagnostic methods relating to cancer stem cells
ES2796111T3 (es) * 2008-11-14 2020-11-25 Brigham & Womens Hospital Inc Métodos terapéuticos relacionados con células madre cancerosas
SI2370593T1 (sl) 2008-11-28 2016-08-31 Emory University Postopek za določanje učinkovitosti antagonista pd-1
KR20190069615A (ko) 2008-12-09 2019-06-19 제넨테크, 인크. 항-ｐｄ-ｌ１ 항체 및 ｔ 세포 기능을 향상시키기 위한 그의 용도
US8741295B2 (en) * 2009-02-09 2014-06-03 Universite De La Mediterranee PD-1 antibodies and PD-L1 antibodies and uses thereof
MY160203A (en) 2009-03-30 2017-02-28 Eisai R&D Man Co Ltd Liposome composition
US20100329983A1 (en) 2009-06-26 2010-12-30 Soricimed Biopharma Inc. Compounds and methods for the detection of trpv-6 cancers and drug delivery
US8394922B2 (en) 2009-08-03 2013-03-12 Medarex, Inc. Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof
WO2011021597A1 (ja) 2009-08-19 2011-02-24 エーザイ・アール・アンド・ディー・マネジメント株式会社 キノリン誘導体含有医薬組成物
CN102740887B (zh) * 2009-09-30 2015-04-15 斯隆凯特林防癌纪念中心 用于治疗癌症的组合免疫疗法
WO2011047383A1 (en) 2009-10-16 2011-04-21 Oncomed Pharmaceuticals, Inc. Therapeutic combination and methods of treatment with a dll4 antagonist and an anti-hypertensive agent
US10016617B2 (en) 2009-11-11 2018-07-10 The Trustees Of The University Of Pennsylvania Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers
TW201134488A (en) * 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
EP2545078A1 (en) 2010-03-11 2013-01-16 UCB Pharma, S.A. Pd-1 antibody
US10787701B2 (en) 2010-04-05 2020-09-29 Prognosys Biosciences, Inc. Spatially encoded biological assays
US20110288545A1 (en) * 2010-04-22 2011-11-24 Old Dominion University Research Foundation Method and Device for Ablation of Cancer and Resistance to New Cancer Growth
EP3699266B1 (en) 2010-05-14 2025-07-02 The General Hospital Corporation Neoantigen specific cytotoxic t cells for use in treating cancer
WO2011146382A1 (en) * 2010-05-17 2011-11-24 Bristol-Myers Squibb Company Improved immunotherapeutic dosing regimens and combinations thereof
US8628554B2 (en) 2010-06-13 2014-01-14 Virender K. Sharma Intragastric device for treating obesity
US10010439B2 (en) 2010-06-13 2018-07-03 Synerz Medical, Inc. Intragastric device for treating obesity
US10420665B2 (en) 2010-06-13 2019-09-24 W. L. Gore & Associates, Inc. Intragastric device for treating obesity
US9526648B2 (en) 2010-06-13 2016-12-27 Synerz Medical, Inc. Intragastric device for treating obesity
JP2013532153A (ja) 2010-06-18 2013-08-15 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド 慢性免疫病に対する免疫治療のためのｔｉｍ−３およびｐｄ−１に対する二重特異性抗体
TWI588157B (zh) 2010-07-28 2017-06-21 吉林尼克公司 產生依序多聚體化免疫球蛋白ｆｃ組合物之天然人類蛋白質片段之融合蛋白
US8822663B2 (en) 2010-08-06 2014-09-02 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2622064B1 (en) 2010-10-01 2019-05-29 Modernatx, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
EP2621527A4 (en) 2010-10-01 2015-12-09 Univ Pennsylvania USE OF LISTERIA VACCINE VECTORS TO REVERSE VACCINE IMMUNITY IN PATIENTS WITH PARASITIC INFECTIONS
US20140031250A1 (en) 2010-10-07 2014-01-30 David Tsai Ting Biomarkers of Cancer
EP2655409A4 (en) 2010-12-22 2015-07-01 Univ Leland Stanford Junior SUPERAGONISTS AND ANTAGONISTS OF INTERLEUKIN-2
EP2683400A4 (en) 2011-03-11 2014-09-17 Advaxis ADJUVANZIA ON LISTERIA BASE
DK2691112T3 (en) * 2011-03-31 2018-07-30 Merck Sharp & Dohme STABLE FORMULATIONS OF ANTIBODIES AGAINST HUMAN PD (PROGRAMMED DEATH) 1- RECEPTOR AND RELATED TREATMENTS
US8710200B2 (en) 2011-03-31 2014-04-29 Moderna Therapeutics, Inc. Engineered nucleic acids encoding a modified erythropoietin and their expression
RS57324B1 (sr) 2011-04-20 2018-08-31 Medimmune Llc Antitela i drugi molekuli koji vezuju b7-h1 i pd-1
HUE046152T2 (hu) 2011-05-24 2020-02-28 Biontech Rna Pharmaceuticals Gmbh Rák elleni egyedi vakcinák
US8852599B2 (en) 2011-05-26 2014-10-07 Bristol-Myers Squibb Company Immunoconjugates, compositions for making them, and methods of making and use
ES2705950T3 (es) 2011-06-03 2019-03-27 Eisai R&D Man Co Ltd Biomarcadores para predecir y valorar la capacidad de respuesta de sujetos con cáncer de tiroides y de riñón a compuestos de lenvatinib
US9132281B2 (en) * 2011-06-21 2015-09-15 The Johns Hopkins University Focused radiation for augmenting immune-based therapies against neoplasms
US9416132B2 (en) 2011-07-21 2016-08-16 Tolero Pharmaceuticals, Inc. Substituted imidazo[1,2-b]pyridazines as protein kinase inhibitors
TR201820873T4 (tr) * 2011-08-01 2019-01-21 Hoffmann La Roche Pd-1 ekseni bağlayıcı antagonistler ve mek inhibitörlerinin kullanıldığı kanser tedavisine yönelik yöntemler.
WO2013022091A1 (ja) 2011-08-11 2013-02-14 小野薬品工業株式会社 Ｐｄ－１アゴニストからなる自己免疫疾患治療剤
EP2750768B1 (en) 2011-08-30 2018-10-03 Astex Pharmaceuticals, Inc. Decitabine derivative formulations
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
MY188192A (en) 2011-09-23 2021-11-24 Oncomed Pharm Inc Vegf/dll4 binding agents and uses thereof
EP3492109B1 (en) 2011-10-03 2020-03-04 ModernaTX, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
JP6489353B2 (ja) 2011-10-11 2019-03-27 ウニヴェルズィテート チューリッヒ 腫瘍療法のためのｉｌ−１２とｔ細胞阻害分子遮断薬とを含む医薬組成物
US11951157B2 (en) 2011-10-11 2024-04-09 Universitat Zurich Methods of treating malignant tumour with IL-12 and anti-PD-1 antibody
WO2013059740A1 (en) 2011-10-21 2013-04-25 Foundation Medicine, Inc. Novel alk and ntrk1 fusion molecules and uses thereof
HRP20161377T1 (hr) 2011-11-29 2017-02-10 Ono Pharmaceutical Co., Ltd. Purinonski derivati klorovodika
HRP20220717T1 (hr) 2011-12-16 2022-07-22 Modernatx, Inc. Modificirani pripravci mrna
DK2797942T3 (en) 2011-12-28 2018-12-10 Galectin Therapeutics Inc Composition of Hitherto-Unknown Carbohydrate Drugs for the Treatment of Human Diseases
CA2899433A1 (en) * 2012-01-27 2013-08-01 Gliknik Inc. Fusion proteins comprising igg2 hinge domains
EP3520809B1 (en) * 2012-02-03 2025-08-06 Emory University Immunostimulatory compositions.
LT2814829T (lt) 2012-02-13 2017-02-27 Bristol-Myers Squibb Company En-diino junginiai, jų konjugatai ir jų panaudojimas bei jo būdai
EP2814587B1 (en) 2012-02-15 2018-05-02 F.Hoffmann-La Roche Ag Fc-receptor based affinity chromatography
CN104411327A (zh) 2012-03-12 2015-03-11 阿德瓦希斯公司 李斯特菌疫苗治疗以后的抑制细胞功能抑制
WO2013143555A1 (en) 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
WO2013151665A2 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins associated with human disease
PL2836234T3 (pl) 2012-04-12 2020-02-28 Yale University Podłoża do kontrolowanego dostarczania różnych środków farmaceutycznych
WO2013169693A1 (en) 2012-05-09 2013-11-14 Bristol-Myers Squibb Company Methods of treating cancer using an il-21 polypeptide and an anti-pd-1 antibody
KR20240135058A (ko) 2012-05-15 2024-09-10 브리스톨-마이어스 스큅 컴퍼니 Pd-1/pd-l1 신호전달을 방해하는 것에 의한 암 면역요법
AU2013267267B2 (en) 2012-05-31 2017-10-26 Genentech, Inc. Methods of treating cancer using PD-L1 axis binding antagonists and VEGF antagonists
PH12019502809B1 (en) 2012-06-13 2024-04-24 Incyte Holdings Corp Substituted tricyclic compounds as fgfr inhibitors
UY34887A (es) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
WO2014009535A2 (en) * 2012-07-12 2014-01-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the survival time and treatment responsiveness of a patient suffering from a solid cancer with a signature of at least 7 genes
CN112587658A (zh) 2012-07-18 2021-04-02 博笛生物科技有限公司 癌症的靶向免疫治疗
EP2890715B1 (en) * 2012-08-03 2020-12-16 Dana-Farber Cancer Institute, Inc. Single agent anti-pd-l1 and pd-l2 dual binding antibodies and methods of use
US9682143B2 (en) 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
US10131712B2 (en) * 2012-08-14 2018-11-20 Ibc Pharmaceuticals, Inc. Combination therapy with T-cell redirecting bispecific antibodies and checkpoint inhibitors
US20150231241A1 (en) 2012-08-14 2015-08-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
US9315567B2 (en) * 2012-08-14 2016-04-19 Ibc Pharmaceuticals, Inc. T-cell redirecting bispecific antibodies for treatment of disease
MX2015002269A (es) 2012-08-20 2015-07-06 Gliknik Inc Moleculas con actividad de union al antigeno y al receptor fc gamma polivalente.
ES2871910T3 (es) 2012-08-30 2021-11-02 Amgen Inc Un método para tratar el melanoma usando un virus de herpes simple y un inhibidor de puntos de control inmunitario
DK2900061T3 (da) * 2012-09-17 2020-03-02 Galectin Therapeutics Inc Fremgangsmåde til forstærkning af specifikke immunterapier ved cancerbehandling
WO2014047085A2 (en) * 2012-09-20 2014-03-27 Rongfu Wang Prostate-specific tumor antigen and uses thereof
HRP20171788T1 (hr) * 2012-10-02 2017-12-29 Bristol-Myers Squibb Company Kombinacija anti-kir antitijela i anti-pd-1 antitijela u liječenju raka
CA3201072A1 (en) * 2012-10-12 2014-04-17 The Brigham And Women's Hospital, Inc. Enhancement of the immune response
EP2909337B1 (en) 2012-10-17 2019-01-09 Spatial Transcriptomics AB Methods and product for optimising localised or spatial detection of gene expression in a tissue sample
US10047164B2 (en) * 2012-10-19 2018-08-14 Opsona Therapeutics Limited Methods and compositions for the treatment of pancreatic cancer
DK2722341T3 (en) 2012-10-22 2018-03-12 Fountain Biopharma Inc Interleukin-6 antibodies and their applications
HK1214831A1 (zh) 2012-11-05 2016-08-05 Foundation Medicine, Inc. 新型融合分子及其应用
US9597380B2 (en) 2012-11-26 2017-03-21 Modernatx, Inc. Terminally modified RNA
EP3417874B1 (en) 2012-11-28 2024-09-11 BioNTech SE Individualized vaccines for cancer
PT2925350T (pt) 2012-12-03 2019-03-25 Bristol Myers Squibb Co Melhoria da atividade anticancerosa de proteínas de fusão de fc imunomoduladoras
UA117466C2 (uk) 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
US10980804B2 (en) 2013-01-18 2021-04-20 Foundation Medicine, Inc. Methods of treating cholangiocarcinoma
CN103965363B (zh) * 2013-02-06 2021-01-15 上海白泽生物科技有限公司 与pd-1和vegf高效结合的融合蛋白、其编码序列及用途
US20150377891A1 (en) 2013-02-07 2015-12-31 (Institute National De La Santé Et De La Rechere Médicale) Methods for Predicting the Survival Time of Patients Suffering from Diffuse Large B-Cell Lymphomas
CN105073139B (zh) 2013-02-14 2019-01-11 百时美施贵宝公司 妥布赖森化合物、制备和使用方法
KR102313997B1 (ko) 2013-02-20 2021-10-20 노파르티스 아게 인간화 항-EGFRvIII 키메라 항원 수용체를 사용한 암의 치료
EP3744736A1 (en) 2013-02-20 2020-12-02 Novartis AG Effective targeting of primary human leukemia using anti-cd123 chimeric antigen receptor engineered t cells
SG10201710472PA (en) 2013-02-22 2018-02-27 Curevac Ag Combination of vaccination and inhibition of the pd-1 pathway
DK3292873T3 (da) 2013-02-22 2019-06-03 Curevac Ag Kombination af vaccination og hæmning af PD-1-vejen
KR102363191B1 (ko) * 2013-02-26 2022-02-17 메모리얼 슬로안 케터링 캔서 센터 면역치료용 조성물 및 방법
EP3563836A1 (en) 2013-03-01 2019-11-06 Astex Pharmaceuticals, Inc. Drug combinations
EP3342770B1 (en) 2013-03-06 2022-03-30 AstraZeneca AB Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor
DK2970473T3 (da) 2013-03-14 2017-11-27 Bristol Myers Squibb Co Kombination af dr5-agonist og anti-pd-1-antagonist og fremgangsmåder til anvendelse heraf
MX374488B (es) * 2013-03-15 2025-03-06 Genentech Inc Biomarcadores y su uso en el tratamiento de condiciones relacionadas con pd-1 y pd-l1.
US9308236B2 (en) 2013-03-15 2016-04-12 Bristol-Myers Squibb Company Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
TWI654206B (zh) 2013-03-16 2019-03-21 諾華公司 使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症
EP2981821B2 (en) 2013-04-02 2021-11-03 Merck Sharp & Dohme Corp. Immunohistochemical assay for detecting expression of programmed death ligand 1 (pd-l1) in tumor tissue
EP2981281B1 (en) * 2013-04-03 2020-07-15 IBC Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
KR20160004299A (ko) 2013-04-09 2016-01-12 릭스트 바이오테크놀로지, 인코포레이티드 옥사바이시클로헵탄류 및 옥사바이시클로헵텐류의 제형
KR20150139955A (ko) 2013-04-09 2015-12-14 보스톤 바이오메디칼, 인크. 암 치료에 사용하기 위한 2-아세틸나프토[2,3-b]푸란-4,9-디온
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
MY181497A (en) 2013-04-19 2020-12-23 Incyte Holdings Corp Bicyclic heterocycles as fgfr inhibitors
HUE053069T2 (hu) 2013-05-02 2021-06-28 Anaptysbio Inc Programozott halál-1 (PD-1) ellen irányuló ellenanyagok
WO2014180490A1 (en) 2013-05-10 2014-11-13 Biontech Ag Predicting immunogenicity of t cell epitopes
CN103242448B (zh) * 2013-05-27 2015-01-14 郑州大学 一种全人源化抗pd-1单克隆抗体及其制备方法和应用
WO2014194293A1 (en) 2013-05-30 2014-12-04 Amplimmune, Inc. Improved methods for the selection of patients for pd-1 or b7-h4 targeted therapies, and combination therapies thereof
JP6720075B2 (ja) * 2013-05-31 2020-07-08 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 癌のための併用療法
CA3175360C (en) * 2013-05-31 2024-05-28 Sorrento Therapeutics, Inc. Antigen binding proteins that bind pd-1
US20160145355A1 (en) * 2013-06-24 2016-05-26 Biomed Valley Discoveries, Inc. Bispecific antibodies
CN104250302B (zh) 2013-06-26 2017-11-14 上海君实生物医药科技股份有限公司 抗pd‑1抗体及其应用
KR20160030936A (ko) 2013-07-16 2016-03-21 제넨테크, 인크. Pd-1 축 결합 길항제 및 tigit 억제제를 사용한 암을 치료하는 방법
JP2016531907A (ja) 2013-08-02 2016-10-13 アデュロ・バイオテック・ホールディングス・ヨーロッパ・ベスローテン・フエンノートシャップＡｄｕｒｏ Ｂｉｏｔｅｃｈ Ｈｏｌｄｉｎｇｓ， Ｅｕｒｏｐｅ Ｂ．Ｖ． 免疫刺激のためのｃｄ２７アゴニストと免疫チェックポイント阻害との組み合わせ
CN105579062A (zh) 2013-08-08 2016-05-11 赛腾制药 组合的药物组合物
HRP20231437T1 (hr) 2013-08-08 2024-02-16 Cytune Pharma Il-15 i il-15ralpha sushi domena na temelju modulokina
CA2921401A1 (en) 2013-08-14 2015-02-19 William Marsh Rice University Derivatives of uncialamycin, methods of synthesis and their use as antitumor agents
AR097306A1 (es) 2013-08-20 2016-03-02 Merck Sharp & Dohme Modulación de la inmunidad tumoral
JP6586087B2 (ja) 2013-08-20 2019-10-02 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｐｄ−１アンタゴニストとジナシクリブとの組合せでの癌治療
DK3363790T3 (da) 2013-09-06 2020-04-27 Aurigene Discovery Tech Ltd 1,2,4-oxadiazolderivater som immunmodulatorer
CN105849092A (zh) 2013-09-06 2016-08-10 奥瑞基尼探索技术有限公司 作为免疫调节剂的1，3，4-*二唑和1，3，4-噻二唑衍生物
CN105813640A (zh) 2013-09-06 2016-07-27 奥瑞基尼探索技术有限公司 作为免疫调节剂的环肽类化合物
US10077305B2 (en) 2013-09-10 2018-09-18 Medimmune Limited Antibodies against PD-1 and uses thereof
CN108715615B (zh) * 2013-09-13 2020-11-27 百济神州(广州)生物科技有限公司 抗pd1抗体及其作为治疗剂与诊断剂的用途
KR20210141789A (ko) 2013-09-20 2021-11-23 브리스톨-마이어스 스큅 컴퍼니 종양을 치료하기 위한 항-lag-3 항체 및 항-pd-1 항체의 조합물
CN105722860A (zh) 2013-09-24 2016-06-29 梅迪塞纳医疗股份有限公司 白介素-2融合蛋白及其应用
EP3757130A1 (en) 2013-09-26 2020-12-30 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
SG11201602503TA (en) 2013-10-03 2016-04-28 Moderna Therapeutics Inc Polynucleotides encoding low density lipoprotein receptor
CN104558177B (zh) * 2013-10-25 2020-02-18 苏州思坦维生物技术股份有限公司 拮抗抑制程序性死亡受体pd-1与其配体结合的单克隆抗体及其编码序列与用途
CN104560884A (zh) * 2013-10-25 2015-04-29 苏州思坦维生物技术有限责任公司 拮抗抑制程序性死亡受体pd-1与其配体结合的单克隆抗体及分泌它的杂交瘤细胞系与用途
AU2014342004B2 (en) 2013-11-01 2017-10-26 Yale University Modular particles for immunotherapy
WO2015066413A1 (en) 2013-11-01 2015-05-07 Novartis Ag Oxazolidinone hydroxamic acid compounds for the treatment of bacterial infections
IL292510A (en) * 2013-11-05 2022-06-01 Cognate Bioservices Inc Combinations of checkpoint inhibitors and therapeutics to treat cancer
EP3066126B1 (en) 2013-11-07 2019-03-27 F. Hoffmann-La Roche AG Combination therapy of an anti cd20 antibody with a btk inhibitor
EP3068425B1 (en) * 2013-11-11 2021-01-27 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
EA201690987A1 (ru) 2013-11-13 2016-10-31 Новартис Аг Низкодозовые иммуностимулирующие ингибиторы mtor и их применения
AU2014352749A1 (en) 2013-11-22 2016-06-09 Dnatrix, Inc. Adenovirus expressing immune cell stimulatory receptor agonist(s)
US10801070B2 (en) 2013-11-25 2020-10-13 The Broad Institute, Inc. Compositions and methods for diagnosing, evaluating and treating cancer
CA2930218C (en) * 2013-11-25 2020-11-17 Ccam Biotherapeutics Ltd. Compositions comprising anti-ceacam1 and anti-pd antibodies for cancer therapy
CA2932765A1 (en) 2013-12-05 2015-06-11 Rfemb Holdings, Llc Cancer immunotherapy by radiofrequency electrical membrane breakdown (rf-emb)
US11725237B2 (en) 2013-12-05 2023-08-15 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
US10241115B2 (en) 2013-12-10 2019-03-26 Merck Sharp & Dohme Corp. Immunohistochemical proximity assay for PD-1 positive cells and PD-ligand positive cells in tumor tissue
US10344090B2 (en) * 2013-12-12 2019-07-09 Shanghai Hangrui Pharmaceutical Co., Ltd. PD-1 antibody, antigen-binding fragment thereof, and medical application thereof
AU2014364606A1 (en) 2013-12-17 2016-07-07 Genentech, Inc. Combination therapy comprising OX40 binding agonists and PD-1 axis binding antagonists
US9067998B1 (en) * 2014-07-15 2015-06-30 Kymab Limited Targeting PD-1 variants for treatment of cancer
WO2015094992A1 (en) 2013-12-17 2015-06-25 Merck Sharp & Dohme Corp. Ifn-gamma gene signature biomarkers of tumor response to pd-1 antagonists
EP3647324A1 (en) 2013-12-17 2020-05-06 F. Hoffmann-La Roche AG Methods of treating cancers using pd-1 axis binding antagonists and taxanes
EP3083690A1 (en) 2013-12-17 2016-10-26 F.Hoffmann-La Roche Ag Methods of treating cancer using pd-1 axis binding antagonists and an anti-cd20 antibody
CA3225453A1 (en) 2013-12-19 2015-06-25 Novartis Ag Human mesothelin chimeric antigen receptors and uses thereof
CN106456724A (zh) 2013-12-20 2017-02-22 博德研究所 使用新抗原疫苗的联合疗法
CA3185195A1 (en) 2013-12-20 2015-06-25 Intervet International B.V. Antibodies against canine pd-1
EP3092004A4 (en) * 2014-01-06 2017-02-22 The Trustees Of The University Of Pennsylvania Pd1 and pdl1 antibodies and vaccine combinations and use of same for immunotherapy
SG11201605449YA (en) 2014-01-10 2016-08-30 Birdie Biopharmaceuticals Inc Compounds and compositions for immunotherapy
JO3517B1 (ar) 2014-01-17 2020-07-05 Novartis Ag ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
EP3096782A4 (en) * 2014-01-21 2017-07-26 Medlmmune, LLC Compositions and methods for modulating and redirecting immune responses
TWI681969B (zh) * 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
TWI680138B (zh) * 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
JOP20200094A1 (ar) * 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
AU2015214390B2 (en) 2014-02-04 2020-05-07 Merck Sharp & Dohme LLC. Combination of a PD-1 antagonist and a VEGFR inhibitor for treating cancer
EP3102237B1 (en) 2014-02-04 2020-12-02 Incyte Corporation Combination of a pd-1 antagonist and an ido1 inhibitor for treating cancer
US10899840B2 (en) 2014-02-04 2021-01-26 Pfizer Inc. Combination of a PD-1 antagonist and a 4-1BB agonist for treating cancer
CN106132438B (zh) * 2014-02-21 2020-03-03 尼克塔治疗印度私人有限公司 与抗CTLA-4抗体或抗PD-1抗体组合的IL-2Rβ选择性激动剂
ES2808728T3 (es) * 2014-02-21 2021-03-01 Idac Theranostics Inc Agente terapéutico para cáncer sólido
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
EP3114144A1 (en) * 2014-03-05 2017-01-11 Bristol-Myers Squibb Company Treatment of renal cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent
US10519237B2 (en) 2014-03-12 2019-12-31 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
US9394365B1 (en) 2014-03-12 2016-07-19 Yeda Research And Development Co., Ltd Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease
BR112016020919A2 (pt) 2014-03-12 2018-01-23 Yeda Res & Dev redução dos níveis ou da atividade sistêmica de células t regulatórias para o tratamento de doença e lesão do snc
US10307472B2 (en) 2014-03-12 2019-06-04 Curevac Ag Combination of vaccination and OX40 agonists
US10618963B2 (en) 2014-03-12 2020-04-14 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
WO2015138920A1 (en) * 2014-03-14 2015-09-17 Novartis Ag Antibody molecules to lag-3 and uses thereof
EP3593812A3 (en) 2014-03-15 2020-05-27 Novartis AG Treatment of cancer using chimeric antigen receptor
WO2015148379A1 (en) 2014-03-24 2015-10-01 Novartis Ag Monobactam organic compounds for the treatment of bacterial infections
CR20160500A (es) 2014-03-31 2016-12-14 Genentech Inc Anticuerpos anti-ox40 y métodos de uso
EP3126386A1 (en) 2014-03-31 2017-02-08 F. Hoffmann-La Roche AG Combination therapy comprising anti-angiogenesis agents and ox40 binding agonists
CA2944456C (en) * 2014-03-31 2023-10-31 The Johns Hopkins University Use of bacteria, bacterial products, and other immunoregulatory entities in combination with anti-ctla-4 and/or anti-pd-1 antibodies to treat solid tumor malignancies
CN104974253A (zh) * 2014-04-01 2015-10-14 上海中信国健药业股份有限公司 抗ctla-4/pd-1双特异性抗体、其制备方法及应用
US9987258B2 (en) 2014-04-06 2018-06-05 H. Lee Moffitt Cancer Center And Research Institute, Inc. Histone deacetylase as a modulator of PDL1 expression and activity
EP4406610A3 (en) 2014-04-07 2024-10-30 Novartis AG Treatment of cancer using anti-cd19 chimeric antigen receptor
ES2980788T3 (es) 2014-04-10 2024-10-03 H Lee Moffitt Cancer Ct & Res Expansión mejorada de linfocitos infiltrantes de tumores para terapia celular adoptiva
CN106659757B (zh) 2014-04-24 2022-01-28 利兰斯坦福初级大学董事会 白介素2的超级激动剂、部分激动剂和拮抗剂
CN105031630A (zh) * 2014-04-28 2015-11-11 四川大学 同时分泌pd-1中和抗体和gm-csf因子的肿瘤细胞疫苗及其制备方法
ES2836772T3 (es) 2014-04-30 2021-06-28 Fujifilm Corp Composición liposomal y método para producirla
IL248507B (en) * 2014-05-13 2022-07-01 Bavarian Nordic As Combination therapy for treating cancer with a recombinant poxvirus expressing a tumor antigen and an immune checkpoint molecule antagonist or agonist
DK3142689T3 (da) * 2014-05-13 2021-02-15 Bavarian Nordic As Kombinationsbehandling til behandling af cancer med en koppevirus, som udtrykker et tumorantigen, og et monoklonalt antistof mod tim-3
CN106714839A (zh) 2014-05-15 2017-05-24 百时美施贵宝公司 使用抗pd‑1抗体和另一种抗癌剂的组合治疗肺癌
AU2015264102C1 (en) 2014-05-23 2020-10-08 Eisai R&D Management Co., Ltd. Combination therapies for the treatment of cancer
CA2947939A1 (en) 2014-05-28 2015-12-03 Idenix Pharmaceuticals Llc Nucleoside derivatives for the treatment of cancer
PH12022550194A1 (en) 2014-05-28 2022-09-19 Agenus Inc Anti-gitr antibodies and methods of use thereof
HUE047385T2 (hu) 2014-06-06 2020-04-28 Bristol Myers Squibb Co Antitestek glükokortikoid indukált tumornekrózis faktor receptor (GITR) ellen és annak felhasználásai
SG10201811116UA (en) 2014-06-19 2019-01-30 Regeneron Pharma Non-human animals having a humanized programmed cell death 1 gene
WO2015200697A1 (en) 2014-06-25 2015-12-30 The General Hospital Corporation Targeting human satellite ii (hsatii)
TWI693232B (zh) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
WO2016004055A1 (en) * 2014-07-03 2016-01-07 Yale University Dickkopf2 (Dkk2) Inhibition Suppresses Tumor Formation
CN110156892B (zh) 2014-07-03 2023-05-16 百济神州有限公司 抗pd-l1抗体及其作为治疗剂及诊断剂的用途
EP4001311B1 (en) 2014-07-09 2025-11-05 Birdie Biopharmaceuticals Inc. Anti-pd-l1/pd-1 combinations for treating tumors
WO2016007876A1 (en) 2014-07-10 2016-01-14 Biothera, Inc. Beta-glucan in combination with anti-cancer agents affecting the tumor microenvironment
US20160009805A1 (en) 2014-07-11 2016-01-14 Genentech, Inc. Anti-pd-l1 antibodies and diagnostic uses thereof
SG11201700074YA (en) 2014-07-15 2017-02-27 Genentech Inc Compositions for treating cancer using pd-1 axis binding antagonists and mek inhibitors
CN107072984B (zh) * 2014-07-15 2021-10-01 约翰·霍普金斯大学 源自骨髓的抑制细胞的抑制和免疫检查点阻断
KR102504758B1 (ko) 2014-07-16 2023-02-28 트랜스진 종양 세포 붕괴성 바이러스와 면역 체크포인트 조절제의 배합물
RU2696312C2 (ru) 2014-07-16 2019-08-01 Трансген Са Онколитический вирус для экспрессии модуляторов иммунологических контрольных точек
CA2955612C (en) 2014-07-18 2022-05-17 Advaxis, Inc. Combination of a pd-1 antagonist and a listeria-based vaccine for treating prostate cancer
US11542488B2 (en) 2014-07-21 2023-01-03 Novartis Ag Sortase synthesized chimeric antigen receptors
WO2016014530A1 (en) 2014-07-21 2016-01-28 Novartis Ag Combinations of low, immune enhancing. doses of mtor inhibitors and cars
US9777061B2 (en) 2014-07-21 2017-10-03 Novartis Ag Treatment of cancer using a CD33 chimeric antigen receptor
BR112017001385B1 (pt) 2014-07-22 2023-12-05 Cb Therapeutics, Inc. Anticorpo isolado ou fragmento do mesmo que liga a pd-1, uso deste, composição, polinucleotídeo isolado e vetor de expressão
CN105330740B (zh) * 2014-07-30 2018-08-17 珠海市丽珠单抗生物技术有限公司 抗pd-1抗体及其应用
EP4205749A1 (en) 2014-07-31 2023-07-05 Novartis AG Subset-optimized chimeric antigen receptor-containing cells
CN105296433B (zh) 2014-08-01 2018-02-09 中山康方生物医药有限公司 一种ctla4抗体、其药物组合物及其用途
CA2956399A1 (en) 2014-08-05 2016-02-11 Cb Therapeutics, Inc. Anti-pd-l1 antibodies
AU2015298356B2 (en) * 2014-08-05 2020-11-19 MabQuest SA Immunological reagents binding to pd-1
US9982052B2 (en) 2014-08-05 2018-05-29 MabQuest, SA Immunological reagents
WO2016020836A1 (en) 2014-08-06 2016-02-11 Novartis Ag Quinolone derivatives as antibacterials
PL3179992T3 (pl) 2014-08-11 2022-08-16 Acerta Pharma B.V. Kombinacje terapeutyczne inhibitora BTK, inhibitora PD-1 i/lub inhibitora PD-L1
WO2016025645A1 (en) 2014-08-12 2016-02-18 Massachusetts Institute Of Technology Synergistic tumor treatment with il-2, a therapeutic antibody, and an immune checkpoint blocker
EP3646879B1 (en) 2014-08-12 2024-04-03 Massachusetts Institute Of Technology Synergistic tumor treatment with integrin-binding-fc-fusion protein and an immune checkpoint inhibitor
CR20170096A (es) 2014-08-12 2017-06-15 Alligator Bioscience Ab Tratamientos conjuntos con anticuerpos anti cd40
JP6919118B2 (ja) 2014-08-14 2021-08-18 ノバルティス アーゲー ＧＦＲα−４キメラ抗原受容体を用いる癌の治療
EP3183268B1 (en) 2014-08-19 2020-02-12 Novartis AG Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment
EP3192517A4 (en) 2014-08-19 2018-04-25 National University Corporation Okayama University Method for enhancing immune cell function and method for assessing immune cell multifunctionality
JP2017530950A (ja) 2014-08-25 2017-10-19 ファイザー・インコーポレイテッド 癌を処置するためのｐｄ−１アンタゴニストおよびａｌｋ阻害剤の併用
WO2016030455A1 (en) * 2014-08-28 2016-03-03 Medimmune Limited Anti-b7-h1 and anti-ctla-4 antibodies for treating non-small lung cancer
DK3524595T3 (da) 2014-08-28 2022-09-19 Eisai R&D Man Co Ltd Quinolinderivat af høj renhed og fremgangsmåde til fremstilling deraf
TR201907471T4 (tr) 2014-08-28 2019-06-21 Halozyme Inc Bir hiyalüronan ayrıştırıcı enzim ve bir bağışıklık kontrol noktası inhibitörüyle kombinasyon terapisi.
CN112546238A (zh) 2014-09-01 2021-03-26 博笛生物科技有限公司 用于治疗肿瘤的抗-pd-l1结合物
JP2017526702A (ja) * 2014-09-08 2017-09-14 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド ＰＰＡＲ−γアゴニストを投与する段階を含む、癌を治療する方法
US9535074B2 (en) 2014-09-08 2017-01-03 Merck Sharp & Dohme Corp. Immunoassay for soluble PD-L1
KR20170060042A (ko) 2014-09-13 2017-05-31 노파르티스 아게 Alk 억제제의 조합 요법
SG11201701340RA (en) 2014-09-16 2017-03-30 Innate Pharma Neutralization of inhibitory pathways in lymphocytes
KR20250067191A (ko) 2014-09-17 2025-05-14 노파르티스 아게 입양 면역요법을 위한 키메라 수용체에 의한 세포독성 세포의 표적화
US20160082120A1 (en) 2014-09-23 2016-03-24 Genentech, Inc. METHODS OF USING ANTI-CD79b IMMUNOCONJUGATES
WO2016045732A1 (en) 2014-09-25 2016-03-31 Biontech Rna Pharmaceuticals Gmbh Stable formulations of lipids and liposomes
AU2015326996B2 (en) 2014-09-30 2021-05-20 Intervet International B.V. PD-L1 antibodies binding canine PD-L1
KR20170066546A (ko) 2014-10-03 2017-06-14 노파르티스 아게 조합 요법
CN114107424A (zh) 2014-10-08 2022-03-01 诺华股份有限公司 预测针对嵌合抗原受体疗法的治疗应答性的生物标志及其用途
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
AU2015329982B2 (en) 2014-10-10 2021-05-20 Innate Pharma CD73 blockade
US9732119B2 (en) 2014-10-10 2017-08-15 Bristol-Myers Squibb Company Immunomodulators
CN106999574B (zh) 2014-10-10 2022-05-24 伊黛拉制药有限公司 使用tlr9激动剂与检查点抑制剂对癌症的治疗
BR112017007765B1 (pt) 2014-10-14 2023-10-03 Halozyme, Inc Composições de adenosina deaminase-2 (ada2), variantes do mesmo e métodos de usar o mesmo
CN114920840A (zh) 2014-10-14 2022-08-19 诺华股份有限公司 针对pd-l1的抗体分子及其用途
WO2016059602A2 (en) * 2014-10-16 2016-04-21 Glaxo Group Limited Methods of treating cancer and related compositions
CN112168967A (zh) 2014-10-16 2021-01-05 Epizyme股份有限公司 治疗癌症的方法
US9724395B2 (en) 2014-10-21 2017-08-08 Sciclone Pharmaceuticals, Inc. Treatment of cancer with immune stimulators
GB201419084D0 (en) * 2014-10-27 2014-12-10 Agency Science Tech & Res Anti-PD-1 antibodies
CN107567336B (zh) 2014-10-29 2021-12-31 戊瑞治疗有限公司 癌症的联合治疗
ES2808153T3 (es) * 2014-10-31 2021-02-25 Mereo Biopharma 5 Inc Terapia de combinación para tratamiento de enfermedad
RU2017119009A (ru) 2014-11-03 2018-12-05 Дженентек, Инк. Анализы для обнаружения субпопуляций иммунных т-клеток и способы их применения
SG11201703521UA (en) 2014-11-03 2017-05-30 Genentech Inc Methods and biomarkers for predicting efficacy and evaluation of an ox40 agonist treatment
US11236139B2 (en) 2014-11-05 2022-02-01 The Regents Of The University Of California Combination immunotherapy
EP3215163B1 (en) * 2014-11-06 2021-03-10 Biothera, Inc. Beta-glucan methods and compositions that affect the tumor microenvironment
EP3215528B1 (en) 2014-11-06 2019-08-07 F.Hoffmann-La Roche Ag Fc-region variants with modified fcrn-binding and methods of use
US10077287B2 (en) 2014-11-10 2018-09-18 Bristol-Myers Squibb Company Tubulysin analogs and methods of making and use
EP3218409A2 (en) * 2014-11-11 2017-09-20 Sutro Biopharma, Inc. Anti-pd-1 antibodies, compositions comprising anti-pd-1 antibodies and methods of using anti-pd-1 antibodies
KR20190135563A (ko) 2014-11-13 2019-12-06 더 존스 홉킨스 유니버시티 관문 차단 및 미소부수체 불안정성
US9856292B2 (en) 2014-11-14 2018-01-02 Bristol-Myers Squibb Company Immunomodulators
MA40913A (fr) 2014-11-14 2017-09-20 Novartis Ag Conjugués anticorps-médicament
JP2017537090A (ja) 2014-11-17 2017-12-14 ジェネンテック， インコーポレイテッド Ｏｘ４０結合アゴニスト及びｐｄ−１軸結合アンタゴニストを含む併用療法
EP4141032B1 (en) * 2014-11-20 2024-05-29 F. Hoffmann-La Roche AG Combination therapy of t cell activating bispecific antigen binding molecules and pd-1 axis binding antagonists
EP3220927B1 (en) 2014-11-20 2022-01-05 Promega Corporation Systems and methods for assessing modulators of immune checkpoints
MX386942B (es) 2014-11-21 2025-03-19 Bristol Myers Squibb Co Anticuerpos que comprenden regiones constantes pesadas modificadas.
HUE050596T2 (hu) 2014-11-21 2020-12-28 Bristol Myers Squibb Co Antitestek CD73 ellen és azok felhasználásai
MX383917B (es) 2014-11-25 2025-03-14 Bristol Myers Squibb Co Nuevos péptidos que se unen al ligando-1 de muerte programada (pd-l1) para formación de imagen.
CN107207379B (zh) 2014-11-25 2021-08-10 百时美施贵宝公司 用于生物制品的18f-放射性标记的方法和组合物
EP3632915A1 (en) 2014-11-27 2020-04-08 Genentech, Inc. 4,5,6,7-tetrahydro-1 h-pyrazolo[4,3-c]pyridin-3-amine compounds as cbp and/or ep300 inhibitors
WO2016090034A2 (en) 2014-12-03 2016-06-09 Novartis Ag Methods for b cell preconditioning in car therapy
TWI721959B (zh) 2014-12-04 2021-03-21 美商健生生物科技公司 治療急性骨髓性白血病之抗ｃｄ３８抗體
EA201791049A1 (ru) 2014-12-04 2017-10-31 Бристол-Майерс Сквибб Компани Комбинация анти-cs1 и анти-pd1 антител для лечения рака (миеломы)
CN107206088A (zh) 2014-12-05 2017-09-26 豪夫迈·罗氏有限公司 使用pd‑1轴拮抗剂和hpk1拮抗剂用于治疗癌症的方法和组合物
EP3226688B1 (en) 2014-12-05 2020-07-01 Merck Sharp & Dohme Corp. Tricyclic compounds as inhibitors of mutant idh enzymes
US10508108B2 (en) 2014-12-05 2019-12-17 Merck Sharp & Dohme Corp. Tricyclic compounds as inhibitors of mutant IDH enzymes
WO2016089833A1 (en) 2014-12-05 2016-06-09 Merck Sharp & Dohme Corp. Novel tricyclic compounds as inhibitors of mutant idh enzymes
WO2016089610A1 (en) 2014-12-06 2016-06-09 H. Lee Moffitt Cancer Center And Research Institute, Inc. Bispecific antibody for cancer immunotherapy
EP3229837B1 (en) 2014-12-08 2025-02-05 Dana-Farber Cancer Institute, Inc. Methods for upregulating immune responses using combinations of anti-rgmb and anti-pd-1 agents
BR112017012222A2 (pt) 2014-12-09 2018-01-30 Merck Sharp & Dohme métodos para derivar um biomarcador de assinatura gênica e para tratar um paciente que tem um tumor, método e sistema para testar uma amostra de tumor removida de um paciente, e, kit.
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
PT3233843T (pt) 2014-12-16 2019-11-26 Novartis Ag Compostos de ácido isoxazol hidroxámico como inibidores de lxpc
US9861680B2 (en) 2014-12-18 2018-01-09 Bristol-Myers Squibb Company Immunomodulators
CN107580626A (zh) 2014-12-18 2018-01-12 美国安进公司 稳定冷冻病毒制剂
WO2016100975A1 (en) 2014-12-19 2016-06-23 Massachsetts Institute Ot Technology Molecular biomarkers for cancer immunotherapy
US20170340733A1 (en) 2014-12-19 2017-11-30 Novartis Ag Combination therapies
US9944678B2 (en) 2014-12-19 2018-04-17 Bristol-Myers Squibb Company Immunomodulators
EP3757211B1 (en) 2014-12-19 2025-07-30 The Broad Institute, Inc. Methods for profiling the t-cell-receptor repertoire
CA2971734C (en) 2014-12-22 2025-11-18 Enumeral Biomedical Holdings Inc Anti-pd-1 antibodies
US11639385B2 (en) 2014-12-22 2023-05-02 Pd-1 Acquisition Group, Llc Anti-PD-1 antibodies
WO2016106160A1 (en) * 2014-12-22 2016-06-30 Enumeral Biomedical Holdings, Inc. Methods for screening therapeutic compounds
AU2015370665B2 (en) 2014-12-23 2020-05-14 4D Pharma Research Limited Pirin polypeptide and immune modulation
TWI708786B (zh) 2014-12-23 2020-11-01 美商必治妥美雅史谷比公司 針對ｔｉｇｉｔ之抗體
CN104479020B (zh) * 2014-12-26 2019-08-02 上海复宏汉霖生物技术股份有限公司 一种抗pd-1人源抗体
GB201500319D0 (en) 2015-01-09 2015-02-25 Agency Science Tech & Res Anti-PD-L1 antibodies
PE20171185A1 (es) 2015-01-14 2017-08-22 Bristol Myers Squibb Co Dimeros de benzodiazepina unidos con puentes de heteroarileno, conjugados de estos, y sus metodos de preparacion y uso
US20170369570A1 (en) * 2015-01-20 2017-12-28 Immunexcite, Inc. Compositions and methods for cancer immunotherapy
MA41414A (fr) 2015-01-28 2017-12-05 Centre Nat Rech Scient Protéines de liaison agonistes d' icos
JP6723249B2 (ja) 2015-01-30 2020-07-15 アールエフイーエムビー ホールディングス リミテッド ライアビリティ カンパニー 軟部組織を切除するためのシステムおよび方法
HK1247861A1 (zh) 2015-01-30 2018-10-05 President And Fellows Of Harvard College 用於癌症治疗的肿瘤周围和肿瘤内部材料
WO2016126608A1 (en) 2015-02-02 2016-08-11 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
US20160222060A1 (en) 2015-02-04 2016-08-04 Bristol-Myers Squibb Company Immunomodulators
US10983128B2 (en) 2015-02-05 2021-04-20 Bristol-Myers Squibb Company CXCL11 and SMICA as predictive biomarkers for efficacy of anti-CTLA4 immunotherapy
US20180244779A1 (en) * 2015-02-06 2018-08-30 Kadmon Corporation Llc Immunomodulatory agents
WO2016128912A1 (en) 2015-02-12 2016-08-18 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor, a pd-1 inhibitor, and/or a pd-l1 inhibitor
WO2016130839A1 (en) * 2015-02-12 2016-08-18 Beyondspring Pharmaceuticals, Inc. Use of plinabulin in combination with immune checkpoint inhibitors
WO2016128060A1 (en) 2015-02-12 2016-08-18 Biontech Ag Predicting t cell epitopes useful for vaccination
WO2016128542A1 (en) * 2015-02-13 2016-08-18 Transgene Sa Immunotherapeutic vaccine and antibody combination therapy
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
PE20171514A1 (es) 2015-02-20 2017-10-20 Incyte Corp Heterociclos biciclicos como inhibidores de fgfr
DK3263106T3 (da) 2015-02-25 2024-01-08 Eisai R&D Man Co Ltd Fremgangsmåde til undertrykkelse af bitterhed af quinolinderivat
AU2016222928B2 (en) 2015-02-26 2021-05-13 Merck Patent Gmbh PD-1 / PD-L1 inhibitors for the treatment of cancer
AR103726A1 (es) * 2015-02-27 2017-05-31 Merck Sharp & Dohme Cristales de anticuerpos monoclonales anti-pd-1 humanos
RU2737216C2 (ru) * 2015-03-04 2020-11-26 Мерк Шарп Энд Дохме Корп. Комбинация антагониста pd-1 и эрибулина для лечения рака
WO2016140717A1 (en) 2015-03-04 2016-09-09 Merck Sharp & Dohme Corp. Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
SG11201707127VA (en) 2015-03-06 2017-09-28 Beyondspring Pharmaceuticals Inc Method of treating cancer associated with a ras mutation
HK1249051A1 (zh) 2015-03-06 2018-10-26 BeyondSpring Pharmaceuticals Inc. 治疗脑肿瘤的方法
CN114159430B (zh) 2015-03-10 2024-10-25 奥瑞基尼探索技术有限公司 作为免疫调节剂的1,2,4-噁二唑和噻二唑化合物
CA2979215A1 (en) 2015-03-10 2016-09-15 Aduro Biotech, Inc. Compositions and methods for activating "stimulator of interferon gene"-dependent signalling
MA42971A (fr) 2015-03-13 2018-08-15 Cytomx Therapeutics Inc Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation
EP3067062A1 (en) * 2015-03-13 2016-09-14 Ipsen Pharma S.A.S. Combination of tasquinimod or a pharmaceutically acceptable salt thereof and a pd1 and/or pdl1 inhibitor, for use as a medicament
US9809625B2 (en) 2015-03-18 2017-11-07 Bristol-Myers Squibb Company Immunomodulators
CA2980390A1 (en) 2015-03-23 2016-09-29 Bayer Pharma Aktiengesellschaft Anti-ceacam6 antibodies and uses thereof
EP3286311B1 (en) * 2015-03-26 2021-05-05 OncoSec Medical Incorporated Method for the treatment of malignancies
CN114380909A (zh) 2015-03-30 2022-04-22 斯特库比股份有限公司 特异性针对糖基化的pd-l1的抗体及其使用方法
US11933786B2 (en) 2015-03-30 2024-03-19 Stcube, Inc. Antibodies specific to glycosylated PD-L1 and methods of use thereof
MA41866A (fr) * 2015-03-31 2018-02-06 Massachusetts Gen Hospital Molécules à auto-assemblage pour l'administration ciblée de médicaments
CN107847589B (zh) 2015-04-01 2022-03-29 安奈普泰斯生物有限公司 针对t细胞免疫球蛋白和粘蛋白蛋白3(tim-3)的抗体
EP3277325B1 (en) 2015-04-03 2020-10-28 H. Lee Moffitt Cancer Center And Research Institute, Inc. Combination immunotherapy for cancer
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
EP3770171A1 (en) 2015-04-03 2021-01-27 XOMA Technology Ltd. Treatment of cancer using inhibitors of tgf-beta and pd-1
RU2709015C2 (ru) 2015-04-07 2019-12-13 Ситлимик Инк. Лекарственное средство
WO2016164480A1 (en) 2015-04-07 2016-10-13 Genentech, Inc. Antigen binding complex having agonistic activity and methods of use
ES2876974T3 (es) 2015-04-07 2021-11-15 Novartis Ag Combinación de terapia con receptor de antígeno quimérico y derivados de amino pirimidina
US10253086B2 (en) 2015-04-08 2019-04-09 Novartis Ag CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric antigen receptor (CAR)-expressing cell
RS61531B1 (sr) 2015-04-13 2021-04-29 Five Prime Therapeutics Inc Kombinovana terapija za kancer
MA53243A (fr) 2015-04-17 2021-06-23 Bristol Myers Squibb Co Compositions comprenant une combinaison de ipilimumab et nivolumab
EP3839510A3 (en) 2015-04-17 2021-08-25 Merck Sharp & Dohme Corp. Blood-based biomarkers of tumor sensitivity to pd-1 antagonists
ES2948133T3 (es) 2015-04-17 2023-08-31 Novartis Ag Métodos para mejorar la eficacia y expansión de células que expresan un receptor de antígeno quimérico
US12128069B2 (en) 2015-04-23 2024-10-29 The Trustees Of The University Of Pennsylvania Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
WO2016176504A1 (en) 2015-04-28 2016-11-03 Bristol-Myers Squibb Company Treatment of pd-l1-positive melanoma using an anti-pd-1 antibody
EP3288982A1 (en) 2015-04-28 2018-03-07 Bristol-Myers Squibb Company Treatment of pd-l1-negative melanoma using an anti-pd-1 antibody and an anti-ctla-4 antibody
US10585100B2 (en) 2015-04-30 2020-03-10 Kyoto University Method of predicting effect of treatment by PD-1/PD-L1 blockade using abnormality of PD-L1 (CD274) as index
DE112016002056T5 (de) 2015-05-06 2018-02-08 Snipr Technologies Limited Verändern mikrobieller Populationen und Modifizieren von Mikrobiomen
DK3294770T4 (da) 2015-05-12 2024-05-21 Hoffmann La Roche Terapeutiske og diagnostiske fremgangsmåder til cancer
CN104987421A (zh) * 2015-05-13 2015-10-21 北京比洋生物技术有限公司 抗ctla-4和pd-1的双重可变结构域免疫球蛋白
EP3527574B1 (en) 2015-05-18 2022-04-06 Sumitomo Dainippon Pharma Oncology, Inc. Alvocidib prodrugs having increased bioavailability
MX389805B (es) 2015-05-20 2025-03-11 Janssen Biotech Inc Anticuerpos anti-cd38 para el tratamiento de amiloidosis de cadena ligera y otras enfermedades malignas hematológicas positivas para cd38.
PE20180670A1 (es) 2015-05-20 2018-04-19 Broad Inst Inc Neoantigenos compartidos
MX383614B (es) 2015-05-21 2025-03-14 Harpoon Therapeutics Inc Proteinas de union triespecificas y metodos de uso.
CN107921126A (zh) * 2015-05-22 2018-04-17 转化药物开发有限责任公司 苯甲酰胺和活性化合物的组合物及其使用方法
CN104931690A (zh) * 2015-05-22 2015-09-23 华中科技大学同济医学院附属协和医院 一种pd-1抗体检测试剂盒及其应用
WO2016189055A1 (en) 2015-05-27 2016-12-01 Idenix Pharmaceuticals Llc Nucleotides for the treatment of cancer
US20180155429A1 (en) 2015-05-28 2018-06-07 Bristol-Myers Squibb Company Treatment of pd-l1 positive lung cancer using an anti-pd-1 antibody
US20160347836A1 (en) * 2015-05-28 2016-12-01 Bristol-Myers Squibb Company Treatment of hodgkin's lymphoma using an anti-pd-1 antibody
US11078278B2 (en) 2015-05-29 2021-08-03 Bristol-Myers Squibb Company Treatment of renal cell carcinoma
LT3303394T (lt) 2015-05-29 2020-10-12 Agenus Inc. Anti-ctla-4 antikūnai ir jų naudojimo būdai
IL255372B (en) 2015-05-29 2022-07-01 Genentech Inc Therapeutic and diagnostic methods for cancer
RU2017145558A (ru) 2015-05-29 2019-07-01 Мерк Шарп И Доум Корп. Комбинация антагониста pd-1 и олигонуклеотида типа cpg-c для лечения рака
CN108137687B (zh) 2015-05-29 2021-10-29 百时美施贵宝公司 抗ox40抗体及其用途
CN107613980A (zh) * 2015-05-31 2018-01-19 源生公司 用于免疫疗法的组合组合物
AU2016270750B2 (en) * 2015-06-01 2022-06-16 The University Of Chicago Treatment of cancer by manipulation of commensal microflora
CA2988126A1 (en) 2015-06-03 2016-12-08 Boston Biomedical, Inc. Compositions comprising a cancer stemness inhibitor and an immunotherapeutic agent for use in treating cancer
US10995140B2 (en) 2015-06-05 2021-05-04 H. Lee Moffitt Cancer Center And Research Institute, Inc. GM-CSF/CD40L vaccine and checkpoint inhibitor combination therapy
TWI773646B (zh) 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 結合lag-3的分子和其使用方法
EP3303399A1 (en) 2015-06-08 2018-04-11 H. Hoffnabb-La Roche Ag Methods of treating cancer using anti-ox40 antibodies
CN105061597B (zh) * 2015-06-09 2016-04-27 北京东方百泰生物科技有限公司 一种抗pd-1的单克隆抗体及其获得方法
US20180179282A1 (en) 2015-06-12 2018-06-28 Bristol-Myers Squibb Company Treatment of cancer by combined blockade of the pd-1 and cxcr4 signaling pathways
HK1254289A1 (zh) * 2015-06-12 2019-07-19 台湾基督长老教会马偕医疗财团法人马偕纪念医院 调控免疫反应的方法及抗体
TWI870335B (zh) 2015-06-12 2025-01-21 美商宏觀基因股份有限公司 變異的嵌合4d5抗體及其與抗pd-1抗體聯合用於治療癌症的應用
JP6426265B2 (ja) 2015-06-15 2018-11-21 フォーディー ファーマ リサーチ リミテッド４Ｄ Ｐｈａｒｍａ Ｒｅｓｅａｒｃｈ Ｌｉｍｉｔｅｄ 細菌株を含む組成物
MA41010B1 (fr) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
BR112017026564B1 (pt) 2015-06-15 2022-05-03 4D Pharma Research Limited Células de bactéria, usos das mesmas, e composição
LT3307288T (lt) 2015-06-15 2019-10-10 4D Pharma Research Limited Kompozicijos, apimančios bakterijų kamienus
US11369623B2 (en) 2015-06-16 2022-06-28 Prism Pharma Co., Ltd. Anticancer combination of a CBP/catenin inhibitor and an immune checkpoint inhibitor
WO2016205277A1 (en) 2015-06-16 2016-12-22 Merck Patent Gmbh Pd-l1 antagonist combination treatments
CA2986263A1 (en) 2015-06-17 2016-12-22 Genentech, Inc. Methods of treating locally advanced or metastatic breast cancers using pd-1 axis binding antagonists and taxanes
EP3310813A1 (en) 2015-06-17 2018-04-25 Novartis AG Antibody drug conjugates
TWI773647B (zh) * 2015-06-23 2022-08-11 史隆凱特林紀念癌症中心 新穎pd-1免疫調控劑
US20160376373A1 (en) 2015-06-24 2016-12-29 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
DK3313528T3 (da) 2015-06-29 2021-09-20 Bristol Myers Squibb Co Immunterapeutiske doseringsskemaer omfattende pomalidomid og et anti-cs1-antistof til behandling af cancer
KR20180021833A (ko) 2015-06-29 2018-03-05 더 락커펠러 유니버시티 증진된 효능제 활성을 갖는 cd40에 대한 항체
WO2017004421A1 (en) * 2015-06-30 2017-01-05 The Trustees Of The University Of Pennsylvania Resiquimod topical and injectable compositions for the treatment of neoplastic skin conditions
KR20180024010A (ko) 2015-07-02 2018-03-07 오쓰까 세이야꾸 가부시키가이샤 동결건조된 약제학적 조성물
WO2017004532A1 (en) 2015-07-02 2017-01-05 Celgene Corporation Combination therapy for treatment of hematological cancers and solid tumors
GB201511790D0 (en) 2015-07-06 2015-08-19 Iomet Pharma Ltd Pharmaceutical compound
MA42447A (fr) * 2015-07-13 2018-05-23 Cytomx Therapeutics Inc Anticorps anti-pd-1, anticorps anti-pd-1 activables, et leurs procédés d'utilisation
CN113735834B (zh) 2015-07-13 2023-06-13 大连万春布林医药有限公司 普那布林组合物
DK3858859T3 (da) 2015-07-14 2025-12-15 Bristol Myers Squibb Co Fremgangsmåde til behandling af kræft under anvendelse af en immun checkpointinhibitor; antistof som binder til programmeret død-1 receptor (pd-1) eller programmeret død ligand 1 (pd-l1)
HK1248115A1 (zh) 2015-07-16 2018-10-12 Bioxcel Therapeutics, Inc. 一种使用免疫调节治疗癌症的新颖方法
CN116196426A (zh) 2015-07-16 2023-06-02 百欧肯治疗有限公司 治疗癌症的组合物及方法
CN109476722A (zh) 2015-07-21 2019-03-15 诺华股份有限公司 用于改善免疫细胞的功效和扩张的方法
RS61586B1 (sr) * 2015-07-22 2021-04-29 Inatherys Anti-tfr antitela i njihova upotreba u lečenju proliferativnih i zapaljenjskih poremećaja
IL309260B2 (en) 2015-07-24 2025-01-01 Gliknik Inc Fusion proteins of human protein fragments to create ordered multimeric immunoglobulin FC preparations with enhanced complement binding
CN106699888B (zh) * 2015-07-28 2020-11-06 上海昀怡健康科技发展有限公司 一种pd-1抗体及其制备方法和应用
BR112018000212A2 (pt) 2015-07-29 2018-09-04 Novartis Ag uso combinado de anticorpos anti pd-1 e anti m-csf no tratamento de câncer
US20180177872A1 (en) 2015-07-29 2018-06-28 Yong Jia Combination of PD-1 antagonist with an EGFR inhibitor
CN114272371A (zh) 2015-07-29 2022-04-05 诺华股份有限公司 包含抗pd-1抗体分子的联合疗法
PL3317301T3 (pl) 2015-07-29 2021-11-15 Novartis Ag Terapie skojarzone zawierające cząsteczki przeciwciał przeciw lag-3
EP3878465A1 (en) 2015-07-29 2021-09-15 Novartis AG Combination therapies comprising antibody molecules to tim-3
MA42542B1 (fr) * 2015-07-30 2021-09-30 Macrogenics Inc Molécules se liant à pd-1 et méthodes d'utilisation correspondantes
JP2018522044A (ja) 2015-08-04 2018-08-09 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ 併用治療ならびにその使用およびその方法
EP3331918A1 (en) * 2015-08-04 2018-06-13 GlaxoSmithKline Intellectual Property Development Limited Combination treatments and uses and methods thereof
US20180222990A1 (en) 2015-08-04 2018-08-09 Glaxosmithkline Intellectual Property Development Limited Combination Treatments and Uses and Methods Thereof
WO2017025871A1 (en) 2015-08-07 2017-02-16 Glaxosmithkline Intellectual Property Development Limited Combination therapy comprising anti ctla-4 antibodies
HK1254450A1 (zh) 2015-08-07 2019-07-19 Pieris Pharmaceuticals Gmbh 对lag-3和pd-1特异性的新型融合多肽
WO2017024465A1 (en) * 2015-08-10 2017-02-16 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
WO2017024515A1 (en) * 2015-08-11 2017-02-16 Wuxi Biologics (Cayman) Inc. Novel anti-pd-1 antibodies
HUE068751T2 (hu) * 2015-08-11 2025-01-28 Wuxi Biologics Ireland Ltd Új anti-PD-1 ellenanyagok
US11453697B1 (en) 2015-08-13 2022-09-27 Merck Sharp & Dohme Llc Cyclic di-nucleotide compounds as sting agonists
BR112018002757A8 (pt) 2015-08-13 2023-04-11 Merck Sharp & Dohme Composto, composição farmacêutica, e, métodos para induzir uma resposta imune, para induzir uma produção de interferon tipo i e para tratamento de um distúrbio
MX381976B (es) 2015-08-20 2025-03-13 Eisai R&D Man Co Ltd Agente terapéutico contra tumores.
EP3341732B1 (en) 2015-08-27 2023-07-12 INSERM - Institut National de la Santé et de la Recherche Médicale Methods for predicting the survival time of patients suffering from a lung cancer
WO2017040790A1 (en) 2015-09-01 2017-03-09 Agenus Inc. Anti-pd-1 antibodies and methods of use thereof
CN108348571B (zh) 2015-09-03 2022-03-22 艾瑞朗医疗公司 拟肽大环化合物及其用途
CN116334205A (zh) 2015-09-03 2023-06-27 诺华股份有限公司 预测细胞因子释放综合征的生物标志物
WO2017038997A1 (ja) 2015-09-03 2017-03-09 小野薬品工業株式会社 Ａｌｌｅｒｇｉｎ－１アンタゴニストによるがん免疫増強剤
KR102787845B1 (ko) 2015-09-14 2025-03-31 트웰브 테라퓨틱스, 아이엔씨. 이소퀴놀리논의 고체형, 그의 제조 방법, 이를 포함하는 조성물 및 이를 사용하는 방법
MA44909A (fr) 2015-09-15 2018-07-25 Acerta Pharma Bv Association thérapeutique d'un inhibiteur du cd19 et d'un inhibiteur de la btk
WO2017049143A1 (en) * 2015-09-18 2017-03-23 Dana-Farber Cancer Institute, Inc. Methods of reducing liver pd-1-expressing cd8+t cells using pd-1 fc fusion proteins that bind fc receptors
ES2968074T3 (es) 2015-09-23 2024-05-07 Mereo Biopharma 5 Inc Anticuerpo bi-específico anti-VEGF/DLL4 para su uso en el tratamiento del cáncer de ovario resistente al platino
LT3353210T (lt) 2015-09-25 2025-01-27 F. Hoffmann-La Roche Ag Antikūnai prieš tigit ir jų naudojimo būdai
WO2017058881A1 (en) * 2015-09-28 2017-04-06 The Trustees Of Columbia University In The City Of New York Use of pentoxifylline with immune checkpoint-blockade therapies for the treatment of melanoma
BR112018005349A2 (pt) * 2015-09-28 2018-10-09 Suzhou Suncadia Biopharmaceuticals Co., Ltd. preparação farmacêutica de anticorpo anti-pd-1 estável e sua aplicação em medicamentos
AR106184A1 (es) * 2015-09-29 2017-12-20 Celgene Corp Proteínas de unión a pd-1 y sus métodos de uso
WO2017055321A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of fibroblasts in a tissue sample
WO2017055326A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of myeloid dendritic cells in a tissue sample
WO2017055322A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of neutrophils in a tissue sample
WO2017055327A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of endothelial cells in a tissue sample
WO2017055325A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of nk cells in a tissue sample
WO2017055324A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of cells of monocytic origin in a tissue sample
EP3356551B1 (en) 2015-09-29 2020-09-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for determining the metabolic status of b-lymphomas
CN108368175B (zh) * 2015-09-29 2021-08-06 上海张江生物技术有限公司 Pd-1抗体及其用途
WO2017055319A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of b cells in a tissue sample
WO2017055320A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of cytotoxic lymphocytes in a tissue sample
US20180282415A1 (en) 2015-09-30 2018-10-04 Merck Patent Gmbh Combination of a PD-1 Axis Binding Antagonist and an ALK Inhibitor for Treating ALK-Negative Cancer
MX2018003905A (es) 2015-09-30 2018-09-06 Janssen Biotech Inc Anticuerpos agonistas que se unen específicamente a cd40 humana y métodos de uso.
US20190054090A1 (en) 2015-10-01 2019-02-21 Gilead Sciences, Inc. Combination of a btk inhibitor and a checkpoint inhibitor for treating cancers
AR106188A1 (es) 2015-10-01 2017-12-20 Hoffmann La Roche Anticuerpos anti-cd19 humano humanizados y métodos de utilización
US12030942B2 (en) 2015-10-02 2024-07-09 Les Laboratoires Servier Anti-PD-1 antibodies and compositions
HUE056033T2 (hu) * 2015-10-02 2022-01-28 Hoffmann La Roche Anti-pd1 antitestek és felhasználási módszerek
DK3368572T3 (da) 2015-10-02 2022-08-08 Symphogen As Anti-pd-1-antistoffer og -sammensætninger
CN108137699B (zh) 2015-10-02 2022-05-27 豪夫迈·罗氏有限公司 对pd1和tim3特异性的双特异性抗体
WO2017059902A1 (en) 2015-10-07 2017-04-13 Biontech Rna Pharmaceuticals Gmbh 3' utr sequences for stabilization of rna
KR20250079249A (ko) 2015-10-08 2025-06-04 마크로제닉스, 인크. 암 치료를 위한 조합 치료법
WO2017060397A1 (en) 2015-10-09 2017-04-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the survival time of subjects suffering from melanoma metastases
US20180280435A1 (en) * 2015-10-09 2018-10-04 Virginia Commonwealth University T cell delivery of mda-7/il-24 to improve therapeutic eradication of cancer and generate protective antitumor immunity
EP3362475B1 (en) 2015-10-12 2023-08-30 Innate Pharma Cd73 blocking agents
WO2017066414A1 (en) * 2015-10-14 2017-04-20 Endocyte, Inc. Drug delivery conjugates for use in combination therapy
WO2017066561A2 (en) 2015-10-16 2017-04-20 President And Fellows Of Harvard College Regulatory t cell pd-1 modulation for regulating t cell effector immune responses
EP3365062B1 (en) 2015-10-19 2024-09-18 CG Oncology, Inc. Methods of treating solid or lymphatic tumors by combination therapy
US10149887B2 (en) * 2015-10-23 2018-12-11 Canbas Co., Ltd. Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment
CN105238762A (zh) * 2015-10-26 2016-01-13 无锡傲锐东源生物科技有限公司 抗pd-1蛋白单克隆抗体杂交瘤细胞及其产生的抗pd-1单克隆抗体和应用
MA44334A (fr) 2015-10-29 2018-09-05 Novartis Ag Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
CN106632674B (zh) * 2015-10-30 2018-11-16 泽达生物医药有限公司 一种抗pd-1单克隆抗体、其药物组合物及其用途
CN108884139A (zh) 2015-11-02 2018-11-23 戊瑞治疗有限公司 Cd80胞外域多肽及其在癌症治疗中的用途
WO2017079202A1 (en) 2015-11-02 2017-05-11 Board Of Regents, The University Of Texas System Methods of cd40 activation and immune checkpoint blockade
EP3370768B9 (en) 2015-11-03 2022-03-16 Janssen Biotech, Inc. Antibodies specifically binding pd-1 and their uses
SMT202100192T1 (it) 2015-11-03 2021-05-07 Janssen Biotech Inc Formulazioni sottocutanee di anticorpi anti-cd38 e loro usi.
WO2017079622A1 (en) * 2015-11-04 2017-05-11 Emory University Immune cells with dnmt3a gene modifications and methods related thereto
EP3371210B1 (en) * 2015-11-04 2022-05-25 Taipei Veterans General Hospital Combination therapy for malignant diseases
US11702477B2 (en) 2015-11-06 2023-07-18 Orionis Biosciences BV Bi-functional chimeric proteins and uses thereof
AU2016349632A1 (en) 2015-11-07 2018-05-24 Multivir Inc. Compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer
PT3373959T (pt) 2015-11-12 2022-08-09 Hookipa Biotech Gmbh Partículas de arenavírus como vacinas contra o cancro
CN106699889A (zh) 2015-11-18 2017-05-24 礼进生物医药科技（上海）有限公司 抗pd-1抗体及其治疗用途
EP3377534B1 (en) 2015-11-18 2025-06-18 Bristol-Myers Squibb Company Treatment of lung cancer using a combination of an anti-pd-1 antibody and an anti-ctla-4 antibody
KR20180082563A (ko) 2015-11-19 2018-07-18 브리스톨-마이어스 스큅 컴퍼니 글루코코르티코이드-유도된 종양 괴사 인자 수용체 (gitr)에 대한 항체 및 그의 용도
EP3377107B1 (en) 2015-11-19 2020-08-12 H. Hoffnabb-La Roche Ag Methods of treating cancer using b-raf inhibitors and immune checkpoint inhibitors
PT3209310T (pt) 2015-11-20 2018-04-20 4D Pharma Res Ltd Composições compreendendo estirpes bacterianas
US11447553B2 (en) 2015-11-23 2022-09-20 Five Prime Therapeutics, Inc. FGFR2 inhibitors alone or in combination with immune stimulating agents in cancer treatment
CA3006934A1 (en) 2015-12-01 2017-06-08 Glaxosmithkline Intellectual Property Development Limited Combination of antibodies targeting bcma, pd-1 and ox40 in cancer treatments and uses therof
TWI717432B (zh) 2015-12-02 2021-02-01 美商艾吉納斯公司 抗體和使用彼之方法
WO2017096026A1 (en) 2015-12-02 2017-06-08 Stcube, Inc. Antibodies specific to glycosylated pd-1 and methods of use thereof
PE20181297A1 (es) 2015-12-03 2018-08-07 Glaxosmithkline Ip Dev Ltd Dinucleotidos de purino ciclico como moduladores de sting
WO2017098421A1 (en) 2015-12-08 2017-06-15 Glaxosmithkline Intellectual Property Development Limited Benzothiadiazine compounds
US10590169B2 (en) * 2015-12-09 2020-03-17 Virogin Biotech Canada Ltd Compositions and methods for inhibiting CD279 interactions
CA2997406C (en) 2015-12-09 2024-05-28 F. Hoffmann-La Roche Ag Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies or cytokine release
EP3178848A1 (en) 2015-12-09 2017-06-14 F. Hoffmann-La Roche AG Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies
JP6955507B2 (ja) 2015-12-14 2021-10-27 マクロジェニクス，インコーポレーテッド Ｐｄ‐１及びｃｔｌａ‐４との免疫応答性を有する二重特異性並びにその使用方法
SI3389699T1 (sl) * 2015-12-15 2024-07-31 OncoC4, Inc. Himerna in humanizirana monoklonska protitelesa proti humanemu ctla4 in uporabe le - teh
WO2017106062A1 (en) 2015-12-15 2017-06-22 Merck Sharp & Dohme Corp. Novel compounds as indoleamine 2,3-dioxygenase inhibitors
KR102833068B1 (ko) 2015-12-17 2025-07-14 노파르티스 아게 Pd-1에 대한 항체 분자 및 그의 용도
GB201522309D0 (en) 2015-12-17 2016-02-03 Photocure Asa Use
US10392442B2 (en) 2015-12-17 2019-08-27 Bristol-Myers Squibb Company Use of anti-PD-1 antibody in combination with anti-CD27 antibody in cancer treatment
EP3390361B1 (en) 2015-12-17 2022-03-16 Incyte Corporation N-phenyl-pyridine-2-carboxamide derivatives and their use as pd-1/pd-l1 protein/protein interaction modulators
EP4541807A3 (en) 2015-12-18 2025-09-24 Intervet International B.V. Caninized human antibodies to human and canine il-4r alpha
JP2019506844A (ja) 2015-12-18 2019-03-14 ノバルティス アーゲー ＣＤ３２ｂを標的とする抗体およびその使用方法
US11091556B2 (en) 2015-12-18 2021-08-17 Intervet Inc. Caninized human antibodies to human IL-4R alpha
US11433136B2 (en) 2015-12-18 2022-09-06 The General Hospital Corporation Polyacetal polymers, conjugates, particles and uses thereof
CA3008678A1 (en) 2015-12-21 2017-06-29 Bristol-Myers Squibb Company Variant antibodies for site-specific conjugation
JP7126941B2 (ja) 2015-12-22 2022-08-29 リジェネロン・ファーマシューティカルズ・インコーポレイテッド がんを治療するための抗ｐｄ－１抗体と二重特異性抗ｃｄ２０／抗ｃｄ３抗体の組合せ
JP7082055B2 (ja) 2015-12-22 2022-06-07 ノバルティス アーゲー 抗癌治療における組み合わせ使用のためのメソテリンキメラ抗原受容体（ｃａｒ）およびｐｄ－ｌ１阻害剤に対する抗体
TWI767896B (zh) 2015-12-22 2022-06-21 美商英塞特公司 作為免疫調節劑之雜環化合物
CN105669864B (zh) * 2015-12-23 2018-10-16 杭州尚健生物技术有限公司 抗人程序性死亡受体1抗体及其制备方法和用途
EP3405478A4 (en) * 2015-12-23 2019-10-30 Moonshot Pharma LLC METHOD FOR INDUCING AN IMMUNE RESPONSE BY INHIBITING NONSENSE-MEDIATED CRASH
RS63135B1 (sr) 2015-12-23 2022-05-31 Modernatx Inc Postupci upotrebe polinukleotida koji kodiraju ox40 ligand
US20200264165A1 (en) 2016-01-04 2020-08-20 Inserm (Institut National De La Sante Et De Larecherche Medicale) Use of pd-1 and tim-3 as a measure for cd8+ cells in predicting and treating renal cell carcinoma
CN106943597A (zh) 2016-01-07 2017-07-14 博笛生物科技（北京）有限公司 用于治疗肿瘤的抗-egfr组合
CN106943598A (zh) 2016-01-07 2017-07-14 博笛生物科技（北京）有限公司 用于治疗肿瘤的抗-her2组合
CN106943596A (zh) 2016-01-07 2017-07-14 博笛生物科技（北京）有限公司 用于治疗肿瘤的抗-cd20组合
US10596257B2 (en) 2016-01-08 2020-03-24 Hoffmann-La Roche Inc. Methods of treating CEA-positive cancers using PD-1 axis binding antagonists and anti-CEA/anti-CD3 bispecific antibodies
BR112018013761A2 (pt) 2016-01-08 2018-12-11 Celgene Corp compostos antiproliferativos e suas composições farmacêuticas e usos
SG11201805777QA (en) 2016-01-08 2018-08-30 Celgene Corp Formulations of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide
US10189808B2 (en) 2016-01-08 2019-01-29 Celgene Corporation Solid forms of 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide, and their pharmaceutical compositions and uses
EP3402819A1 (en) 2016-01-11 2018-11-21 Novartis AG Immune-stimulating humanized monoclonal antibodies against human interleukin-2, and fusion proteins thereof
ES2839408T3 (es) 2016-01-13 2021-07-05 Acerta Pharma Bv Combinaciones terapéuticas de un antifolato y un inhibidor de BTK
CN109069628A (zh) 2016-01-14 2018-12-21 Bps生物科学有限公司 抗pd-1抗体及其用途
CA3011460A1 (en) 2016-01-15 2017-07-20 Rfemb Holdings, Llc Immunologic treatment of cancer
SG10202000645SA (en) 2016-01-21 2020-03-30 Innate Pharma Neutralization of Inhibitory Pathways in Lymphocytes
US11214617B2 (en) 2016-01-22 2022-01-04 MabQuest SA Immunological reagents
EP3964529B1 (en) 2016-01-22 2025-03-26 Mabquest SA Non-blocking pd1 specific antibodies
JP7252760B2 (ja) 2016-01-22 2023-04-05 メルク・シャープ・アンド・ドーム・エルエルシー 抗凝固因子ｘｉ抗体
US20210206854A1 (en) * 2016-01-27 2021-07-08 Bristol-Myers Squibb Company Treatment of lung cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent
JP6970099B2 (ja) 2016-01-28 2021-11-24 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル ガンの処置のための方法及び医薬組成物
EP3407912B1 (en) 2016-01-28 2022-05-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for enhancing the potency of the immune checkpoint inhibitors
WO2017129763A1 (en) 2016-01-28 2017-08-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of signet ring cell gastric cancer
JP7166923B2 (ja) 2016-02-05 2022-11-08 オリオニス バイオサイエンシズ ビーブイ 標的療法剤およびその使用
AU2017217426B2 (en) * 2016-02-08 2022-12-01 Beyondspring Pharmaceuticals, Inc. Compositions containing tucaresol or its analogs
KR20180107151A (ko) 2016-02-17 2018-10-01 노파르티스 아게 Tgf베타 2 항체
CN109312347A (zh) 2016-02-19 2019-02-05 希望之城 双特异性适配子
MX384799B (es) 2016-02-19 2025-03-14 Novartis Ag Compuestos tetraciclicos de piridona como antivirales.
CA3013333A1 (en) 2016-02-26 2017-08-31 Inserm (Institut National De La Sante Et De La Recherche Medicale) Antibodies having specificity for btla and uses thereof
MX2018010361A (es) 2016-02-29 2019-07-08 Genentech Inc Métodos terapéuticos y de diagnóstico para el cáncer.
CN109476731A (zh) 2016-02-29 2019-03-15 基础医药有限公司 治疗癌症的方法
ES2731579T3 (es) 2016-03-04 2019-11-18 4D Pharma Plc Composiciones que comprenden cepas de blautia bacteriana para tratar hipersensibilidad visceral
SG10201601719RA (en) 2016-03-04 2017-10-30 Agency Science Tech & Res Anti-LAG-3 Antibodies
GB201612191D0 (en) 2016-07-13 2016-08-24 4D Pharma Plc Compositions comprising bacterial strains
US20200281973A1 (en) 2016-03-04 2020-09-10 Novartis Ag Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
JP2019514844A (ja) 2016-03-04 2019-06-06 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 抗ｃｄ７３抗体を用いた併用療法
US10143746B2 (en) 2016-03-04 2018-12-04 Bristol-Myers Squibb Company Immunomodulators
WO2017155981A1 (en) 2016-03-07 2017-09-14 Massachusetts Institute Of Technology Protein-chaperoned t-cell vaccines
JP7270379B2 (ja) 2016-03-08 2023-05-10 イナート・ファルマ・ソシエテ・アノニム Ｓｉｇｌｅｃ中和抗体
EP3426271B1 (en) 2016-03-10 2025-08-27 CG Oncology, Inc. Methods of treating solid tumors by combination therapy
WO2017153952A1 (en) 2016-03-10 2017-09-14 Glaxosmithkline Intellectual Property Development Limited 5-sulfamoyl-2-hydroxybenzamide derivatives
WO2017156483A1 (en) * 2016-03-11 2017-09-14 University Of Louisville Research Foundation, Inc. Methods and compositions for treating tumors
WO2017160599A1 (en) 2016-03-14 2017-09-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of cd300b antagonists to treat sepsis and septic shock
AU2017235097B2 (en) 2016-03-15 2023-08-31 Chugai Seiyaku Kabushiki Kaisha Methods of treating cancers using PD-1 axis binding antagonists and anti-GPC3 antibodies
EP4302782A3 (en) 2016-03-15 2024-03-27 Mersana Therapeutics, Inc. Napi2b-targeted antibody-drug conjugates and methods of use thereof
CN110753755B (zh) 2016-03-21 2023-12-29 丹娜法伯癌症研究院 T细胞耗竭状态特异性基因表达调节子及其用途
EP3433257B1 (en) 2016-03-24 2023-10-11 Novartis AG Alkynyl nucleoside analogs as inhibitors of human rhinovirus
WO2017165778A1 (en) 2016-03-24 2017-09-28 Millennium Pharmaceuticals, Inc. Methods of treating gastrointestinal immune-related adverse events in immune oncology treatments
WO2017165742A1 (en) 2016-03-24 2017-09-28 Millennium Pharmaceuticals, Inc. Methods of treating gastrointestinal immune-related adverse events in anti-ctla4 anti-pd-1 combination treatments
WO2017165681A1 (en) * 2016-03-24 2017-09-28 Gensun Biopharma Inc. Trispecific inhibitors for cancer treatment
ES2883297T3 (es) 2016-03-29 2021-12-07 Stcube Inc Anticuerpos de función doble específicos para PD-L1 glucosilado y métodos de uso de los mismos
KR20180130541A (ko) 2016-03-29 2018-12-07 주식회사 에스티큐브앤컴퍼니 글리코실화된 면역체크포인트 단백질에 특이적으로 결합하는 항체를 선택하는 방법
CN109715207B (zh) 2016-03-29 2023-03-31 南加利福尼亚大学 靶向癌症的嵌合抗原受体
EP3436829A1 (en) 2016-03-30 2019-02-06 Centre Léon-Bérard Lymphocytes expressing cd73 in cancerous patient dictates therapy
WO2017173091A1 (en) 2016-03-30 2017-10-05 Musc Foundation For Research Development Methods for treatment and diagnosis of cancer by targeting glycoprotein a repetitions predominant (garp) and for providing effective immunotherapy alone or in combination
CN109310757B (zh) * 2016-03-31 2025-07-15 江苏亚虹医药科技股份有限公司 硝羟喹啉和其类似物与化学疗法和免疫疗法在癌症治疗中的组合用途
CN107286242B (zh) * 2016-04-01 2019-03-22 中山康方生物医药有限公司 抗pd-1的单克隆抗体
EP3225253A1 (en) 2016-04-01 2017-10-04 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Cancer therapy with an oncolytic virus combined with a checkpoint inhibitor
WO2017176925A1 (en) 2016-04-05 2017-10-12 Bristol-Myers Squibb Company Cytokine profiling analysis for predicting prognosis of a patient in need of an anti-cancer treatment
US10358463B2 (en) 2016-04-05 2019-07-23 Bristol-Myers Squibb Company Immunomodulators
WO2017175156A1 (en) 2016-04-07 2017-10-12 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides useful as protein modulators
CN113549110B (zh) 2016-04-07 2024-08-16 葛兰素史密斯克莱知识产权发展有限公司 用作蛋白质调节剂的杂环酰胺
CA3019003A1 (en) 2016-04-08 2017-10-12 Gilead Sciences, Inc. Compositions and methods for treating cancer, inflammatory diseases and autoimmune diseases
KR102466763B1 (ko) 2016-04-13 2022-11-11 오리맵스 리미티드 항- psma 항체 및 이의 용도
MX392707B (es) 2016-04-13 2025-03-24 Vivia Biotech Sl LINFOCITOS T ACTIVADOS POR BiTE EX VIVO.
PL3443350T3 (pl) 2016-04-15 2021-05-31 F. Hoffmann-La Roche Ag Sposoby monitorowania i leczenia nowotworu
AU2017248766A1 (en) 2016-04-15 2018-11-01 Genentech, Inc. Methods for monitoring and treating cancer
CN116059351A (zh) 2016-04-18 2023-05-05 塞德斯医疗公司 结合人cd40的激动性抗体及其用途
US10779980B2 (en) 2016-04-27 2020-09-22 Synerz Medical, Inc. Intragastric device for treating obesity
WO2017188350A1 (ja) 2016-04-28 2017-11-02 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍の成長を抑制する方法
ES2913073T3 (es) 2016-04-29 2022-05-31 Icahn School Med Mount Sinai Direccionamiento del sistema inmunitario innato para inducir tolerancia a largo plazo y resolver la acumulación de macrófagos en aterosclerosis
EP4029950A1 (en) 2016-04-29 2022-07-20 Board of Regents, The University of Texas System Targeted measure of transcriptional activity related to hormone receptors
WO2017192874A1 (en) 2016-05-04 2017-11-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Albumin-binding immunomodulatory compositions and methods of use thereof
CN109328188A (zh) 2016-05-05 2019-02-12 葛兰素史密斯克莱知识产权（第2 号）有限公司 Zeste增强子同源物2抑制剂
MX2018013520A (es) * 2016-05-05 2019-06-10 Univ Pennsylvania Anticuerpos monoclonales de adn dirigidos a moléculas de punto de control.
IL321475A (en) 2016-05-06 2025-08-01 Medimmune Llc Bispecific binding proteins and their uses
SG10201603721TA (en) 2016-05-10 2017-12-28 Agency Science Tech & Res Anti-CTLA-4 Antibodies
EP3454909A1 (en) 2016-05-10 2019-03-20 Bristol-Myers Squibb Company Antibody-drug conjugates of tubulysin analogs with enhanced stability
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh) * 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
EP3243832A1 (en) 2016-05-13 2017-11-15 F. Hoffmann-La Roche AG Antigen binding molecules comprising a tnf family ligand trimer and pd1 binding moiety
CA3023883A1 (en) 2016-05-13 2017-11-16 Orionis Biosciences Nv Targeted mutant interferon-beta and uses thereof
TWI822521B (zh) * 2016-05-13 2023-11-11 美商再生元醫藥公司 藉由投予pd-1抑制劑治療皮膚癌之方法
US11753463B2 (en) 2016-05-13 2023-09-12 Orionis Biosciences BV Therapeutic targeting of non-cellular structures
CA3024509A1 (en) 2016-05-18 2017-11-23 Modernatx, Inc. Mrna combination therapy for the treatment of cancer
WO2017201325A1 (en) 2016-05-18 2017-11-23 Modernatx, Inc. Combinations of mrnas encoding immune modulating polypeptides and uses thereof
JP7246930B2 (ja) 2016-05-18 2023-03-28 モデルナティエックス インコーポレイテッド インターロイキン－１２（ｉｌ１２）をコードするポリヌクレオチドおよびその使用
EP3458485B1 (en) 2016-05-19 2021-12-29 The General Hospital Corporation Tethered interleukin-2 to its receptor il-2rbeta, a platform to enhance natural killer and regulatory t cell activity
CA3025024A1 (en) 2016-05-20 2017-11-23 Eli Lilly And Company Combination therapy with notch and pd-1 or pd-l1 inhibitors
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
CA3025019A1 (en) 2016-05-20 2017-11-23 Biohaven Pharmaceutical Holding Company Ltd. Use of glutamate modulating agents with immunotherapies to treat cancer
CN105968200B (zh) 2016-05-20 2019-03-15 瑞阳(苏州)生物科技有限公司 抗人pd-l1人源化单克隆抗体及其应用
US20190292259A1 (en) 2016-05-24 2019-09-26 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of non small cell lung cancer (nsclc) that coexists with chronic obstructive pulmonary disease (copd)
JP7160688B2 (ja) 2016-05-24 2022-10-25 ジェネンテック， インコーポレイテッド Ｃｂｐ／ｅｐ３００の複素環式インヒビターおよびがんの処置におけるそれらの使用
MA45146A (fr) 2016-05-24 2021-03-24 Constellation Pharmaceuticals Inc Dérivés de pyrazolopyridine pour le traitement du cancer
CN106008714B (zh) * 2016-05-24 2019-03-15 瑞阳(苏州)生物科技有限公司 抗人pd-1人源化单克隆抗体及其应用
JP7563872B2 (ja) 2016-05-25 2024-10-08 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 癌を処置するための方法及び組成物
MY195089A (en) 2016-05-27 2023-01-10 Agenus Inc Anti-Tim-3 Antibodies and Methods of use thereof
WO2017210335A1 (en) 2016-06-01 2017-12-07 Bristol-Myers Squibb Company Imaging methods using 18f-radiolabeled biologics
KR102397783B1 (ko) 2016-06-01 2022-05-12 브리스톨-마이어스 스큅 컴퍼니 Pd-l1 결합 폴리펩티드에 의한 pet 영상화
PL3464368T3 (pl) 2016-06-02 2023-08-28 Bristol-Myers Squibb Company Zastosowanie przeciwciała anty-pd-1 w skojarzeniu z przeciwciałem anty-cd30 w leczeniu chłoniaka
SMT202300290T1 (it) 2016-06-02 2023-11-13 Bristol Myers Squibb Co Blocco di pd-1 con nivolumab nel linfoma di hodgkin refrattario
US11419927B2 (en) 2016-06-02 2022-08-23 Ultimovacs As Vaccine in combination with an immune checkpoint inhibitor for use in treating cancer
JP2019517511A (ja) 2016-06-03 2019-06-24 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 腫瘍を処置する方法において使用するための抗ｐｄ−１抗体
EP3464373B1 (en) 2016-06-03 2021-10-27 Bristol-Myers Squibb Company Use of anti-pd-1 antibody in the treatment of patients with colorectal cancer
US20190292260A1 (en) 2016-06-03 2019-09-26 Bristol-Myers Squibb Company Anti-pd-1 antibody for use in a method of treatment of recurrent small cell lung cancer
GB201609811D0 (en) 2016-06-05 2016-07-20 Snipr Technologies Ltd Methods, cells, systems, arrays, RNA and kits
AU2017278245B2 (en) 2016-06-06 2022-09-15 Beyondspring Pharmaceuticals, Inc. Composition and method for reducing neutropenia
WO2017214182A1 (en) * 2016-06-07 2017-12-14 The United States Of America. As Represented By The Secretary, Department Of Health & Human Services Fully human antibody targeting pdi for cancer immunotherapy
EP3464347B1 (en) 2016-06-07 2023-05-31 Gliknik Inc. Cysteine-optimized stradomers
CA3026983A1 (en) 2016-06-08 2017-12-14 Glaxosmithkline Intellectual Property Development Limited Chemical compounds
KR20190015748A (ko) 2016-06-08 2019-02-14 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 Atf4 경로 억제제로서의 화학적 화합물
US10077308B2 (en) * 2016-06-13 2018-09-18 Askgene Pharma Inc. PD-L1 specific monoclonal antibodies for disease treatment and diagnosis
HRP20201524T1 (hr) 2016-06-14 2021-03-05 Novartis Ag Kristalni oblik (r)-4-(5-(ciklopropiletinil) izoksazol-3 -il)-n-hidroksi-2-metil-2-(metilsufonil) butanamid kao antibakterijsko sredstvo
WO2017218371A1 (en) 2016-06-14 2017-12-21 Merck Sharp & Dohme Corp. Anti-coagulation factor xi antibodies
WO2017216686A1 (en) 2016-06-16 2017-12-21 Novartis Ag 8,9-fused 2-oxo-6,7-dihydropyrido-isoquinoline compounds as antivirals
WO2017216685A1 (en) 2016-06-16 2017-12-21 Novartis Ag Pentacyclic pyridone compounds as antivirals
MA45404A (fr) * 2016-06-16 2019-04-24 Univ Leland Stanford Junior Anticorps monoclonaux humanisés et chimériques dirigés contre cd81
CN109890819B (zh) 2016-06-20 2022-11-22 因赛特公司 作为免疫调节剂的杂环化合物
EP3471754A1 (en) 2016-06-20 2019-04-24 Kymab Limited Anti-pd-l1 antibodies
SG11201811237WA (en) 2016-06-24 2019-01-30 Infinity Pharmaceuticals Inc Combination therapies
US11098077B2 (en) 2016-07-05 2021-08-24 Chinook Therapeutics, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
JP6993056B2 (ja) 2016-07-05 2022-02-15 ベイジーン リミテッド 癌治療のためのｐｄ－１アンタゴニスト及びｒａｆ阻害剤の組合せ
US11306143B2 (en) 2016-07-06 2022-04-19 Bristol-Myers Squibb Company Combination of TIM-4 antagonist and PD-1 antagonist and methods of use
JP7093771B2 (ja) 2016-07-07 2022-06-30 アイオバンス バイオセラピューティクス，インコーポレイテッド プログラム死１リガンド１（ｐｄ－ｌ１）結合タンパク質及びその使用方法
WO2018011166A2 (en) 2016-07-12 2018-01-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of myeloid dendritic cells in a tissue sample
TWI802545B (zh) 2016-07-13 2023-05-21 英商４Ｄ製藥有限公司 包含細菌菌株之組合物
RU2656181C1 (ru) * 2016-07-13 2018-05-31 Закрытое Акционерное Общество "Биокад" Анти-pd-1-антитела, способ их получения и способ применения
US20190248893A1 (en) 2016-07-14 2019-08-15 Bristol-Myers Squibb Company Antibodies against tim3 and uses thereof
EP3484516A4 (en) 2016-07-14 2020-03-18 Fred Hutchinson Cancer Research Center MULTIPLE CONSTRUCTIONS OF BI-SPECIFIC LINK AREAS HAVING A DIFFERENT EPITOPE LINK TO TREAT CANCER
CN109715173A (zh) 2016-07-15 2019-05-03 维拉克塔治疗公司 供基于nk细胞的疗法使用的hdac抑制剂
JP2019528251A (ja) 2016-07-20 2019-10-10 エスティーキューブ，インコーポレイテッド グリコシル化ｐｄ−ｌ１に結合する抗体の組合せを使用するがんの処置および治療の方法
CN116769050A (zh) 2016-07-20 2023-09-19 犹他大学研究基金会 Cd229 car t细胞及其使用方法
CN109789135A (zh) 2016-07-20 2019-05-21 葛兰素史密斯克莱知识产权发展有限公司 作为perk抑制剂的异喹啉衍生物
NL2017267B1 (en) 2016-07-29 2018-02-01 Aduro Biotech Holdings Europe B V Anti-pd-1 antibodies
US20190269666A1 (en) 2016-07-29 2019-09-05 Eli Lilly And Company Combination therapy with merestinib and anti-pd-l1 or anti-pd-1 inhibitors for use in the treatment of cancer
WO2018026606A1 (en) 2016-08-01 2018-02-08 Threshold Pharmaceuticals, Inc. Administration of hypoxia activated prodrugs in combination with immune modulatory agents for treating cancer
WO2018027039A1 (en) 2016-08-03 2018-02-08 Nextcure, Inc. Compositions and methods for modulating lair signal transduction
US11649289B2 (en) 2016-08-04 2023-05-16 Glaxosmithkline Intellectual Property Development Limited Anti-ICOS and anti-PD-1 antibody combination therapy
WO2018026248A1 (ko) * 2016-08-05 2018-02-08 주식회사 와이바이오로직스 프로그램화된 세포 사멸 단백질(pd-1)에 대한 신규 항체 및 이의 용도
CN109963871A (zh) 2016-08-05 2019-07-02 豪夫迈·罗氏有限公司 具有激动活性的多价及多表位抗体以及使用方法
CA3032783C (en) * 2016-08-05 2022-05-31 Y-Biologics Inc. Antibody to programmed cell death 1 (pd-1) and use thereof
JP7250674B2 (ja) 2016-08-08 2023-04-03 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト がんの治療及び診断方法
KR102604433B1 (ko) * 2016-08-09 2023-11-24 키맵 리미티드 항-icos 항체
WO2018027524A1 (en) 2016-08-09 2018-02-15 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibody formulation
WO2018029336A1 (en) 2016-08-12 2018-02-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for determining whether a subject was administered with an activator of the ppar beta/delta pathway.
MX2019001635A (es) 2016-08-12 2019-06-10 Genentech Inc Terapia de combinacion con un inhibidor de mek, un inhibidor del eje de pd-1, y un inhibidor de vegf.
CA3033900A1 (en) * 2016-08-15 2018-02-22 National University Corporation Hokkaido University Anti-pd-1 antibody
JP7023933B2 (ja) 2016-08-19 2022-02-22 ブリストル－マイヤーズ スクイブ カンパニー セコ－シクロプロパピロロインドール化合物、その抗体－薬物コンジュゲート、ならびに製造および使用方法
DK3500299T3 (da) 2016-08-19 2024-01-29 Beigene Switzerland Gmbh Kombination af zanubrutinib med et anti-CD20- eller et anti-PD-1-antistof til anvendelse i behandling af cancer
WO2018039131A1 (en) 2016-08-22 2018-03-01 Protiva Biotherapeutics, Inc. Anti-pd-1 antibodies, or fragments thereof, for treating hepatitis b
WO2018035710A1 (en) 2016-08-23 2018-03-01 Akeso Biopharma, Inc. Anti-ctla4 antibodies
CN106977602B (zh) 2016-08-23 2018-09-25 中山康方生物医药有限公司 一种抗pd1单克隆抗体、其药物组合物及其用途
CN112481217A (zh) 2016-09-01 2021-03-12 嵌合体生物工程公司 Gold优化的car t-细胞
CN109906082A (zh) 2016-09-07 2019-06-18 塔夫茨大学信托人 使用免疫dash抑制剂和pge2拮抗剂的组合治疗
AU2017322501A1 (en) 2016-09-09 2019-03-28 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Combination of an anti-CD20 antibody, PI3 kinase-delta inhibitor, and anti-PD-1 or anti-PD-L1 antibody for treating hematological cancers
TW201811788A (zh) 2016-09-09 2018-04-01 瑞士商諾華公司 作為抗病毒劑之多環吡啶酮化合物
US20190218294A1 (en) 2016-09-09 2019-07-18 Bristol-Myers Squibb Company Use of an anti-pd-1 antibody in combination with an anti-mesothelin antibody in cancer treatment
WO2018046736A1 (en) 2016-09-12 2018-03-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the survival time of patients suffering from cancer
WO2018046738A1 (en) 2016-09-12 2018-03-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the survival time of patients suffering from cancer
JP7262774B2 (ja) * 2016-09-13 2023-04-24 ノース カロライナ ステート ユニバーシティ 治療剤送達のための血小板組成物及び方法
HUE051700T2 (hu) 2016-09-14 2021-03-29 Abbvie Biotherapeutics Inc Anti-PD-1 antitestek
JP7072576B2 (ja) 2016-09-16 2022-05-20 シャンハイ・ヘンリウス・バイオテック・インコーポレイテッド 抗ｐｄ－１抗体
US11090391B2 (en) 2016-09-16 2021-08-17 The Johns Hopkins University Protein nanocages with enhanced mucus penetration for targeted tissue and intracellular delivery
EA201990747A1 (ru) 2016-09-19 2019-10-31 Способы лечения иммунных нарушений с применением белков, связывающих pd–1
US11524988B2 (en) 2016-09-19 2022-12-13 H. Lee Moffitt Cancer Center And Research Institute, Inc. Artificial antigen presenting cells for genetic engineering of immune cells
EP3515943A4 (en) 2016-09-19 2020-05-06 Celgene Corporation METHODS OF TREATING VITILIGO WITH PD-1 BINDING PROTEINS
WO2018057735A1 (en) 2016-09-21 2018-03-29 Nextcure, Inc. Antibodies for siglec-15 and methods of use thereof
CN114456269A (zh) * 2016-09-21 2022-05-10 基石药业（苏州）有限公司 一种新的pd-1单克隆抗体
WO2018057585A1 (en) 2016-09-21 2018-03-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric antigen receptor (car) that targets chemokine receptor ccr4 and its use
JP7101169B2 (ja) 2016-09-21 2022-07-14 シーストーン ファーマシューティカルズ プログラム死１（ｐｄ－１）に対する新規モノクローナル抗体
EP4360714A3 (en) 2016-09-21 2024-07-24 Nextcure, Inc. Antibodies for siglec-15 and methods of use thereof
EP3515453A1 (en) 2016-09-22 2019-07-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for reprograming immune environment in a subject in need thereof
US11673971B2 (en) 2016-09-23 2023-06-13 Marengo Therapeutics, Inc. Multispecific antibody molecules comprising lambda and kappa light chains
JP7089507B2 (ja) 2016-09-26 2022-06-22 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｐｄ－１軸阻害剤への応答を予測すること
AU2017335732B2 (en) 2016-09-27 2024-11-21 Board Of Regents, The University Of Texas System Methods for enhancing immune checkpoint blockade therapy by modulating the microbiome
EP3519827A1 (en) 2016-09-27 2019-08-07 Oncologie, Inc. Methods for treating cancer with bavituximab based on levels of 2-glycoprotein 1, and assays therefor
JOP20190061A1 (ar) 2016-09-28 2019-03-26 Novartis Ag مثبطات بيتا-لاكتاماز
CN109862917A (zh) 2016-09-29 2019-06-07 基因泰克公司 Mek抑制剂,pd-1轴抑制剂,和紫杉烷的组合疗法
TN2020000159A1 (en) 2016-10-04 2022-04-04 Merck Sharp & Dohme BENZO[b]THIOPHENE COMPOUNDS AS STING AGONISTS
CA3038712A1 (en) 2016-10-06 2018-04-12 Genentech, Inc. Therapeutic and diagnostic methods for cancer
CA3039451A1 (en) 2016-10-06 2018-04-12 Pfizer Inc. Dosing regimen of avelumab for the treatment of cancer
CN117866991A (zh) 2016-10-07 2024-04-12 诺华股份有限公司 用于治疗癌症的嵌合抗原受体
TWI764943B (zh) * 2016-10-10 2022-05-21 大陸商蘇州盛迪亞生物醫藥有限公司 一種抗pd-1抗體和vegfr抑制劑聯合在製備治療癌症的藥物中的用途
IL265962B2 (en) 2016-10-10 2025-10-01 Nat Institute For Biotechnology In The Negev Ltd Non-cytotoxic adapted cells and their use
RU2759728C2 (ru) 2016-10-11 2021-11-17 Ситлимик Инк. Лекарственное средство
CN117586403A (zh) 2016-10-11 2024-02-23 艾吉纳斯公司 抗lag-3抗体及其使用方法
CA3040458A1 (en) 2016-10-12 2018-04-19 Board Of Regents, The University Of Texas System Methods and compositions for tusc2 immunotherapy
MX2019003994A (es) 2016-10-14 2019-09-19 Merck Sharp & Dohme Combinacion de un antagonista de proteina de muerte programada-1 (pd-1) y eribulina para el tratamiento de cancer urotelial.
WO2018071576A1 (en) 2016-10-14 2018-04-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Treatment of tumors by inhibition of cd300f
TW201819380A (zh) 2016-10-18 2018-06-01 瑞士商諾華公司 作為抗病毒劑之稠合四環吡啶酮化合物
WO2018075447A1 (en) 2016-10-19 2018-04-26 The Trustees Of Columbia University In The City Of New York Combination of braf inhibitor, talimogene laherparepvec, and immune checkpoint inhibitor for use in the treatment cancer (melanoma)
US10398783B2 (en) 2016-10-20 2019-09-03 Bristol-Myers Squibb Company Antiproliferative compounds and conjugates made therefrom
CN110114368B (zh) 2016-10-24 2024-08-02 奥睿尼斯生物科学私人有限公司 靶向突变干扰素-γ及其用途
CN110099998A (zh) 2016-10-26 2019-08-06 艾欧凡斯生物治疗公司 冷冻保存的肿瘤浸润淋巴细胞的再刺激
WO2018081621A1 (en) 2016-10-28 2018-05-03 Bristol-Myers Squibb Company Methods of treating urothelial carcinoma using an anti-pd-1 antibody
EP3532091A2 (en) 2016-10-29 2019-09-04 H. Hoffnabb-La Roche Ag Anti-mic antibidies and methods of use
CN109963589B (zh) * 2016-10-30 2023-05-05 上海复宏汉霖生物技术股份有限公司 抗-pd-l1抗体及变异体
TWI788307B (zh) 2016-10-31 2023-01-01 美商艾歐凡斯生物治療公司 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
US11155624B2 (en) 2016-11-01 2021-10-26 Anaptysbio, Inc. Antibodies directed against programmed death-1 (PD-1)
KR20190098741A (ko) 2016-11-01 2019-08-22 아납티스바이오, 아이엔씨. T 세포 면역글로불린 및 뮤신 단백질 3(tim-3)에 대한 항체
EA201990787A1 (ru) 2016-11-02 2019-12-30 Энгмаб Сарл Биспецифичное антитело к всма и cd3 и иммунологическое лекарственное средство для комбинированного применения в лечении множественной миеломы
UY37463A (es) 2016-11-02 2018-05-31 Glaxosmithkline Ip No 2 Ltd Proteínas de unión
KR20190088480A (ko) 2016-11-02 2019-07-26 조운스 테라퓨틱스, 인크. Pd-1에 대한 항체 및 그의 용도
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
WO2018085555A1 (en) 2016-11-03 2018-05-11 Bristol-Myers Squibb Company Activatable anti-ctla-4 antibodies and uses thereof
US10342785B2 (en) 2016-11-04 2019-07-09 Askat Inc. Use of EP4 receptor antagonists for the treatment of NASH-associated liver cancer
US10988507B2 (en) 2016-11-07 2021-04-27 Bristol-Myers Squibb Company Immunomodulators
AU2017356860A1 (en) 2016-11-08 2019-05-16 Qilu Puget Sound Biotherapeutics Corporation Anti-PD1 and anti-CTLA4 antibodies
CA3043356A1 (en) 2016-11-09 2018-05-17 Musc Foundation For Research Development Cd38-nad+ regulated metabolic axis in anti-tumor immunotherapy
WO2018089688A1 (en) 2016-11-09 2018-05-17 Jinjun Shi Restoration of tumor suppression using mrna-based delivery system
US20190345500A1 (en) 2016-11-14 2019-11-14 |Nserm (Institut National De La Santé Et De La Recherche Médicale) Methods and pharmaceutical compositions for modulating stem cells proliferation or differentiation
CA3042435A1 (en) 2016-11-15 2018-05-24 Genentech, Inc. Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
MX419719B (es) 2016-11-17 2025-01-14 Iovance Biotherapeutics Inc Linfocitos infiltrantes de tumores remanentes y metodos de preparacion y uso de los mismos.
KR102585006B1 (ko) 2016-11-17 2023-10-05 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 Egfr 또는 her2 엑손 20 돌연변이를 갖는 암 세포에 대한 항종양 활성을 갖는 화합물
WO2018094282A1 (en) * 2016-11-18 2018-05-24 The Regents Of The University Of California Engineered antibodies and uses thereof
US11359018B2 (en) 2016-11-18 2022-06-14 Symphogen A/S Anti-PD-1 antibodies and compositions
US11279694B2 (en) 2016-11-18 2022-03-22 Sumitomo Dainippon Pharma Oncology, Inc. Alvocidib prodrugs and their use as protein kinase inhibitors
EP3541825A1 (en) 2016-11-21 2019-09-25 Idenix Pharmaceuticals LLC. Cyclic phosphate substituted nucleoside derivatives for the treatment of liver diseases
WO2018098352A2 (en) 2016-11-22 2018-05-31 Jun Oishi Targeting kras induced immune checkpoint expression
US11135307B2 (en) 2016-11-23 2021-10-05 Mersana Therapeutics, Inc. Peptide-containing linkers for antibody-drug conjugates
JP7626577B2 (ja) 2016-11-28 2025-02-07 中外製薬株式会社 リガンド結合活性が調整可能なリガンド結合分子
CA3045306A1 (en) 2016-11-29 2018-06-07 Boston Biomedical, Inc. Naphthofuran derivatives, preparation, and methods of use thereof
TW201825119A (zh) 2016-11-30 2018-07-16 日商協和醱酵麒麟有限公司 使用抗ccr4抗體及抗pd-1抗體治療癌症之方法
US11230596B2 (en) 2016-11-30 2022-01-25 Mereo Biopharma 5, Inc. Methods for treatment of cancer comprising TIGIT-binding agents
EP3548069A1 (en) 2016-12-01 2019-10-09 GlaxoSmithKline Intellectual Property Development Limited Combination therapy
WO2018102682A1 (en) 2016-12-01 2018-06-07 Regeneron Pharmaceuticals, Inc. Radiolabeled anti-pd-l1 antibodies for immuno-pet imaging
JP2020511407A (ja) 2016-12-01 2020-04-16 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ 併用療法
BR112019011025A2 (pt) 2016-12-03 2019-10-08 Juno Therapeutics Inc métodos para modulação de células t car
WO2018106738A1 (en) 2016-12-05 2018-06-14 Massachusetts Institute Of Technology Brush-arm star polymers, conjugates and particles, and uses thereof
JP6992068B2 (ja) 2016-12-07 2022-02-03 アジェナス インコーポレイテッド 抗ｃｔｌａ－４抗体およびそれらの使用方法
CN110300599B (zh) * 2016-12-07 2024-07-02 艾吉纳斯公司 抗体和其使用方法
CA3046515A1 (en) 2016-12-08 2018-06-14 Lixte Biotechnology, Inc. Oxabicycloheptanes for modulation of immune response
US11331372B2 (en) 2016-12-09 2022-05-17 Gliknik Inc. Methods of treating inflammatory disorders with multivalent Fc compounds
CN110177802A (zh) 2016-12-09 2019-08-27 格利克尼克股份有限公司 多聚化stradomer GL-2045的制造优化
MX2019006331A (es) 2016-12-12 2019-07-12 Genentech Inc Métodos para tratar el cáncer usando anticuerpos anti-pd-l1 y antiandrógenos.
CA3046961A1 (en) 2016-12-12 2018-06-21 Multivir Inc. Methods and compositions comprising viral gene therapy and an immune checkpoint inhibitor for treatment and prevention of cancer and infectious diseases
CA3046293A1 (en) 2016-12-12 2018-06-21 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate and immune checkpoint inhibitor
US20200095301A1 (en) 2016-12-14 2020-03-26 The Board Of Trustees Of The Leland Stanford Junior University Il-13 superkine: immune cell targeting constructs and methods of use thereof
WO2018112364A1 (en) 2016-12-16 2018-06-21 Evelo Biosciences, Inc. Combination therapies for treating melanoma
WO2018112360A1 (en) 2016-12-16 2018-06-21 Evelo Biosciences, Inc. Combination therapies for treating cancer
US11267883B2 (en) * 2016-12-21 2022-03-08 Cephalon, Inc. Antibodies that specifically bind to human IL-15 and uses thereof
SG11201906223TA (en) 2016-12-22 2019-08-27 Amgen Inc Benzisothiazole, isothiazolo[3,4-b]pyridine, quinazoline, phthalazine, pyrido[2,3-d]pyridazine and pyrido[2,3-d]pyrimidine derivatives as kras g12c inhibitors for treating lung, pancreatic or colorectal cancer
CN106519034B (zh) * 2016-12-22 2020-09-18 鲁南制药集团股份有限公司 抗pd-1抗体及其用途
GEAP202215134A (en) 2016-12-22 2022-05-10 Incyte Corp Heterocyclic compounds as immunomodulators
EP3558963B1 (en) 2016-12-22 2022-03-23 Incyte Corporation Bicyclic heteroaromatic compounds as immunomodulators
WO2018115458A1 (en) 2016-12-23 2018-06-28 Virttu Biologics Limited Treatment of cancer
JP7122758B2 (ja) * 2016-12-23 2022-08-22 アールイーエムディー バイオセラピューティクス，インコーポレイテッド プログラム死－１（ｐｄ－１）に結合する抗体を使用する免疫療法
KR102564766B1 (ko) * 2016-12-23 2023-08-08 각고호우징 게이오기주크 Cd8+ t-세포들의 유도를 위한 조성물 및 방법
WO2018122245A1 (en) 2016-12-28 2018-07-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of predicting the survival time of patients suffering from cms3 colorectal cancer
WO2018122249A1 (en) 2016-12-28 2018-07-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the survival time of patients suffering from a microsatellite stable colorectal cancer
EP3565837B1 (en) 2017-01-05 2024-04-10 Netris Pharma Combined treatment with netrin-1 interfering drug and immune checkpoint inhibitors drugs
CN110431135A (zh) 2017-01-06 2019-11-08 大连万春布林医药有限公司 微管蛋白结合化合物及其治疗用途
CA3049165A1 (en) 2017-01-06 2018-07-12 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof
WO2018129533A1 (en) 2017-01-09 2018-07-12 Shuttle Pharmaceuticals, Llc Selective histone deacetylase inhibitors for the treatment of human disease
CN110382000A (zh) 2017-01-09 2019-10-25 泰萨罗公司 用抗tim-3抗体治疗癌症的方法
US11584733B2 (en) 2017-01-09 2023-02-21 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
ES2945745T3 (es) 2017-01-09 2023-07-06 Tesaro Inc Métodos de tratamiento de cánceres con anticuerpos anti-PD-1
EP3565560B1 (en) 2017-01-09 2024-05-29 OnkosXcel Therapeutics, LLC Predictive and diagnostic methods for prostate cancer
WO2018132427A1 (en) 2017-01-10 2018-07-19 The General Hospital Corporation Targeted t cells with cytotoxicity toward immunosuppressive cells
MX2019008346A (es) 2017-01-13 2019-09-09 Agenus Inc Receptores de celulas t que se unen a ny-eso-1 y metodos de uso de estos.
WO2018134279A1 (en) 2017-01-18 2018-07-26 Pieris Pharmaceuticals Gmbh Novel fusion polypeptides specific for lag-3 and pd-1
EP3570870A1 (en) 2017-01-20 2019-11-27 Novartis AG Combination therapy for the treatment of cancer
CN108341871A (zh) * 2017-01-24 2018-07-31 三生国健药业（上海）股份有限公司 抗pd-1单克隆抗体及其制备方法和应用
WO2018140391A1 (en) 2017-01-24 2018-08-02 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
US11555038B2 (en) 2017-01-25 2023-01-17 Beigene, Ltd. Crystalline forms of (S)-7-(1-(but-2-ynoyl)piperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
WO2018140671A1 (en) 2017-01-27 2018-08-02 Celgene Corporation 3-(1-oxo-4-((4-((3-oxomorpholino) methyl)benzyl)oxy)isoindolin-2-yl)piperidine-2,6-dione and isotopologues thereof
KR20240110997A (ko) 2017-02-01 2024-07-16 비욘드스프링 파마수티컬스, 인코포레이티드. 호중구감소증의 감소 방법
JOP20190187A1 (ar) 2017-02-03 2019-08-01 Novartis Ag مترافقات عقار جسم مضاد لـ ccr7
KR102642385B1 (ko) 2017-02-06 2024-03-04 오리오니스 바이오사이언시스 엔브이 표적화된 키메라 단백질 및 이의 용도
EP3577138A1 (en) 2017-02-06 2019-12-11 Innate Pharma Immunomodulatory antibody drug conjugates binding to a human mica polypeptide
JP7586579B2 (ja) 2017-02-06 2024-11-19 オリオンズ バイオサイエンス インコーポレイテッド 標的化改変型インターフェロン及びその使用
WO2018146148A1 (en) 2017-02-07 2018-08-16 INSERM (Institut National de la Santé et de la Recherche Médicale) A method for predicting the response to checkpoint blockade cancer immunotherapy
WO2018146128A1 (en) 2017-02-07 2018-08-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Detection of kit polymorphism for predicting the response to checkpoint blockade cancer immunotherapy
WO2018147275A1 (ja) 2017-02-08 2018-08-16 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍治療用医薬組成物
PL3579874T3 (pl) 2017-02-10 2022-02-28 Novartis Ag 1-(4-amino-5-bromo-6-(1 h-pirazol-1-ilo)pirymidyn-2-ylo)-1 h-pirazol-4-ol i jego zastosowanie w leczeniu nowotworu złośliwego
US20190375847A1 (en) 2017-02-15 2019-12-12 Glaxosmithkline Intellectual Property Development Limited Combination treatment for cancer
US20200291089A1 (en) 2017-02-16 2020-09-17 Elstar Therapeutics, Inc. Multifunctional molecules comprising a trimeric ligand and uses thereof
CN117442719A (zh) 2017-02-21 2024-01-26 瑞泽恩制药公司 用于治疗肺癌的抗pd-1抗体
WO2018156434A1 (en) 2017-02-22 2018-08-30 H. Lee Moffitt Cancer Center And Research Institute Inc. Tim3-binding chimeric antigen receptors
US12077590B2 (en) 2017-02-22 2024-09-03 H. Lee Moffitt Cancer Center And Research Institute, Inc. Bispecific antibody for cancer immunotherapy
EP3585431A4 (en) 2017-02-24 2020-12-16 MacroGenics, Inc. BISPECIFIC BINDING MOLECULES CAPABLE OF BINDING TO CD137 AND TUMOR ANTIGENS, AND THEIR USES
EP3585437B1 (en) 2017-02-24 2022-12-21 Bayer Pharma Aktiengesellschaft Combinations of copanlisib with anti-pd-1 antibody
CA3054571A1 (en) 2017-02-24 2018-08-30 Board Of Regents,The University Of Texas System Assay for detection of early stage pancreatic cancer
WO2018156888A1 (en) 2017-02-24 2018-08-30 Biothera Pharmaceuticals, Inc. Beta glucan immunopharmacodynamics
CN110573504A (zh) 2017-02-27 2019-12-13 葛兰素史克知识产权开发有限公司 作为激酶抑制剂的杂环酰胺
US20200069685A1 (en) 2017-02-27 2020-03-05 Novartis Ag Dosing schedule for a combination of Ceritinib and an anti-PD-1 antibody molecule
TW201834697A (zh) 2017-02-28 2018-10-01 美商梅爾莎納醫療公司 Her2標靶抗體－藥物結合物之組合療法
CR20190444A (es) 2017-02-28 2019-12-17 Sanofi Sa Arn terapéutico
EP3366703B1 (en) 2017-02-28 2019-04-03 Ralf Kleef Immune checkpoint therapy with hyperthermia
AU2018227428A1 (en) 2017-02-28 2019-10-17 Bristol-Myers Squibb Company Use of anti-CTLA-4 antibodies with enhanced ADCC to enhance immune response to a vaccine
KR20190134631A (ko) 2017-03-01 2019-12-04 제넨테크, 인크. 암의 진단 및 치료 방법
CN110637031B (zh) * 2017-03-04 2024-04-16 湘潭腾华生物科技有限公司 程序性死亡蛋白1(pd-1)的重组抗体及其用途
WO2018163051A1 (en) 2017-03-06 2018-09-13 Novartis Ag Methods of treatment of cancer with reduced ubb expression
WO2018167778A1 (en) 2017-03-12 2018-09-20 Yeda Research And Development Co. Ltd. Methods of diagnosing and prognosing cancer
WO2018167780A1 (en) 2017-03-12 2018-09-20 Yeda Research And Development Co. Ltd. Methods of prognosing and treating cancer
IL269000B2 (en) 2017-03-15 2024-06-01 Cue Biopharma Inc Methods for modulating an immune response
WO2018170288A1 (en) 2017-03-15 2018-09-20 Pandion Therapeutics, Inc. Targeted immunotolerance
JP2020510050A (ja) 2017-03-15 2020-04-02 アムジエン・インコーポレーテツド がんを治療するための、腫瘍溶解性ウイルスの単独又はチェックポイント阻害剤との組み合わせでの使用
MX2019010848A (es) 2017-03-16 2019-10-30 Innate Pharma Composiciones y procedimientos para el tratamiento del cancer.
EP3600427A1 (en) 2017-03-24 2020-02-05 INSERM - Institut National de la Santé et de la Recherche Médicale Methods and compositions for treating melanoma
CN108623686A (zh) 2017-03-25 2018-10-09 信达生物制药(苏州)有限公司 抗ox40抗体及其用途
WO2018183488A1 (en) 2017-03-28 2018-10-04 Ohio State Innovation Foundation Human pd1 peptide vaccines and uses thereof
US11254913B1 (en) 2017-03-29 2022-02-22 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
JOP20190224A1 (ar) 2017-03-29 2019-09-26 Iovance Biotherapeutics Inc عمليات من أجل إنتاج الخلايا اللمفاوية المرتشحة للأورام واستخداماتها في العلاج المناعي
KR20190141658A (ko) * 2017-03-29 2019-12-24 셀진 코포레이션 Pd-1 결합 단백질을 포함하는 제제 및 이의 제조 방법
KR102328463B1 (ko) 2017-03-31 2021-11-17 후지필름 가부시키가이샤 리포솜 조성물 및 의약 조성물
KR102775647B1 (ko) 2017-03-31 2025-03-06 브리스톨-마이어스 스큅 컴퍼니 종양을 치료하는 방법
JP2020515600A (ja) 2017-03-31 2020-05-28 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗がん併用療法
US20200031944A1 (en) 2017-03-31 2020-01-30 Five Prime Therapeutics, Inc. Combination therapy for cancer using anti-gitr antibodies
CR20190426A (es) 2017-04-03 2019-11-01 Hoffmann La Roche Inmunoconjugados
US11571459B2 (en) 2017-04-03 2023-02-07 Oncxerna Therapeutics, Inc. Methods for treating cancer using PS-targeting antibodies with immuno-oncology agents
WO2018185618A1 (en) 2017-04-03 2018-10-11 Novartis Ag Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment
EP3606550A2 (en) 2017-04-03 2020-02-12 Neon Therapeutics, Inc. Protein antigens and uses thereof
JP2020516604A (ja) 2017-04-05 2020-06-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗がん併用療法
WO2018185043A1 (en) 2017-04-05 2018-10-11 F. Hoffmann-La Roche Ag Bispecific antibodies specifically binding to pd1 and lag3
US11939380B2 (en) 2017-04-05 2024-03-26 Les Laboratoires Servier Combination therapies targeting PD-1, TIM-3, and LAG-3
US11603407B2 (en) 2017-04-06 2023-03-14 Regeneron Pharmaceuticals, Inc. Stable antibody formulation
TWI788340B (zh) 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 抗icos促效劑抗體及其用途
KR20190136076A (ko) 2017-04-13 2019-12-09 에프. 호프만-라 로슈 아게 암 치료 방법에 사용하기 위한 인터루킨-2 면역접합체, cd40 작용제 및 임의적인 pd-1 축 결합 길항제
WO2018191502A2 (en) 2017-04-13 2018-10-18 Agenus Inc. Anti-cd137 antibodies and methods of use thereof
AU2018251993A1 (en) 2017-04-14 2019-10-24 Genentech, Inc. Diagnostic and therapeutic methods for cancer
CN108728444A (zh) 2017-04-18 2018-11-02 长春华普生物技术股份有限公司 免疫调节性多核苷酸及其应用
US12460208B2 (en) 2017-04-18 2025-11-04 Parr Biotechnology Co., Ltd. Immunomodulatory polynucleotides and uses thereof
JP7264060B2 (ja) 2017-04-18 2023-04-25 テンペスト セラピューティクス，インク． 二環式化合物および癌の処置におけるそれらの使用
CA3058944A1 (en) 2017-04-19 2018-10-25 Elstar Therapeutics, Inc. Multispecific molecules and uses thereof
CN106939049B (zh) * 2017-04-20 2019-10-01 苏州思坦维生物技术股份有限公司 拮抗抑制人pd-1抗原与其配体结合的单克隆抗体及其制备方法与应用
JOP20180040A1 (ar) 2017-04-20 2019-01-30 Gilead Sciences Inc مثبطات pd-1/pd-l1
KR20190137911A (ko) 2017-04-21 2019-12-11 신라젠(주) 항암 백시니아 바이러스와 관문 저해제 병용 요법
US11760777B2 (en) 2017-04-26 2023-09-19 Bristol-Myers Squibb Company Methods of antibody production that minimize disulfide bond reduction
CN118515666A (zh) 2017-04-27 2024-08-20 博笛生物科技有限公司 2-氨基-喹啉衍生物
AR111419A1 (es) 2017-04-27 2019-07-10 Novartis Ag Compuestos fusionados de indazol piridona como antivirales
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
WO2018201056A1 (en) 2017-04-28 2018-11-01 Novartis Ag Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
EA201992586A1 (ru) 2017-04-28 2020-03-03 Файв Прайм Терапьютикс, Инк. Способы лечения с помощью полипептидов внеклеточного домена cd80
CN110678750A (zh) 2017-04-28 2020-01-10 美国默沙东药厂 用于癌症治疗的生物标志物
AR111651A1 (es) 2017-04-28 2019-08-07 Novartis Ag Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
EP3615068A1 (en) 2017-04-28 2020-03-04 Novartis AG Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
CA3059769A1 (en) 2017-04-28 2018-11-01 Elstar Therapeutics, Inc. Multispecific molecules comprising a non-immunoglobulin heterodimerization domain and uses thereof
EP3619230A4 (en) * 2017-05-01 2021-04-21 The Children's Medical Center Corporation PROCEDURES AND COMPOSITIONS RELATED TO ANTI-PD1 ANTIBODY REAGENTS
MA50957A (fr) 2017-05-01 2020-10-14 Agenus Inc Anticorps anti-tigit et leurs méthodes d'utilisation
AU2018263868A1 (en) 2017-05-02 2019-12-12 Merck Sharp & Dohme Llc Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
BR112019022695A2 (pt) * 2017-05-02 2020-05-26 Merck Sharp & Dohme Corp. Formulações estáveis de anticorpos anti-ctla4 isolados e em combinação com anticorpos do receptor de morte programada 1 (pd-1) e métodos de uso das mesmas
UY37718A (es) 2017-05-05 2018-11-30 Novartis Ag 2-quinolinonas triciclicas como agentes antibacteriales
WO2018209270A1 (en) 2017-05-11 2018-11-15 Northwestern University Adoptive cell therapy using spherical nucleic acids (snas)
CN110891974B (zh) 2017-05-12 2021-08-06 哈普恩治疗公司 间皮素结合蛋白质
US11466047B2 (en) 2017-05-12 2022-10-11 Merck Sharp & Dohme Llc Cyclic di-nucleotide compounds as sting agonists
WO2018213297A1 (en) 2017-05-16 2018-11-22 Bristol-Myers Squibb Company Treatment of cancer with anti-gitr agonist antibodies
CA3061888A1 (en) 2017-05-16 2018-11-22 Eisai R&D Management Co., Ltd. Treatment of hepatocellular carcinoma
WO2018213424A1 (en) 2017-05-17 2018-11-22 Boston Biomedical, Inc. Methods for treating cancer
US11421011B2 (en) 2017-05-18 2022-08-23 Modernatx, Inc. Polynucleotides encoding tethered interleukin-12 (IL12) polypeptides and uses thereof
CA3060618A1 (en) 2017-05-19 2018-11-22 Wuxi Biologics (Shanghai) Co. Ltd. Novel monoclonal antibodies to cytotoxic t-lymphocyte-associated protein 4 (ctla-4)
AR111760A1 (es) 2017-05-19 2019-08-14 Novartis Ag Compuestos y composiciones para el tratamiento de tumores sólidos mediante administración intratumoral
CN108948194B (zh) * 2017-05-19 2023-02-17 上海药明生物技术有限公司 一种新的ctla-4单克隆抗体
DK3630136T3 (da) 2017-05-22 2021-05-25 4D Pharma Res Ltd Sammensætninger, der omfatter bakteriestammer
JOP20190272A1 (ar) 2017-05-22 2019-11-21 Amgen Inc مثبطات kras g12c وطرق لاستخدامها
CN108948206B (zh) * 2017-05-23 2022-08-23 赵磊 一种抗egfr/pd-1双靶向抗体、其制备方法及用途
WO2018215937A1 (en) 2017-05-24 2018-11-29 Novartis Ag Interleukin-7 antibody cytokine engrafted proteins and methods of use in the treatment of cancer
TW201907931A (zh) 2017-05-24 2019-03-01 英商4D製藥研究有限公司 包含細菌菌株之組合物
WO2018215938A1 (en) 2017-05-24 2018-11-29 Novartis Ag Antibody-cytokine engrafted proteins and methods of use
MY206158A (en) 2017-05-24 2024-12-02 Novartis Ag Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer
MX2019013517A (es) 2017-05-24 2020-08-17 Pandion Operations Inc Inmunotolerancia dirigida.
CA3064321A1 (en) 2017-05-25 2018-11-29 Bristol-Myers Squibb Company Antibodies comprising modified heavy constant regions
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
WO2018219956A1 (en) 2017-05-29 2018-12-06 Gamamabs Pharma Cancer-associated immunosuppression inhibitor
CN110678200B (zh) 2017-05-30 2024-05-17 百时美施贵宝公司 包含抗lag-3抗体或抗lag-3抗体和抗pd-1或抗pd-l1抗体的组合物
JP2020522691A (ja) 2017-05-30 2020-07-30 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｌａｇ−３陽性腫瘍の処置
EP3630842A2 (en) 2017-05-30 2020-04-08 Bristol-Myers Squibb Company Compositions comprising a combination of an anti-lag-3 antibody, a pd-1 pathway inhibitor, and an immunotherapeutic agent
EP3630836A1 (en) 2017-05-31 2020-04-08 Elstar Therapeutics, Inc. Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof
JOP20190279A1 (ar) 2017-05-31 2019-11-28 Novartis Ag الصور البلورية من 5-برومو -2، 6-داي (1h-بيرازول -1-يل) بيريميدين -4- أمين وأملاح جديدة
WO2018222685A1 (en) 2017-05-31 2018-12-06 Stcube & Co., Inc. Methods of treating cancer using antibodies and molecules that immunospecifically bind to btn1a1
US20200181274A1 (en) 2017-06-01 2020-06-11 Novartis Ag Bispecific antibodies that bind cd 123 cd3
BR112019025188A2 (pt) 2017-06-01 2020-06-23 Cytomx Therapeutics, Inc. Anticorpos anti-pdl1 ativáveis e métodos de uso dos mesmos
WO2018223004A1 (en) 2017-06-01 2018-12-06 Xencor, Inc. Bispecific antibodies that bind cd20 and cd3
JP7780857B2 (ja) 2017-06-01 2025-12-05 ブリストル－マイヤーズ スクイブ カンパニー 抗ｐｄ－１抗体を用いる腫瘍の治療方法
CN118662614A (zh) 2017-06-02 2024-09-20 朱诺治疗学股份有限公司 使用过继细胞疗法治疗的制品和方法
WO2018222989A1 (en) 2017-06-02 2018-12-06 The Penn State Research Foundation Ceramide nanoliposomes, compositions and methods of using for immunotherapy
MX2019014199A (es) 2017-06-02 2020-01-23 Boehringer Ingelheim Int Tratamiento de combinacion antineoplasico.
EP3635097A1 (en) 2017-06-05 2020-04-15 Iovance Biotherapeutics, Inc. Methods of using tumor infiltrating lymphocytes in double-refractory melanoma
US11542331B2 (en) 2017-06-06 2023-01-03 Stcube & Co., Inc. Methods of treating cancer using antibodies and molecules that bind to BTN1A1 or BTN1A1-ligands
WO2018225093A1 (en) 2017-06-07 2018-12-13 Glaxosmithkline Intellectual Property Development Limited Chemical compounds as atf4 pathway inhibitors
WO2018226336A1 (en) 2017-06-09 2018-12-13 Providence Health & Services - Oregon Utilization of cd39 and cd103 for identification of human tumor reactive cells for treatment of cancer
WO2018224166A1 (en) 2017-06-09 2018-12-13 Biontech Rna Pharmaceuticals Gmbh Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy
CA3066048A1 (en) 2017-06-09 2018-12-13 Glaxosmithkline Intellectual Property Development Limited Combination therapy
IL283973B (en) 2017-06-14 2022-08-01 4D Pharma Res Ltd Compositions comprising bacterial strains
MA49425A (fr) 2017-06-14 2020-04-22 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
WO2018229188A1 (en) 2017-06-14 2018-12-20 4D Pharma Research Limited Compositions comprising bacterial strains
WO2018229715A1 (en) 2017-06-16 2018-12-20 Novartis Ag Compositions comprising anti-cd32b antibodies and methods of use thereof
AU2018287317B2 (en) 2017-06-19 2024-06-20 Medicenna Therapeutics Inc. Uses and methods for IL-2 superagonists, agonists, and fusions thereof
JP2020524157A (ja) 2017-06-20 2020-08-13 アンスティテュート キュリー がん併用療法における使用のためのｓｕｖ３９ｈ１ヒストンメチルトランスフェラーゼの阻害剤
JP2020525434A (ja) 2017-06-22 2020-08-27 ムーンショット ファーマ エルエルシー アンレキサノクス及び免疫調節剤を含む組成物で癌を治療する方法
MX2019015731A (es) 2017-06-22 2020-08-03 Celgene Corp Tratamiento de carcinoma hepatocelular caracterizado por infeccion por virus de hepatitis b.
US20200172628A1 (en) 2017-06-22 2020-06-04 Novartis Ag Antibody molecules to cd73 and uses thereof
CU24606B1 (es) 2017-06-22 2022-06-06 Novartis Ag Moléculas de anticuerpo que se unen a cd73
JP7080501B2 (ja) 2017-06-23 2022-06-06 バーディー バイオファーマシューティカルズ インコーポレイテッド 医薬品組成物
CN110997698B (zh) 2017-06-23 2023-12-26 百时美施贵宝公司 充当pd-1拮抗剂的免疫调节剂
CN110799537B (zh) * 2017-06-25 2023-07-28 西雅图免疫公司 抗pd-1抗体及其制备和使用方法
CN110831972B (zh) * 2017-06-25 2023-05-12 西雅图免疫公司 抗pd-l1抗体及其制备和使用方法
CN110799543A (zh) 2017-06-26 2020-02-14 百济神州有限公司 肝细胞癌的免疫治疗
KR20220031738A (ko) 2017-06-27 2022-03-11 주식회사 뉴라클사이언스 암 치료를 위한 항-fam19a5 항체의 용도
CA3066747A1 (en) 2017-06-27 2019-01-03 Novartis Ag Dosage regimens for anti-tim-3 antibodies and uses thereof
WO2019006427A1 (en) 2017-06-29 2019-01-03 Juno Therapeutics, Inc. WALL MODEL FOR ASSESSING TOXICITIES ASSOCIATED WITH IMMUNOTHERAPIES
TWI828626B (zh) * 2017-06-30 2024-01-11 日商小野藥品工業股份有限公司 併用包含溶血性鏈球菌之菌體的製劑的療法
DK3644999T3 (da) 2017-06-30 2023-03-06 Celgene Corp Sammensætninger og fremgangsmåder til anvendelse af 2-(4-chlorphenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoracetamid
US20210145771A1 (en) 2017-07-03 2021-05-20 Glaxosmithkline Intellectual Property Development Limited N-(3-(2-(4-chlorophenoxy)acetamido)bicyclo[1.1.1] pentan-1-yl)-2-cyclobutane-1- carboxamide derivatives and related compounds as atf4 inhibitors for treating cancer and other diseases
US20200140383A1 (en) 2017-07-03 2020-05-07 Glaxosmithkline Intellectual Property Development Limited 2-(4-chlorophenoxy)-n-((1 -(2-(4-chlorophenoxy)ethynazetidin-3-yl)methyl)acetamide derivatives and related compounds as atf4 inhibitors for treating cancer and other diseases
IL271833B2 (en) 2017-07-06 2024-09-01 Merus Nv Antibodies that modulate a biological activity expressed by a cell
IL313753A (en) 2017-07-06 2024-08-01 Merus Nv Bispecific anti pd1-anti tim3 antibodies
JP7438098B2 (ja) * 2017-07-06 2024-02-26 メルス ナムローゼ フェンノートシャップ 細胞により発現される生物学的活性を調節する結合分子
GB201710973D0 (en) 2017-07-07 2017-08-23 Avacta Life Sciences Ltd Scaffold proteins
WO2019010383A1 (en) 2017-07-07 2019-01-10 H. Lee Moffitt Cancer Center And Research Institute, Inc. CHIMERIC ANTIGENIC RECEPTORS WITH MUTED CD28 COSTIMULATORY DOMAINS
CA3066514A1 (en) 2017-07-10 2019-01-17 Innate Pharma Siglec-9-neutralizing antibodies
ES2992913T3 (en) 2017-07-10 2024-12-19 Celgene Corp 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-l-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-l-yl)-3-fluorobenzonitrile as antiproliferative compound
WO2019016174A1 (en) 2017-07-18 2019-01-24 Institut Gustave Roussy METHOD FOR ASSESSING RESPONSE TO TARGETING DRUG PD-1 / PDL-1 MEDICINES
IL319798A (en) 2017-07-20 2025-05-01 Novartis Ag ANTI-LAG-3 Antibody Dosage Regimens and Their Uses
KR20200093518A (ko) 2017-07-21 2020-08-05 제넨테크, 인크. 암에 대한 치료 및 진단 방법
EP3658173A1 (en) 2017-07-25 2020-06-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for modulating monocytopoiesis
CA3070446A1 (en) 2017-07-25 2019-01-31 Immutics, Inc. Treating cancer by blocking the interaction of tim-3 and its ligand
WO2019021208A1 (en) 2017-07-27 2019-01-31 Glaxosmithkline Intellectual Property Development Limited USEFUL INDAZOLE DERIVATIVES AS PERK INHIBITORS
JP7274454B2 (ja) 2017-07-28 2023-05-16 ブリストル－マイヤーズ スクイブ カンパニー チェックポイント阻害薬のための予測末梢血バイオマーカー
EP3661522A2 (en) 2017-08-03 2020-06-10 Otsuka Pharmaceutical Co., Ltd. Drug compound and purification methods thereof
KR102414120B1 (ko) 2017-08-03 2022-06-28 암젠 인크 인터류킨-21 뮤테인 및 치료 방법
MA49772A (fr) 2017-08-04 2021-04-21 Merck Sharp & Dohme Agonistes benzo[b]thiophène de sting pour le traitement du cancer
EP3661499A4 (en) 2017-08-04 2021-04-21 Merck Sharp & Dohme Corp. COMBINATIONS OF PD-1 ANTAGONISTS AND BENZO [B]
US10457681B2 (en) 2017-08-16 2019-10-29 Bristol_Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a tricyclic moiety, conjugates thereof, and methods and uses therefor
US10472361B2 (en) 2017-08-16 2019-11-12 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a benzotriazole moiety, conjugates thereof, and methods and uses therefor
US10487084B2 (en) 2017-08-16 2019-11-26 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a heterobiaryl moiety, conjugates thereof, and methods and uses therefor
US10508115B2 (en) 2017-08-16 2019-12-17 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having heteroatom-linked aromatic moieties, conjugates thereof, and methods and uses therefor
US10494370B2 (en) 2017-08-16 2019-12-03 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a pyridine or pyrazine moiety, conjugates thereof, and methods and uses therefor
MX2020001875A (es) 2017-08-18 2020-07-29 Tragara Pharmaceuticals Inc Forma polimorfica de tg02.
CN111511762B (zh) 2017-08-21 2025-05-06 天演药业公司 抗cd137分子及其用途
CN107383174B (zh) * 2017-08-21 2019-01-18 生工生物工程（上海）股份有限公司 一种能与pd-1特异性结合的肿瘤抑制肽及其用途
KR20200044899A (ko) 2017-08-28 2020-04-29 브리스톨-마이어스 스큅 컴퍼니 암의 치료 및 진단을 위한 tim-3 길항제
KR20200052327A (ko) 2017-09-04 2020-05-14 아게누스 인코포레이티드 혼합 계통 백혈병 (mll)-특이적 포스포펩타이드에 결합하는 t 세포 수용체 및 그것의 사용 방법
UY37866A (es) 2017-09-07 2019-03-29 Glaxosmithkline Ip Dev Ltd Nuevos compuestos derivados de benzoimidazol sustituidos que reducen la proteína myc (c-myc) en las células e inhiben la histona acetiltransferasa de p300/cbp.
WO2019051164A1 (en) 2017-09-07 2019-03-14 Augusta University Research Institute, Inc. ANTIBODIES AGAINST PROTEIN 1 OF PROGRAMMED CELL DEATH
EP4403175A3 (en) 2017-09-08 2024-10-02 Amgen Inc. Inhibitors of kras g12c and methods of using the same
WO2019053617A1 (en) 2017-09-12 2019-03-21 Glaxosmithkline Intellectual Property Development Limited CHEMICAL COMPOUNDS
WO2019055579A1 (en) 2017-09-12 2019-03-21 Tolero Pharmaceuticals, Inc. TREATMENT REGIME FOR CANCERS THAT ARE INSENSITIVE TO BCL-2 INHIBITORS USING THE MCL-1 ALVOCIDIB INHIBITOR
KR20200051024A (ko) 2017-09-13 2020-05-12 파이브 프라임 테라퓨틱스, 인크. 췌장암에 대한 조합 항-csf1r 및 항-pd-1 항체 조합 요법
EP3684410A1 (en) 2017-09-19 2020-07-29 Institut Curie Agonist of aryl hydrocarbon receptor for use in cancer combination therapy
EP3684413A1 (en) 2017-09-20 2020-07-29 Chugai Seiyaku Kabushiki Kaisha Dosage regimen for combination therapy using pd-1 axis binding antagonists and gpc3 targeting agent
KR102760684B1 (ko) 2017-09-29 2025-01-24 브리스톨-마이어스 스큅 컴퍼니 암을 치료하기 위한 조성물 및 방법
WO2019061324A1 (en) 2017-09-29 2019-04-04 Curis Inc. CRYSTALLINE FORMS OF IMMUNOMODULATORS
EP3687573A1 (en) 2017-09-29 2020-08-05 Boehringer Ingelheim International GmbH Anti igf, anti pd-1 anti-cancer combination therapy
WO2019070643A1 (en) 2017-10-03 2019-04-11 Bristol-Myers Squibb Company IMMUNOMODULATORS
WO2019069269A1 (en) 2017-10-05 2019-04-11 Glaxosmithkline Intellectual Property Development Limited INTERFERON GENE STIMULATOR MODULATORS USEFUL IN THE TREATMENT OF HIV
CN111417630B (zh) 2017-10-05 2023-06-06 葛兰素史克知识产权开发有限公司 干扰素基因刺激因子(sting)的调节剂
AU2018346447B2 (en) 2017-10-06 2025-06-19 Innate Pharma Restoration of T cell activity via the CD39/CD73 axis
WO2019072566A1 (en) 2017-10-10 2019-04-18 Biotest Ag COMBINATION OF ANTI-IL10 AND ANTI-PD1 ANTIBODIES FOR THE TREATMENT OF CANCER
JP7618445B2 (ja) 2017-10-11 2025-01-21 オーリジーン オンコロジー リミテッド ３－置換１，２，４－オキサジアゾールの結晶形態
CN119930795A (zh) 2017-10-12 2025-05-06 得克萨斯大学体系董事会 用于免疫疗法的t细胞受体
PE20201183A1 (es) 2017-10-13 2020-11-03 Harpoon Therapeutics Inc Proteinas trispecificas y metodos de uso
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
JP2020536894A (ja) 2017-10-15 2020-12-17 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 腫瘍処置法
WO2019077062A1 (en) 2017-10-18 2019-04-25 Vivia Biotech, S.L. C-CELLS ACTIVATED BY BIT
US11685782B2 (en) 2017-10-23 2023-06-27 Children's Medical Center Corporation Methods of treating cancer using LSD1 inhibitors in combination with immunotherapy
US20210040205A1 (en) 2017-10-25 2021-02-11 Novartis Ag Antibodies targeting cd32b and methods of use thereof
US11718679B2 (en) 2017-10-31 2023-08-08 Compass Therapeutics Llc CD137 antibodies and PD-1 antagonists and uses thereof
AU2018359527A1 (en) 2017-10-31 2020-05-07 Janssen Biotech, Inc. Methods of treating high risk multiple myeloma
WO2019089858A2 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Methods of assessing or monitoring a response to a cell therapy
WO2019089412A1 (en) 2017-11-01 2019-05-09 Merck Sharp & Dohme Corp. Novel substituted tetrahydroquinolin compounds as indoleamine 2,3-dioxygenase (ido) inhibitors
US11603410B2 (en) 2017-11-01 2023-03-14 Bristol-Myers Squibb Company Immunostimulatory agonistic antibodies for use in treating cancer
JP7159007B2 (ja) 2017-11-01 2022-10-24 小野薬品工業株式会社 脳腫瘍の治療のための医薬
EP3703688A2 (en) 2017-11-01 2020-09-09 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for b-cell maturation antigen
ES3003809T3 (en) 2017-11-01 2025-03-11 Juno Therapeutics Inc Chimeric antigen receptors specific for b-cell maturation antigen and encoding polynucleotides
MY206121A (en) 2017-11-03 2024-11-29 Aurigene Discovery Tech Ltd Dual inhibitors of tim-3 and pd-1 pathways
AU2018360790A1 (en) 2017-11-06 2020-06-11 Bristol-Myers Squibb Company Methods of treating a tumor
WO2019090263A1 (en) 2017-11-06 2019-05-09 Genentech, Inc. Diagnostic and therapeutic methods for cancer
AU2018360389B2 (en) 2017-11-06 2024-09-19 Aurigene Oncology Limited Conjoint therapies for immunomodulation
CN111601823B (zh) 2017-11-07 2024-09-24 德克萨斯大学体系董事会 用car-t或car-nk细胞在癌症治疗中靶向lilrb4
CA3081539A1 (en) * 2017-11-08 2019-05-16 Yafei Shanghai Biolog Medicine Science & Technology Co., Ltd. Conjugates of biomolecule and use thereof
JP7544598B2 (ja) 2017-11-10 2024-09-03 アーモ・バイオサイエンシーズ・インコーポレイテッド 免疫チェックポイント経路阻害剤と併用したインターロイキン－１０の組成物および使用方法
CN109467603B (zh) * 2017-11-14 2020-02-21 拜西欧斯（北京）生物技术有限公司 抗pd-1抗体及其制备方法和应用
CA3082287C (en) 2017-11-14 2023-02-28 Pfizer Inc. Ezh2 inhibitor combination therapies
CA3082108A1 (en) 2017-11-14 2019-05-23 Merck Sharp & Dohme Corp. Novel substituted biaryl compounds as indoleamine 2,3-dioxygenase (ido) inhibitors
EP3709986B1 (en) 2017-11-14 2023-11-01 Merck Sharp & Dohme LLC Novel substituted biaryl compounds as indoleamine 2,3-dioxygenase (ido) inhibitors
CA3081602A1 (en) 2017-11-16 2019-05-23 Novartis Ag Combination therapies
CN111315749A (zh) 2017-11-17 2020-06-19 诺华股份有限公司 新颖的二氢异噁唑化合物及其在治疗乙型肝炎中的用途
EP3710576B1 (en) 2017-11-17 2024-10-02 Iovance Biotherapeutics, Inc. Til expansion from fine needle aspirates and small biopsies
CA3082409A1 (en) 2017-11-17 2019-05-23 Merck Sharp & Dohme Corp. Antibodies specific for immunoglobulin-like transcript 3 (ilt3) and uses thereof
KR102752418B1 (ko) 2017-11-24 2025-01-10 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 암 치료를 위한 방법 및 조성물
US11638760B2 (en) 2017-11-27 2023-05-02 Mersana Therapeutics, Inc. Pyrrolobenzodiazepine antibody conjugates
JP7482630B2 (ja) 2017-11-28 2024-05-14 中外製薬株式会社 抗原結合ドメインおよび運搬部分を含むポリペプチド
KR20200089312A (ko) 2017-11-28 2020-07-24 추가이 세이야쿠 가부시키가이샤 리간드 결합 활성을 조정 가능한 리간드 결합 분자
CN111801334B (zh) * 2017-11-29 2023-06-09 百济神州瑞士有限责任公司 使用包含btk抑制剂的组合治疗惰性或侵袭性b-细胞淋巴瘤
SG11202005005YA (en) 2017-11-30 2020-06-29 Novartis Ag Bcma-targeting chimeric antigen receptor, and uses thereof
WO2019104716A1 (en) * 2017-12-01 2019-06-06 Adagene Inc. Methods for using cd137 ligand as biomarker for treatment with anti-cd137 antibody
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
EP3720881A1 (en) 2017-12-08 2020-10-14 Elstar Therapeutics, Inc. Multispecific molecules and uses thereof
US11946094B2 (en) 2017-12-10 2024-04-02 Augusta University Research Institute, Inc. Combination therapies and methods of use thereof
US12006356B2 (en) 2017-12-15 2024-06-11 Juno Therapeutics, Inc. Anti-CCT5 binding molecules and chimeric antigen receptors comprising the same
US11793867B2 (en) 2017-12-18 2023-10-24 Biontech Us Inc. Neoantigens and uses thereof
EP3541837A4 (en) 2017-12-19 2020-05-13 The Rockefeller University HUMAN IgG Fc DOMAIN VARIANTS WITH IMPROVED EFFECTOR FUNCTION
JP2021507906A (ja) 2017-12-20 2021-02-25 ノバルティス アーゲー 抗ウイルス剤としての融合三環式ピラゾロ−ジヒドロピラジニル−ピリドン化合物
EP3727401A4 (en) 2017-12-20 2022-04-06 Merck Sharp & Dohme Corp. CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS
CN111757757A (zh) 2017-12-21 2020-10-09 梅尔莎纳医疗公司 吡咯并苯并二氮呯抗体共轭物
WO2019129137A1 (zh) 2017-12-27 2019-07-04 信达生物制药(苏州)有限公司 抗lag-3抗体及其用途
CN115925943A (zh) * 2017-12-27 2023-04-07 信达生物制药(苏州)有限公司 抗pd-l1抗体及其用途
CN109970856B (zh) 2017-12-27 2022-08-23 信达生物制药(苏州)有限公司 抗lag-3抗体及其用途
US11306149B2 (en) 2017-12-27 2022-04-19 Bristol-Myers Squibb Company Anti-CD40 antibodies and uses thereof
WO2019133809A1 (en) 2017-12-28 2019-07-04 The General Hospital Corporation Targeting the cbm signalosome complex induces regulatory t cells to inflame the tumor microenvironment
WO2019133847A1 (en) 2017-12-29 2019-07-04 Oncorus, Inc. Oncolytic viral delivery of therapeutic polypeptides
US20210072244A1 (en) 2018-01-04 2021-03-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating melanoma resistant
US11324774B2 (en) 2018-01-05 2022-05-10 Augusta University Research Institute, Inc. Compositions of oral alkaline salts and metabolic acid inducers and uses thereof
US11713446B2 (en) 2018-01-08 2023-08-01 Iovance Biotherapeutics, Inc. Processes for generating TIL products enriched for tumor antigen-specific T-cells
EP3737408A1 (en) 2018-01-08 2020-11-18 Novartis AG Immune-enhancing rnas for combination with chimeric antigen receptor therapy
CA3087706A1 (en) 2018-01-08 2019-07-11 H. Lee Moffitt Cancer Center And Research Institute Inc. Compositions and methods for targeting cd99-expressing cancers
WO2019136459A1 (en) 2018-01-08 2019-07-11 Iovance Biotherapeutics, Inc. Processes for generating til products enriched for tumor antigen-specific t-cells
CN117866899A (zh) 2018-01-08 2024-04-12 艾欧凡斯生物治疗公司 产生富含肿瘤抗原特异性t细胞的til产品的方法
BR112020013954A2 (pt) 2018-01-09 2020-12-01 H. Lee Moffitt Cancer Center And Research Institute Inc. composições e métodos para alvejamento de cânceres que expressam clec12a
US11407723B2 (en) 2018-01-09 2022-08-09 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
EP3737692A4 (en) 2018-01-09 2021-09-29 Elstar Therapeutics, Inc. CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES
CN120192415A (zh) 2018-01-12 2025-06-24 百时美施贵宝公司 抗tim3抗体及其用途
CA3084370A1 (en) 2018-01-12 2019-07-18 Bristol-Myers Squibb Company Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer
CR20200330A (es) 2018-01-12 2020-12-23 Amgen Inc Anticuerpos anti-pd-1 y métodos de tratamiento
KR20200109339A (ko) 2018-01-16 2020-09-22 브리스톨-마이어스 스큅 컴퍼니 Tim3에 대한 항체를 사용하여 암을 치료하는 방법
US20210038559A1 (en) 2018-01-22 2021-02-11 Thomas Richard Gadek Cannabinoids and derivatives for promoting immunogenicity of tumor and infected cells
SG11202006823XA (en) 2018-01-22 2020-08-28 Bristol Myers Squibb Co Compositions and methods of treating cancer
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
US12286478B2 (en) 2018-01-23 2025-04-29 Nextcure, Inc. B7-H4 antibodies and methods of use thereof
AU2019212118A1 (en) 2018-01-24 2020-09-03 Beyondspring Pharmaceuticals, Inc. Composition and method for reducing thrombocytopenia via the administration of plinabulin
EP3743448A4 (en) 2018-01-26 2021-11-03 Orionis Biosciences, Inc. XCR1 BINDING AGENTS AND USES THEREOF
MX2020007765A (es) 2018-01-26 2020-09-25 Exelixis Inc Compuestos para el tratamiento de trastornos dependientes de cinasas.
US11673897B2 (en) 2018-01-26 2023-06-13 Exelixis, Inc. Compounds for the treatment of kinase-dependent disorders
CN112312909B (zh) 2018-01-26 2024-07-02 埃克塞里艾克西斯公司 用于治疗激酶依赖性病症的化合物
US20210069246A1 (en) 2018-01-31 2021-03-11 Celgene Corporation Combination therapy using adoptive cell therapy and checkpoint inhibitor
CA3090249A1 (en) 2018-01-31 2019-08-08 Novartis Ag Combination therapy using a chimeric antigen receptor
CN108314734B (zh) * 2018-01-31 2021-11-05 中国药科大学 抗pd-1单克隆抗体及其应用
JP2021511793A (ja) 2018-01-31 2021-05-13 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Ｌａｇ３に結合する抗原結合部位を含む二重特異性抗体
WO2019148445A1 (en) 2018-02-02 2019-08-08 Adagene Inc. Precision/context-dependent activatable antibodies, and methods of making and using the same
WO2019152979A1 (en) 2018-02-05 2019-08-08 Orionis Biosciences, Inc. Fibroblast binding agents and use thereof
EP3749323A4 (en) 2018-02-05 2021-11-03 Shenzhen Ionova Life Science Co., Ltd. HETEROBICYCLIC CARBONIC ACIDS FOR TREATMENT OF CANCER OR INFLAMMATORY DISEASES
EP4317972A3 (en) 2018-02-06 2024-03-13 The General Hospital Corporation Repeat rna as biomarkers of tumor immune response
WO2019157124A1 (en) 2018-02-08 2019-08-15 Bristol-Myers Squibb Company Combination of a tetanus toxoid, anti-ox40 antibody and/or anti-pd-1 antibody to treat tumors
TWI804572B (zh) 2018-02-09 2023-06-11 日商小野藥品工業股份有限公司 雙特異性抗體
WO2019156234A1 (en) 2018-02-09 2019-08-15 Keio University Compositions and methods for the induction of cd8+ t-cells
NL2020422B1 (en) 2018-02-12 2019-08-19 Stichting Het Nederlands Kanker Inst Antoni Van Leeuwenhoek Ziekenhuis Methods for Predicting Treatment Outcome and/or for Selecting a Subject Suitable for Immune Checkpoint Therapy.
EP3752203A1 (en) 2018-02-13 2020-12-23 Novartis AG Chimeric antigen receptor therapy in combination with il-15r and il15
US20210047409A1 (en) * 2018-02-13 2021-02-18 Merck Sharp & Dohme Corp. Methods for treating cancer with anti pd-1 antibodies and anti ctla4 antibodies
JP2021513541A (ja) 2018-02-13 2021-05-27 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 抗ｐｄ−１抗体によるがんの処置方法
MX2020008404A (es) 2018-02-13 2020-09-25 Gilead Sciences Inc Inhibidores de molecula de muerte programada 1 (pd-1)/ligando de molecula de muerte programada 1 (pd-l1).
WO2019158645A1 (en) 2018-02-14 2019-08-22 Abba Therapeutics Ag Anti-human pd-l2 antibodies
WO2019162325A1 (en) 2018-02-21 2019-08-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of sk1 as biomarker for predicting response to immunecheckpoint inhibitors
WO2019165195A1 (en) 2018-02-22 2019-08-29 Srivastava Satish Combination therapy for the treatment of cancer
CA3092470A1 (en) 2018-02-27 2019-09-06 Incyte Corporation Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitors
CN111801331A (zh) 2018-02-28 2020-10-20 诺华股份有限公司 吲哚-2-羰基化合物及其用于治疗乙型肝炎的用途
WO2019169229A1 (en) 2018-03-01 2019-09-06 Nextcure, Inc. Klrg1 binding compositions and methods of use thereof
TWI708787B (zh) 2018-03-02 2020-11-01 美商美國禮來大藥廠 Pd-1促效劑抗體及其用途
CA3090620A1 (en) 2018-03-06 2019-09-12 Institut Curie Inhibitor of setdb1 histone methyltransferase for use in cancer combination therapy
IL277095B2 (en) 2018-03-07 2025-10-01 Pfizer Preparations containing anti-PD-1 antibody
GB201803746D0 (en) * 2018-03-08 2018-04-25 Ultrahuman Eight Ltd PD1 binding agents
GB201803745D0 (en) * 2018-03-08 2018-04-25 Ultrahuman Eight Ltd PD1 binding agents
KR20210004966A (ko) 2018-03-12 2021-01-13 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 암 치료를 위한 화학-면역요법 강화용 열량 제한 모방물질의 용도
US12215116B2 (en) 2018-03-13 2025-02-04 Merck Sharp & Dohme Llc Arginase inhibitors and methods of use
CN111867598A (zh) * 2018-03-13 2020-10-30 国立大学法人大阪大学 肿瘤免疫赋活剂
CN108434452A (zh) * 2018-03-13 2018-08-24 安徽瀚海博兴生物技术有限公司 一种将pd-1抗体和jmjd6联合用于制备抗癌药物的应用
EP3765517A1 (en) 2018-03-14 2021-01-20 Elstar Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
BR122022000386B1 (pt) 2018-03-14 2022-09-27 Surface Oncology, Inc Anticorpos que se ligam a cd39, composição farmacêutica e kit dos mesmos
CN110272490B (zh) * 2018-03-14 2021-05-14 上海开拓者生物医药有限公司 靶向ctla-4抗体、其制备方法和用途
US20210009711A1 (en) 2018-03-14 2021-01-14 Elstar Therapeutics, Inc. Multifunctional molecules and uses thereof
US12454561B2 (en) 2018-03-19 2025-10-28 Multivir Inc. Methods and compositions comprising tumor suppressor gene therapy and CD122/CD132 agonists for the treatment of cancer
MX2020009743A (es) * 2018-03-19 2020-10-08 Abeome Corp Anticuerpos monoclonales neutralizantes de alta afinidad dirigidos contra el ligando de muerte programada 1 (pd-l1) y usos de estos.
CN112236454B (zh) * 2018-03-20 2022-09-13 上海药明生物技术有限公司 新型抗pd-1抗体
TWI841554B (zh) 2018-03-21 2024-05-11 丹麥商珍美寶股份有限公司 以鉑為主之劑與抗組織因子抗體－藥物共軛物的組合治療癌症之方法
SG11202008593PA (en) 2018-03-21 2020-10-29 Five Prime Therapeutics Inc ANTIBODIES BINDING TO VISTA AT ACIDIC pH
JP7328983B2 (ja) 2018-03-22 2023-08-17 サーフィス オンコロジー インコーポレイテッド 抗ｉｌ－２７抗体及びその使用
EP3768715A1 (en) 2018-03-23 2021-01-27 Bristol-Myers Squibb Company Antibodies against mica and/or micb and uses thereof
KR20210006344A (ko) 2018-03-25 2021-01-18 에스엔아이피알 바이옴 에이피에스. 미생물 감염의 치료 및 예방
US10760075B2 (en) 2018-04-30 2020-09-01 Snipr Biome Aps Treating and preventing microbial infections
SG11202009498RA (en) 2018-03-27 2020-10-29 Univ Texas Compounds with anti-tumor activity against cancer cells bearing her2 exon 19 mutations
WO2019185792A1 (en) 2018-03-29 2019-10-03 Philogen S.P.A Cancer treatment using immunoconjugates and immune check-point inhibitors
JP7124257B2 (ja) * 2018-03-29 2022-08-24 アイ－エムエービー バイオファーマ ユーエス リミテッド 抗ｐｄ‐ｌ１抗体およびその使用
EP4386080A3 (en) 2018-03-29 2024-12-04 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
CN108588030B (zh) * 2018-03-30 2020-07-14 四川迈克生物新材料技术有限公司 抗人IgM单克隆抗体、其杂交瘤细胞株及应用
WO2019191676A1 (en) 2018-03-30 2019-10-03 Bristol-Myers Squibb Company Methods of treating tumor
PL4212529T3 (pl) 2018-03-30 2025-07-07 Incyte Corporation Związki heterocykliczne jako immunomodulatory
JP7326319B2 (ja) 2018-04-03 2023-08-15 メルク・シャープ・アンド・ドーム・エルエルシー Ｓｔｉｎｇアゴニストとしてのベンゾチオフェン類及び関連する化合物
WO2019195063A1 (en) 2018-04-03 2019-10-10 Merck Sharp & Dohme Corp. Aza-benzothiophene compounds as sting agonists
WO2019195452A1 (en) 2018-04-04 2019-10-10 Bristol-Myers Squibb Company Anti-cd27 antibodies and uses thereof
WO2019193540A1 (en) 2018-04-06 2019-10-10 Glaxosmithkline Intellectual Property Development Limited Heteroaryl derivatives of formula (i) as atf4 inhibitors
WO2019193541A1 (en) 2018-04-06 2019-10-10 Glaxosmithkline Intellectual Property Development Limited Bicyclic aromatic ring derivatives of formula (i) as atf4 inhibitors
CN112218657A (zh) 2018-04-12 2021-01-12 百时美施贵宝公司 Cd73拮抗剂抗体和pd-1/pd-l1轴拮抗剂抗体的抗癌组合疗法
US20210147547A1 (en) 2018-04-13 2021-05-20 Novartis Ag Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
US12037395B1 (en) * 2018-04-15 2024-07-16 Immvira Co., Limited Antibodies binding PD-1 and uses thereof
KR20200143689A (ko) * 2018-04-15 2020-12-24 살루브리스 (청두) 바이오테크 코., 리미티드 Pd-1 결합 항체 및 그의 용도
EP3782618A4 (en) 2018-04-16 2022-01-26 OnQuality Pharmaceuticals China Ltd. METHODS OF PREVENTING OR TREATMENT OF SIDE EFFECTS OF CANCER THERAPY
DK3781550T3 (da) 2018-04-17 2025-01-27 Tempest Therapeutics Inc Bicykliske carboxamider og fremgangsmåder til anvendelse deraf
KR20210010862A (ko) 2018-04-18 2021-01-28 젠코어 인코포레이티드 IL-15/IL-15Rα Fc-융합 단백질 및 PD-1 항원 결합 도메인을 함유하는 PD-1 표적화 이종이량체 융합 단백질 및 이의 용도
CA3097625A1 (en) 2018-04-18 2019-10-24 Xencor, Inc. Il-15/il-15ra heterodimeric fc fusion proteins and uses thereof
ES3035911T3 (en) 2018-04-19 2025-09-11 Gilead Sciences Inc Pd-1/pd-l1 inhibitors
CN112105733B (zh) 2018-04-19 2024-10-29 查美特制药公司 合成rig-i样受体激动剂
EP3781687A4 (en) 2018-04-20 2022-02-09 Merck Sharp & Dohme Corp. NEW RIG-I SUBSTITUTED AGONISTS: COMPOSITIONS AND METHODS THEREOF
WO2019209811A1 (en) 2018-04-24 2019-10-31 Bristol-Myers Squibb Company Macrocyclic toll-like receptor 7 (tlr7) agonists
CN112218883A (zh) 2018-04-26 2021-01-12 艾吉纳斯公司 热休克蛋白结合肽组合物及其使用方法
WO2019207030A1 (en) 2018-04-26 2019-10-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting a response with an immune checkpoint inhibitor in a patient suffering from a lung cancer
WO2019210153A1 (en) 2018-04-27 2019-10-31 Novartis Ag Car t cell therapies with enhanced efficacy
JP6630026B1 (ja) * 2018-04-27 2020-01-15 隆代 大田 免疫チェックポイント阻害剤によるがん治療の効果を評価するためのバイオマーカー
CA3098303A1 (en) 2018-04-27 2019-10-31 Iovance Biotherapeutics, Inc. Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
US12048745B2 (en) 2018-05-01 2024-07-30 Augusta University Research Institute, Inc. Methods for detecting and reversing immune therapy resistance
US20210396739A1 (en) 2018-05-01 2021-12-23 Novartis Ag Biomarkers for evaluating car-t cells to predict clinical outcome
BR112020022371A2 (pt) 2018-05-03 2021-02-02 Shanghai Epimab Biotherapeutics Co., Ltd. anticorpos de alta afinidade para pd-1 e lag-3 e proteínas de ligação biespecífica produzidas a partir dos mesmos
CN112867716B (zh) 2018-05-04 2024-09-13 因赛特公司 Fgfr抑制剂的固体形式和其制备方法
JP7361722B2 (ja) 2018-05-04 2023-10-16 アムジエン・インコーポレーテツド Ｋｒａｓ ｇ１２ｃ阻害剤及び同一物の使用方法
BR112020022145A2 (pt) 2018-05-04 2021-01-26 Merck Patent Gmbh inibição combinada de pd-1/pd-l1, tgfbeta e dna-pk para o tratamento de câncer
KR20210006353A (ko) 2018-05-04 2021-01-18 톨리스 상피 세포 및 골수 세포 모두를 활성화시키는 tlr3 리간드
MA52501A (fr) 2018-05-04 2021-03-10 Amgen Inc Inhibiteurs de kras g12c et leurs procédés d'utilisation
JP7568512B2 (ja) 2018-05-04 2024-10-16 インサイト・コーポレイション Ｆｇｆｒ阻害剤の塩
EP3814379A4 (en) 2018-05-07 2022-03-30 Genmab A/S METHOD OF TREATMENT OF CANCER WITH A COMBINATION OF AN ANTI-PD-1 ANTIBODY AND AN ANTI-TISSUE FACTOR ANTIBODY-DRUG CONJUGATE
WO2019217457A1 (en) * 2018-05-07 2019-11-14 Genmab A/S Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate
WO2019217753A1 (en) 2018-05-10 2019-11-14 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
CA3099045A1 (en) 2018-05-10 2019-11-14 Amgen Inc. Kras g12c inhibitors for the treatment of cancer
JOP20200288A1 (ar) 2018-05-11 2020-11-11 Incyte Corp مشتقات تترا هيدرو – إيميدازو[4، 5-c]بيريدين كمعدِّلات مناعية pd-l1
US10703733B2 (en) 2018-05-14 2020-07-07 Gilead Sciences, Inc. MCL-1 inhibitors
AU2019270277B9 (en) 2018-05-15 2024-12-05 Innate Pharma Treatment of cancer
CN118638832A (zh) 2018-05-15 2024-09-13 杜克大学 用于对阿克曼菌进行基因操纵的系统和方法
GB201807924D0 (en) 2018-05-16 2018-06-27 Ctxt Pty Ltd Compounds
JP7535503B2 (ja) * 2018-05-17 2024-08-16 ナンジン リーズ バイオラブズ カンパニー リミテッド Ｐｄ－１に結合する抗体及びその使用
JP7391046B2 (ja) 2018-05-18 2023-12-04 インサイト・コーポレイション Ａ２ａ／ａ２ｂ阻害剤としての縮合ピリミジン誘導体
EP3569618A1 (en) 2018-05-19 2019-11-20 Boehringer Ingelheim International GmbH Antagonizing cd73 antibody
MX2020012548A (es) 2018-05-23 2021-05-13 Celgene Corp Métodos para el tratamiento de mieloma múltiple y uso de biomarcadores para 4-(4-(4-(((2-(2,6-dioxopiperidin-3-il)-1-oxoiso indolin-4-il)oxi)metil)bencil)piperazin-1- il)-3-fluorobenzonitril o.
EA202092830A1 (ru) 2018-05-23 2021-04-08 Селджин Корпорейшн Антипролиферативные соединения и биспецифические антитела к bcma и cd3 для комбинированного применения
IL278938B2 (en) 2018-05-29 2024-09-01 Bristol Myers Squibb Co Modified self-immolating moieties for use in prodrugs and conjugates and methods of using and making
TWI869346B (zh) 2018-05-30 2025-01-11 瑞士商諾華公司 Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法
TW202017569A (zh) 2018-05-31 2020-05-16 美商佩樂敦治療公司 用於抑制cd73之組合物及方法
CN119490583A (zh) 2018-05-31 2025-02-21 诺华股份有限公司 乙型肝炎抗体
US11352320B2 (en) 2018-05-31 2022-06-07 Merck Sharp & Dohme Corp. Substituted [1.1.1] bicyclo compounds as indoleamine 2,3-dioxygenase inhibitors
US20210214459A1 (en) 2018-05-31 2021-07-15 Novartis Ag Antibody molecules to cd73 and uses thereof
WO2019232433A2 (en) 2018-06-01 2019-12-05 Eisai R&D Management Co., Ltd. Methods of using splicing modulators
WO2019227490A1 (en) * 2018-06-01 2019-12-05 Tayu Huaxia Biotech Medical Group Co., Ltd. Compositions and methods for imaging
US20210214410A1 (en) 2018-06-01 2021-07-15 The Board Of Trustees Of The Leland Stanford Junior University Il-13/il-4 superkines: immune cell targeting constructs and methods of use thereof
CN112533952B (zh) 2018-06-01 2023-03-07 大有华夏生物医药集团有限公司 治疗疾病或病况的组合物及其用途
MX2020012495A (es) 2018-06-01 2021-02-15 Novartis Ag Moleculas de union contra bcma y usos de las mismas.
MX2020012731A (es) 2018-06-01 2021-02-22 Amgen Inc Inhibidores de kras g12c y metodos para su uso.
AU2019276656A1 (en) 2018-06-01 2021-01-07 Novartis Ag Dosing of a bispecific antibody that bind CD123 and CD3
US20210221908A1 (en) 2018-06-03 2021-07-22 Lamkap Bio Beta Ltd. Bispecific antibodies against ceacam5 and cd47
MX2020012204A (es) 2018-06-11 2021-03-31 Amgen Inc Inhibidores de kras g12c para tratar el cáncer.
MX2020012261A (es) 2018-06-12 2021-03-31 Amgen Inc Inhibidores de kras g12c que comprenden un anillo de piperazina y uso de estos en el tratamiento del cancer.
CA3103610A1 (en) 2018-06-12 2019-12-19 The Regents Of The University Of California Single-chain bispecific chimeric antigen receptors for the treatment of cancer
US11608382B2 (en) 2018-06-13 2023-03-21 Novartis Ag BCMA chimeric antigen receptors and uses thereof
KR20210035805A (ko) 2018-06-15 2021-04-01 플래그쉽 파이어니어링 이노베이션스 브이, 인크. 세포후 신호전달 인자의 조절을 통한 면역 활성의 증가
CA3099893A1 (en) 2018-06-18 2019-12-26 Innate Pharma Compositions and methods for treating cancer
WO2019245817A1 (en) 2018-06-19 2019-12-26 Armo Biosciences, Inc. Compositions and methods of use of il-10 agents in conjunction with chimeric antigen receptor cell therapy
WO2019246286A1 (en) 2018-06-19 2019-12-26 Neon Therapeutics, Inc. Neoantigens and uses thereof
WO2019244978A1 (ja) 2018-06-20 2019-12-26 富士フイルム株式会社 ゲムシタビンを内包するリポソーム組成物および免疫チェックポイント阻害剤を含む組合せ医薬
TW202423480A (zh) 2018-06-20 2024-06-16 美商英塞特公司 抗pd-1抗體及其用途
CN112312895B (zh) 2018-06-20 2023-05-09 富士胶片株式会社 包含内含药物的脂质体组合物及免疫检查点抑制剂的组合医药
WO2019245890A1 (en) 2018-06-20 2019-12-26 Merck Sharp & Dohme Corp. Arginase inhibitors and methods of use
TWI890661B (zh) 2018-06-21 2025-07-21 美商再生元醫藥公司 用雙特異性抗CD3xMUC16抗體及抗PD-1抗體治療癌症的方法
SG11202012446UA (en) 2018-06-23 2021-01-28 Genentech Inc Methods of treating lung cancer with a pd-1 axis binding antagonist, a platinum agent, and a topoisomerase ii inhibitor
WO2020005068A2 (en) 2018-06-29 2020-01-02 Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Gene signatures and method for predicting response to pd-1 antagonists and ctla-4 antagonists, and combination thereof
CN112955465A (zh) 2018-07-03 2021-06-11 马伦戈治疗公司 抗tcr抗体分子及其用途
JP7490631B2 (ja) 2018-07-05 2024-05-27 インサイト・コーポレイション Ａ２ａ／ａ２ｂ阻害剤としての縮合ピラジン誘導体
CN112424167A (zh) 2018-07-09 2021-02-26 葛兰素史密斯克莱知识产权发展有限公司 化学化合物
MY201995A (en) 2018-07-09 2024-03-28 Five Prime Therapeutics Inc Antibodies binding to ilt4
KR20210042909A (ko) * 2018-07-09 2021-04-20 프레시전 인코포레이티드 융합 구조물 및 그의 이용 방법
ES2963694T3 (es) 2018-07-10 2024-04-01 Novartis Ag Derivados de 3-(5-hidroxi-1-oxoisoindolin-2-il)piperidin-2,6-diona y su uso en el tratamiento de enfermedades dependientes de la proteína con dedos de cinc 2 de la familia ikaros (ikzf2)
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
SG11202100023XA (en) 2018-07-11 2021-01-28 Actym Therapeutics Inc Engineered immunostimulatory bacterial strains and uses thereof
CN112638948B (zh) 2018-07-11 2025-08-15 戊瑞治疗有限公司 在酸性pH下结合至VISTA的抗体
CA3105381A1 (en) 2018-07-11 2020-01-16 The Brigham And Women's Hospital, Inc. Methods and compositions for delivery of agents across the blood-brain barrier
GB201811410D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd OX40 Binding molecules
IL280002B2 (en) 2018-07-12 2025-05-01 F Star Beta Ltd Antibody molecules that bind CD137 and OX40
SI3820572T1 (sl) 2018-07-13 2023-12-29 Gilead Sciences, Inc. Inhibitorji pd-1/pd-l1
US20210277135A1 (en) 2018-07-13 2021-09-09 Bristol-Myers Squibb Company Ox-40 agonist, pd-1 pathway inhibitor and ctla-4 inhibitor combination for use in a method of treating a cancer or a solid tumor
US20200171146A1 (en) 2018-07-18 2020-06-04 Genentech, Inc. Methods of treating lung cancer with a pd-1 axis binding antagonist, an antimetabolite, and a platinum agent
CN110734493B (zh) * 2018-07-20 2021-12-17 厦门大学 抗pd-1抗体及其用途
EP3827020A1 (en) 2018-07-24 2021-06-02 Amgen Inc. Combination of lilrb1/2 pathway inhibitors and pd-1 pathway inhibitors
CN112534052B (zh) 2018-07-25 2024-09-20 奥美药业有限公司 全新il-21前药及使用方法
SG11202100693UA (en) 2018-07-26 2021-02-25 Bristol Myers Squibb Co Lag-3 combination therapy for the treatment of cancer
WO2020021061A1 (en) 2018-07-26 2020-01-30 Pieris Pharmaceuticals Gmbh Humanized anti-pd-1 antibodies and uses thereof
US11554120B2 (en) 2018-08-03 2023-01-17 Bristol-Myers Squibb Company 1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor
US20210236633A1 (en) 2018-08-06 2021-08-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating cancers
WO2020030571A1 (en) 2018-08-06 2020-02-13 Glaxosmithkline Intellectual Property Development Limited Combinations of a pd-1 antibody and a tlr4 modulator and uses thereof
WO2020031107A1 (en) 2018-08-08 2020-02-13 Glaxosmithkline Intellectual Property Development Limited Chemical compounds
US20210317461A1 (en) 2018-08-09 2021-10-14 Verseau Therapeutics, Inc. Oligonucleotide compositions for targeting ccr2 and csf1r and uses thereof
CN113307872B (zh) * 2018-08-11 2022-12-06 广东天科雅生物医药科技有限公司 一种工程化核酸、t细胞及其应用和产生方法
KR102666754B1 (ko) * 2018-08-21 2024-05-17 에이비엘바이오 주식회사 항-pd-l1/항-lag3 이중 특이 항체 및 이의 용도
EP3843849A1 (en) 2018-08-27 2021-07-07 Pieris Pharmaceuticals GmbH Combination therapies comprising cd137/her2 bispecific agents and pd-1 axis inhibitors and uses thereof
EP3844305A2 (en) * 2018-08-28 2021-07-07 10X Genomics, Inc. Methods of generating an array
WO2020044206A1 (en) 2018-08-29 2020-03-05 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides as kinase inhibitors for use in the treatment cancer
TW202031273A (zh) 2018-08-31 2020-09-01 美商艾歐凡斯生物治療公司 抗ｐｄ－１抗體難治療性之非小細胞肺癌（ｎｓｃｌｃ）病患的治療
WO2020047345A1 (en) 2018-08-31 2020-03-05 Yale University Compositions and methods of using cell-penetrating antibodies in combination with immune checkpoint modulators
WO2020044252A1 (en) 2018-08-31 2020-03-05 Novartis Ag Dosage regimes for anti-m-csf antibodies and uses thereof
EP3847154A1 (en) 2018-09-03 2021-07-14 F. Hoffmann-La Roche AG Carboxamide and sulfonamide derivatives useful as tead modulators
WO2020048942A1 (en) 2018-09-04 2020-03-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for enhancing cytotoxic t lymphocyte-dependent immune responses
MX2021002690A (es) 2018-09-07 2021-05-12 Pfizer Anticuerpos anti-avb8 y composiciones y usos de los mismos.
WO2020049534A1 (en) 2018-09-07 2020-03-12 Novartis Ag Sting agonist and combination therapy thereof for the treatment of cancer
WO2020053742A2 (en) 2018-09-10 2020-03-19 Novartis Ag Anti-hla-hbv peptide antibodies
WO2020055840A1 (en) 2018-09-11 2020-03-19 Curis Inc. Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety
CN112996789B (zh) 2018-09-12 2025-11-11 诺华股份有限公司 抗病毒吡啶并吡嗪二酮化合物
US20210317214A1 (en) 2018-09-13 2021-10-14 Merck Sharp & Dohme Corp. Combination therapy of a pd-1 antagonist and lag3 antagonist for treating patients with non-microsatellite instability-high or proficient mismatch repair colorectal cancer
AU2019342099A1 (en) 2018-09-19 2021-04-08 Genentech, Inc. Therapeutic and diagnostic methods for bladder cancer
SG11202102644XA (en) 2018-09-19 2021-04-29 Alpine Immune Sciences Inc Methods and uses of variant cd80 fusion proteins and related constructs
EP3853251A1 (en) 2018-09-19 2021-07-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for the treatment of cancers resistant to immune checkpoint therapy
EP3852524B1 (en) 2018-09-20 2023-06-28 Iovance Biotherapeutics, Inc. Expansion of tils from cryopreserved tumor samples
WO2020061482A1 (en) 2018-09-21 2020-03-26 Harpoon Therapeutics, Inc. Egfr binding proteins and methods of use
CA3111809A1 (en) 2018-09-21 2020-03-26 Genentech, Inc. Diagnostic methods for triple-negative breast cancer
US10815311B2 (en) 2018-09-25 2020-10-27 Harpoon Therapeutics, Inc. DLL3 binding proteins and methods of use
CN113164777B (zh) 2018-09-27 2024-12-13 马伦戈治疗公司 Csf1r/ccr2多特异性抗体
WO2020069405A1 (en) 2018-09-28 2020-04-02 Novartis Ag Cd22 chimeric antigen receptor (car) therapies
EP3856782A1 (en) 2018-09-28 2021-08-04 Novartis AG Cd19 chimeric antigen receptor (car) and cd22 car combination therapies
CA3113618A1 (en) 2018-09-28 2020-04-02 Massachusetts Institute Of Technology Collagen-localized immunomodulatory molecules and methods thereof
CA3113379A1 (en) 2018-09-29 2020-04-02 Novartis Ag Process of manufacture of a compound for inhibiting the activity of shp2
EP3860578A1 (en) 2018-10-01 2021-08-11 Institut National de la Santé et de la Recherche Médicale (INSERM) Use of inhibitors of stress granule formation for targeting the regulation of immune responses
EP3861987A4 (en) 2018-10-01 2021-09-15 FUJIFILM Corporation COMBINATION DRUG CONTAINING A LIPOSOME COMPOSITION ENCAPSULATING A DRUG AND A PLATINUM PREPARATION
JP7612571B2 (ja) 2018-10-03 2025-01-14 ゼンコア インコーポレイテッド Ｉｌ－１２ヘテロ二量体ｆｃ－融合タンパク質
EP3864046A1 (en) 2018-10-09 2021-08-18 Bristol-Myers Squibb Company Anti-mertk antibodies for treating cancer
TWI855000B (zh) 2018-10-11 2024-09-11 日商小野藥品工業股份有限公司 Ｓｔｉｎｇ促效化合物
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
PE20211055A1 (es) 2018-10-12 2021-06-07 Xencor Inc Proteinas de fusion il-15 / il-15 ralpha f c dirigidas a pd-1 y usos en terapias de combinacion de las mismas
EP3868784A4 (en) 2018-10-15 2022-07-27 Industry-Academic Cooperation Foundation, Yonsei University ANTIBODIES WITH INCREASED PRODUCTIVITY AND METHODS FOR THEIR PRODUCTION
US20210348238A1 (en) 2018-10-16 2021-11-11 Novartis Ag Tumor mutation burden alone or in combination with immune markers as biomarkers for predicting response to targeted therapy
WO2020081381A1 (en) 2018-10-17 2020-04-23 Merck Sharp & Dohme Corp. Novel arylalkyl pyrazole compounds as indoleamine 2,3-dioxygenase inhibitors
CN113164600A (zh) 2018-10-17 2021-07-23 百欧林纳克斯有限公司 转移性胰脏腺癌的治疗
EP3867646A1 (en) 2018-10-18 2021-08-25 F. Hoffmann-La Roche AG Diagnostic and therapeutic methods for sarcomatoid kidney cancer
EP3867269A1 (en) 2018-10-18 2021-08-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Combination of a big-h3 antagonist and an immune checkpoint inhibitor for the treatment of solid tumor
LT3866850T (lt) 2018-10-19 2024-09-10 Bristol-Myers Squibb Company Kompleksinė melanomos terapija
EP3870219A1 (en) 2018-10-22 2021-09-01 GlaxoSmithKline Intellectual Property Development Ltd Dosing
JP2022505647A (ja) 2018-10-23 2022-01-14 ブリストル－マイヤーズ スクイブ カンパニー 腫瘍の処置方法
JP7158577B2 (ja) 2018-10-24 2022-10-21 ギリアード サイエンシーズ， インコーポレイテッド Ｐｄ－１／ｐｄ－ｌ１阻害剤
US11564995B2 (en) 2018-10-29 2023-01-31 Wisconsin Alumni Research Foundation Peptide-nanoparticle conjugates
CN113613680A (zh) 2018-10-29 2021-11-05 威斯康星校友研究基金会 用于增强癌症免疫疗法的与免疫检查点抑制剂复合的树枝状聚合物
MX2021004906A (es) 2018-10-29 2021-09-10 Mersana Therapeutics Inc Conjugados de anticuerpo modificado con cisteína-fármaco con enlazadores que contienen péptidos.
TWI844571B (zh) 2018-10-30 2024-06-11 丹麥商珍美寶股份有限公司 使用抗血管內皮生長因子（ｖｅｇｆ）抗體與抗組織因子（ｔｆ）抗體－藥物共軛體之組合以治療癌症之方法
US12257286B2 (en) 2018-10-31 2025-03-25 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
WO2020092839A1 (en) 2018-10-31 2020-05-07 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
US20230053449A1 (en) 2018-10-31 2023-02-23 Novartis Ag Dc-sign antibody drug conjugates
CN113614108A (zh) 2018-11-01 2021-11-05 朱诺治疗学股份有限公司 G蛋白偶合受体c类5族成员d(gprc5d)特异性嵌合抗原受体
US12091405B2 (en) 2018-11-01 2024-09-17 Merck Sharp & Dohme Llc Substituted pyrazole compounds as indoleamine 2,3-dioxygenase inhibitors
AU2019372331A1 (en) 2018-11-01 2021-05-27 Juno Therapeutics, Inc. Methods for treatment using chimeric antigen receptors specific for B-cell maturation antigen
AU2019375416A1 (en) 2018-11-05 2021-05-27 Iovance Biotherapeutics, Inc. Selection of improved tumor reactive T-cells
US12453697B2 (en) 2018-11-05 2025-10-28 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy
CA3118634A1 (en) 2018-11-05 2020-05-14 Iovance Biotherapeutics, Inc. Treatment of nsclc patients refractory for anti-pd-1 antibody
EP3877366A4 (en) 2018-11-06 2022-08-24 Merck Sharp & Dohme Corp. NOVEL SUBSTITUTED TRICYCLIC COMPOUNDS AS INDOLAMINE-2,3-DIOXYGENASE INHIBITORS
CA3118144A1 (en) 2018-11-07 2020-05-14 Merck Sharp & Dohme Corp. Co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
WO2020097409A2 (en) 2018-11-08 2020-05-14 Modernatx, Inc. Use of mrna encoding ox40l to treat cancer in human patients
CA3118892A1 (en) 2018-11-08 2020-05-14 Orionis Biosciences, Inc. Modulation of dendritic cell lineages
AU2019377546A1 (en) 2018-11-09 2021-06-03 Pierian Biosciences, LLC Methods and compositions for determining the composition of a tumor microenvironment
BR112021007448A2 (pt) 2018-11-14 2021-10-26 Bayer Aktiengesellschaft Combinação farmacêutica de anticorpos anti-ceacam6 e anti-pd-1 ou anti-pd-l1 para o tratamento de câncer
TW202028222A (zh) 2018-11-14 2020-08-01 美商Ionis製藥公司 Foxp3表現之調節劑
SI3880186T1 (sl) 2018-11-14 2024-07-31 Regeneron Pharmaceuticals, Inc., Intralezijska uporaba zaviralcev PD-1 za zdravljenje kožnega raka
AU2019379325B2 (en) 2018-11-16 2025-04-24 Genexine, Inc. Method of treating a tumor with a combination of IL-7 protein and an immune checkpoint inhibitor
KR20210093946A (ko) 2018-11-16 2021-07-28 아르퀼 인코포레이티드 암의 치료를 위한 제약 조합물
EP3880238A1 (en) 2018-11-16 2021-09-22 Juno Therapeutics, Inc. Methods of dosing engineered t cells for the treatment of b cell malignancies
JP7516029B2 (ja) 2018-11-16 2024-07-16 アムジエン・インコーポレーテツド Ｋｒａｓ ｇ１２ｃ阻害剤化合物の重要な中間体の改良合成法
MY205758A (en) 2018-11-16 2024-11-12 Bristol Myers Squibb Co Anti-nkg2a antibodies and uses thereof
WO2020106640A1 (en) 2018-11-19 2020-05-28 Amgen Inc. Kras g12c inhibitors and methods of using the same
JP7377679B2 (ja) 2018-11-19 2023-11-10 アムジエン・インコーポレーテツド がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
CN113286813A (zh) 2018-11-19 2021-08-20 得克萨斯大学体系董事会 用于car和tcr转导的模块化多顺反子载体
WO2020106560A1 (en) 2018-11-20 2020-05-28 Merck Sharp & Dohme Corp. Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use
EP3883964A1 (en) 2018-11-20 2021-09-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Bispecific antibody targeting transferrin receptor 1 and soluble antigen
WO2020104479A1 (en) 2018-11-20 2020-05-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating cancers and resistant cancers with anti transferrin receptor 1 antibodies
US12466831B2 (en) 2018-11-20 2025-11-11 Merck Sharp & Dohme Llc Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use
KR20210116437A (ko) 2018-11-20 2021-09-27 코넬 유니버시티 방사성핵종의 마크로사이클릭 복합체 및 암의 방사선 요법에서의 이의 용도
CN113453678A (zh) 2018-11-26 2021-09-28 德彪药业国际股份公司 Hiv感染的联合治疗
TWI818120B (zh) 2018-11-27 2023-10-11 日商小野藥品工業股份有限公司 藉由免疫檢查點阻礙藥與ｆｏｌｆｉｒｉｎｏｘ療法之併用的癌症治療
EA202191463A1 (ru) 2018-11-28 2021-10-13 Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем Мультиплексное редактирование генома иммунных клеток для повышения функциональности и устойчивости к подавляющей среде
EP3886845B1 (en) 2018-11-28 2024-09-04 Merck Sharp & Dohme LLC Novel substituted piperazine amide compounds as indoleamine 2, 3-dioxygenase (ido) inhibitors
KR20210096167A (ko) 2018-11-28 2021-08-04 브리스톨-마이어스 스큅 컴퍼니 변형된 중쇄 불변 영역을 포함하는 항체
US20220018828A1 (en) 2018-11-28 2022-01-20 Inserm (Institut National De La Santé Et La Recherche Médicale Methods and kit for assaying lytic potential of immune effector cells
US20220033778A1 (en) 2018-11-29 2022-02-03 Board Of Regents, The University Of Texas System Methods for ex vivo expansion of natural killer cells and use thereof
WO2020109570A1 (en) 2018-11-30 2020-06-04 Gbg Forschungs Gmbh Method for predicting the response to cancer immunotherapy in cancer patients
EP3886914B1 (en) 2018-11-30 2023-03-29 Bristol-Myers Squibb Company Antibody comprising a glutamine-containing light chain c-terminal extension, conjugates thereof, and methods and uses
TWI824069B (zh) 2018-11-30 2023-12-01 英商葛蘭素史密斯克藍智慧財產發展有限公司 用於hiv治療之化合物
BR112021010354A2 (pt) 2018-11-30 2021-11-03 Juno Therapeutics Inc Métodos para o tratamento usando terapia celular adotiva
EA202191498A1 (ru) 2018-11-30 2021-08-20 Мерк Шарп энд Доум Корп. 9-замещенные производные аминотриазолохиназолина в качестве антагонистов аденозиновых рецепторов, фармацевтические композиции и их применение
EP3890778A4 (en) 2018-12-03 2022-08-03 Agensys, Inc. PHARMACEUTICAL COMPOSITIONS COMPRISING ANTI-191P4D12 ANTIBODY CONJUGATES - MEDICINES AND METHODS OF USING THE SAME
JP2022511029A (ja) 2018-12-04 2022-01-28 スミトモ ダイニッポン ファーマ オンコロジー， インコーポレイテッド がんの処置のための薬剤としての使用のためのｃｄｋ９インヒビターおよびその多形
EP4198057A1 (en) 2018-12-05 2023-06-21 F. Hoffmann-La Roche AG Diagnostic methods and compositions for cancer immunotherapy
EP3891270A1 (en) 2018-12-07 2021-10-13 Institut National de la Santé et de la Recherche Médicale (INSERM) Use of cd26 and cd39 as new phenotypic markers for assessing maturation of foxp3+ t cells and uses thereof for diagnostic purposes
WO2020115261A1 (en) 2018-12-07 2020-06-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating melanoma
MA54448A (fr) 2018-12-11 2021-10-20 Theravance Biopharma R&D Ip Llc Dérivés naphthyridine et quinoléine en tant qu'inhibiteurs de alk5
WO2020120592A1 (en) 2018-12-12 2020-06-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for predicting and treating melanoma
JP7514836B2 (ja) 2018-12-12 2024-07-11 ブリストル－マイヤーズ スクイブ カンパニー トランスグルタミナーゼによるコンジュゲーションのための改変抗体、ならびにそのコンジュゲート、方法および用途
KR20210104064A (ko) 2018-12-13 2021-08-24 서피스 온콜로지, 인크. 항-il-27 항체 및 그의 용도
GB201820547D0 (en) 2018-12-17 2019-01-30 Oxford Univ Innovation Modified antibodies
WO2020127059A1 (en) 2018-12-17 2020-06-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of sulconazole as a furin inhibitor
WO2020131885A1 (en) * 2018-12-17 2020-06-25 Eamonn Hobbs In situ therapeutic cancer vaccine creation system and method
US12240867B2 (en) 2018-12-18 2025-03-04 Merck Sharp & Dohme Llc Arginase inhibitors and methods of use
WO2020126808A1 (en) 2018-12-19 2020-06-25 Bayer Aktiengesellschaft Pharmaceutical combination of anti ceacam6 and tim3 antibodies
US20220064332A1 (en) 2018-12-19 2022-03-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating cancers by immuno-modulation using antibodies against cathespin-d
WO2020132646A1 (en) 2018-12-20 2020-06-25 Xencor, Inc. Targeted heterodimeric fc fusion proteins containing il-15/il-15ra and nkg2d antigen binding domains
EP3897637A1 (en) 2018-12-20 2021-10-27 Novartis AG Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
US12441705B2 (en) 2018-12-20 2025-10-14 Amgen Inc. KIF18A inhibitors
MX2021007104A (es) 2018-12-20 2021-08-11 Amgen Inc Inhibidores de kif18a.
TWI844602B (zh) 2018-12-20 2024-06-11 美商安進公司 Kif18a抑制劑
WO2020132653A1 (en) 2018-12-20 2020-06-25 Amgen Inc. Heteroaryl amides useful as kif18a inhibitors
CN111349162A (zh) * 2018-12-21 2020-06-30 神州细胞工程有限公司 人源化抗pd-1抗体及其用途
KR20210108978A (ko) 2018-12-21 2021-09-03 오제 이뮈노테라프틱스 이작용성 항-pd-1/il-7 분자
CR20210324A (es) 2018-12-21 2021-07-14 Novartis Ag Anticuerpos anti-pmel 17 y conjugados de los mismos
PH12021551419A1 (en) 2018-12-21 2022-05-02 Onxeo New conjugated nucleic acid molecules and their uses
CN113474048A (zh) 2018-12-21 2021-10-01 Aim免疫科技有限公司 用于癌症治疗的组合物和方法
WO2020127885A1 (en) 2018-12-21 2020-06-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Compositions for treating cancers and resistant cancers
CN113574067A (zh) 2018-12-21 2021-10-29 Ose免疫疗法公司 双功能抗PD-1/SIRPα分子
JP2022516140A (ja) 2018-12-26 2022-02-24 インネート・ファルマ 白血球免疫グロブリン様受容体２中和抗体
MX2021007768A (es) 2018-12-26 2021-08-24 Xilio Dev Inc Anticuerpos anti-ctla4 y metodos de uso de los mismos.
KR20210121046A (ko) * 2018-12-27 2021-10-07 기가젠, 인코포레이티드 항-pd-1 결합 단백질 및 이의 사용 방법
MX2021007639A (es) 2018-12-27 2021-08-11 Amgen Inc Formulaciones de virus liofilizadas.
EP4059569A1 (en) 2019-01-03 2022-09-21 Institut National De La Sante Et De La Recherche Medicale (Inserm) Methods and pharmaceutical compositions for enhancing cd8+ t cell-dependent immune responses in subjects suffering from cancer
EP4461370A3 (en) 2019-01-09 2025-01-08 Celgene Corporation Antiproliferative compounds and second active agents for use in treating multiple myeloma
KR20210113290A (ko) 2019-01-09 2021-09-15 셀진 코포레이션 (s)-4-(4-(4-(((2-(2,6-다이옥소피페리딘-3-일)-1-옥소아이소인돌린-4-일)옥시)메틸)벤질)피페라진-1-일)-3-플루오로벤조나이트릴을 포함하는 약제학적 조성물 및 이의 사용 방법
MX2021008295A (es) 2019-01-09 2021-10-13 Celgene Corp Formas sólidas que comprenden (s)-4-(4-(4-(((2-(2,6-dioxopiperidin -3-il)-1-oxoisoindolin-4-il)oxi)metil)bencil)piperazin-1-il)-3-fl uorobenzonitrilo y sales del mismo, composiciones que comprenden y métodos de utilización del mismo.
CN111423510B (zh) 2019-01-10 2024-02-06 迈威(上海)生物科技股份有限公司 重组抗人pd-1抗体及其应用
AU2020208193A1 (en) 2019-01-14 2021-07-29 BioNTech SE Methods of treating cancer with a PD-1 axis binding antagonist and an RNA vaccine
EP3911670B1 (en) 2019-01-15 2024-12-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Mutated interleukin-34 (il-34) polypeptides and uses thereof in therapy
JP7636330B2 (ja) 2019-01-17 2025-02-26 ジョージア テック リサーチ コーポレイション 酸化コレステロールを含有する薬物送達システム
CN113438947A (zh) 2019-01-18 2021-09-24 羿尊生物医药股份有限公司 Don前药和免疫检查点抑制剂的联合治疗
WO2020154189A1 (en) 2019-01-21 2020-07-30 Sanofi Therapeutic rna and anti-pd1 antibodies for advanced stage solid tumor cancers
US11235032B2 (en) 2019-01-23 2022-02-01 Massachusetts Institute Of Technology Combination immunotherapy dosing regimen for immune checkpoint blockade
EP3914623A4 (en) 2019-01-23 2022-11-23 Tayu Huaxia Biotech Medical Group Co., Ltd. ANTI-PD-L1 DIABODIES AND THEIR USE
TWI894135B (zh) 2019-01-25 2025-08-21 德商百靈佳殷格翰國際股份有限公司 編碼ccl21之重組棒狀病毒
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
WO2020160050A1 (en) 2019-01-29 2020-08-06 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ror1)
AU2020214796A1 (en) 2019-01-30 2021-07-29 Truebinding, Inc. Anti-Gal3 antibodies and uses thereof
JP7442536B2 (ja) 2019-01-30 2024-03-04 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル ガンを患っている被験体が免疫チェックポイント阻害剤で反応を達成するかを特定するための方法及び組成物
CA3128064A1 (en) 2019-02-01 2020-08-06 Glaxosmithkline Intellectual Property Development Limited Combination treatments for cancer comprising belantamab mafodotin and an anti ox40 antibody and uses and methods thereof
MX2021009041A (es) 2019-02-03 2021-08-19 Jiangsu Hengrui Medicine Co Anticuerpo anti-pd-1, fragmento de union a antigeno del mismo y uso farmaceutico del mismo.
US20220117911A1 (en) 2019-02-04 2022-04-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for modulating blood-brain barrier
EP3921443A1 (en) 2019-02-08 2021-12-15 F. Hoffmann-La Roche AG Diagnostic and therapeutic methods for cancer
CA3129031A1 (en) 2019-02-12 2020-08-20 Novartis Ag Pharmaceutical combination comprising tno155 and a pd-1 inhibitor
WO2020167990A1 (en) 2019-02-12 2020-08-20 Tolero Pharmaceuticals, Inc. Formulations comprising heterocyclic protein kinase inhibitors
EP3924520A1 (en) 2019-02-13 2021-12-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for selecting a cancer treatment in a subject suffering from cancer
WO2020165374A1 (en) 2019-02-14 2020-08-20 Ose Immunotherapeutics Bifunctional molecule comprising il-15ra
WO2020168244A1 (en) 2019-02-15 2020-08-20 Incelldx, Inc. Assaying bladder-associated samples, identifying and treating bladder-associated neoplasia, and kits for use therein
EP3924054B1 (en) 2019-02-15 2025-04-02 Novartis AG 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
US11384083B2 (en) 2019-02-15 2022-07-12 Incyte Corporation Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors
CA3123519A1 (en) 2019-02-15 2020-08-20 Novartis Ag Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
AU2020221293A1 (en) 2019-02-15 2021-09-02 Incyte Corporation Cyclin-dependent kinase 2 biomarkers and uses thereof
WO2020169472A2 (en) 2019-02-18 2020-08-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of inducing phenotypic changes in macrophages
ES2980469T3 (es) 2019-02-19 2024-10-01 Turnstone Biologics Corp Métodos para producir linfocitos T autólogos útiles para tratar cánceres y composiciones de los mismos
SG11202109061YA (en) 2019-02-21 2021-09-29 Marengo Therapeutics Inc Multifunctional molecules that bind to t cell related cancer cells and uses thereof
CA3130508A1 (en) 2019-02-21 2020-08-27 Marengo Therapeutics, Inc. Antibody molecules that bind to nkp30 and uses thereof
EP3931328A4 (en) 2019-02-27 2023-09-13 Ionis Pharmaceuticals, Inc. MODULATORS OF MALAT1 EXPRESSION
MA55084A (fr) 2019-02-28 2022-01-05 Regeneron Pharma Administration d'inhibiteurs de pd-1 pour le traitement du cancer de la peau
AU2020232616A1 (en) 2019-03-01 2021-09-09 Revolution Medicines, Inc. Bicyclic heterocyclyl compounds and uses thereof
JP2022522777A (ja) 2019-03-01 2022-04-20 レボリューション メディシンズ インコーポレイテッド 二環式ヘテロアリール化合物及びその使用
WO2020180959A1 (en) 2019-03-05 2020-09-10 Incyte Corporation Pyrazolyl pyrimidinylamine compounds as cdk2 inhibitors
MX2021010458A (es) 2019-03-05 2021-09-21 Amgen Inc Uso de virus oncoliticos para el tratamiento del cancer.
JP7548924B2 (ja) 2019-03-06 2024-09-10 リジェネロン・ファーマシューティカルズ・インコーポレイテッド がんの処置における増強された有効性のためのｉｌ－４／ｉｌ－１３経路阻害剤
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
MA55316A (fr) 2019-03-13 2022-01-19 Merck Sharp & Dohme Polythérapies anticancéreuses comprenant des agents de blocage de ctla-4 et pd-1
WO2020183011A1 (en) 2019-03-14 2020-09-17 Institut Curie Htr1d inhibitors and uses thereof in the treatment of cancer
TW202100556A (zh) 2019-03-14 2021-01-01 美商建南德克公司 使用her2 t細胞依賴性雙特異性抗體之治療
EP3942024A4 (en) 2019-03-18 2023-03-22 The Regents of the University of California ENHANCEMENT OF T LYMPHOCYTE ACTIVATION BY OSCILLATORY FORCES AND MODIFIED ANTIGEN-PRESENTING CELLS
EP3941503A1 (en) 2019-03-19 2022-01-26 Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron Combination therapy with omomyc and an antibody binding pd-1 or ctla-4 for the treatment of cancer
WO2020191326A1 (en) 2019-03-20 2020-09-24 Sumitomo Dainippon Pharma Oncology, Inc. Treatment of acute myeloid leukemia (aml) with venetoclax failure
WO2020198077A1 (en) 2019-03-22 2020-10-01 Sumitomo Dainippon Pharma Oncology, Inc. Compositions comprising pkm2 modulators and methods of treatment using the same
CA3134822A1 (en) 2019-03-26 2020-10-01 The Regents Of The Universtiy Of Michigan Small molecule degraders of stat3
WO2020198676A1 (en) 2019-03-28 2020-10-01 Bristol-Myers Squibb Company Methods of treating tumor
KR20210146348A (ko) 2019-03-28 2021-12-03 브리스톨-마이어스 스큅 컴퍼니 종양을 치료하는 방법
TW202102543A (zh) 2019-03-29 2021-01-16 美商安進公司 溶瘤病毒在癌症新輔助療法中之用途
AU2020256125A1 (en) 2019-03-29 2021-11-18 Turnstone Biologics Corp. Ex vivo methods for producing a T cell therapeutic and related compositions and methods
US20220193198A1 (en) 2019-03-29 2022-06-23 Institut Curie Interleukin-2 Variants with Modified Biological Activity
WO2020205560A1 (en) 2019-03-29 2020-10-08 Incyte Corporation Sulfonylamide compounds as cdk2 inhibitors
WO2020205467A1 (en) 2019-03-29 2020-10-08 The Regents Of The University Of Michigan Stat3 protein degraders
WO2020205626A1 (en) 2019-03-29 2020-10-08 Genentech, Inc. Modulators of cell surface protein interactions and methods and compositions related to same
EP3947640A4 (en) 2019-04-02 2022-12-14 The Brigham & Women's Hospital, Inc. PROCEDURE FOR DETERMINING THE PROGRESSION OF PRIMARY MELANOMA
WO2020201362A2 (en) 2019-04-02 2020-10-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of predicting and preventing cancer in patients having premalignant lesions
CA3131535A1 (en) 2019-04-03 2020-10-08 Targimmune Therapeutics Ag Immunotherapy for the treatment of cancer
EP3946324B1 (en) 2019-04-04 2025-07-30 Merck Sharp & Dohme LLC Inhibitors of histone deacetylase-3 useful for the treatment of cancer, inflammation, neurodegeneration diseases and diabetes
WO2020208060A1 (en) 2019-04-09 2020-10-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of sk2 inhibitors in combination with immune checkpoint blockade therapy for the treatment of cancer
MX2021012406A (es) 2019-04-11 2022-01-19 Bayer Ag Combinaciones de anticuerpos anti-ildr2 y antagonistas de pd-1.
CN110095612B (zh) * 2019-04-12 2022-05-10 河北仁博科技有限公司 一种基于spr快速筛选单克隆抗体的方法
EP3952903A1 (en) 2019-04-12 2022-02-16 Vascular Biogenics Ltd. Methods of anti-tumor therapy
EP3956446A1 (en) 2019-04-17 2022-02-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treatment of nlrp3 inflammasome mediated il-1beta dependent disorders
US20220202818A1 (en) 2019-04-18 2022-06-30 The Regents Of The University Of Michigan Combination with checkpoint inhibitors to treat cancer
EP3725370A1 (en) 2019-04-19 2020-10-21 ImmunoBrain Checkpoint, Inc. Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease
US12404331B2 (en) 2019-04-19 2025-09-02 Tcrcure Biopharma Corp. Anti-PD-1 antibodies and uses thereof
AU2020258480A1 (en) 2019-04-19 2021-10-21 Genentech, Inc. Anti-mertk antibodies and their methods of use
CA3136698A1 (en) 2019-04-23 2020-10-29 Innate Pharma Cd73 blocking antibodies
WO2020221796A1 (en) 2019-04-30 2020-11-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating melanoma
CN110402892A (zh) * 2019-04-30 2019-11-05 梁廷波 选择性敲除胰腺上皮细胞程序性死亡配体1分子的自发胰腺癌小鼠模型的建立方法
WO2020223233A1 (en) 2019-04-30 2020-11-05 Genentech, Inc. Prognostic and therapeutic methods for colorectal cancer
US20200345820A1 (en) 2019-05-01 2020-11-05 Sensei Biotherapeutics, Inc. Combination therapies for cancer
WO2020223558A1 (en) 2019-05-01 2020-11-05 Incyte Corporation Tricyclic amine compounds as cdk2 inhibitors
WO2020223469A1 (en) 2019-05-01 2020-11-05 Incyte Corporation N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer
WO2020227159A2 (en) 2019-05-03 2020-11-12 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity
US20220211847A1 (en) 2019-05-06 2022-07-07 Medimmune Limited Combination of monalizumab, durvalumab, chemotherapy and bevacizumab or cetuximab for the treatment of colorectal cancer
CN114096278A (zh) 2019-05-07 2022-02-25 英谬免疫股份有限公司 通过体外单采血增加对检查点抑制剂的反应
JP7556502B2 (ja) 2019-05-09 2024-09-26 フジフィルム セルラー ダイナミクス，インコーポレイテッド ヘパトサイトの作製方法
AU2020276242B2 (en) 2019-05-13 2025-01-30 Regeneron Pharmaceuticals, Inc. Combination of PD-1 inhibitors and LAG-3 inhibitors for enhanced efficacy in treating cancer
EP3738593A1 (en) 2019-05-14 2020-11-18 Amgen, Inc Dosing of kras inhibitor for treatment of cancers
US20220251079A1 (en) 2019-05-16 2022-08-11 Stingthera, Inc. Benzo[b][1,8]naphthyridine acetic acid derivatives and methods of use
JP2022533390A (ja) 2019-05-16 2022-07-22 スティングセラ インコーポレイテッド オキソアクリジニル酢酸誘導体および使用方法
WO2020236562A1 (en) 2019-05-17 2020-11-26 Cancer Prevention Pharmaceuticals, Inc. Methods for treating familial adenomatous polyposis
IL266728B (en) 2019-05-19 2020-11-30 Yeda Res & Dev Identification of recurrent mutant neopeptides
CA3141327A1 (en) 2019-05-20 2020-11-26 Pandion Operations, Inc. Madcam targeted immunotolerance
CN118834208A (zh) 2019-05-21 2024-10-25 美国安进公司 固态形式
CN113874036A (zh) 2019-05-24 2021-12-31 辉瑞公司 使用cdk抑制剂的联合治疗
WO2020243568A1 (en) 2019-05-30 2020-12-03 Bristol-Myers Squibb Company Methods of identifying a subject suitable for an immuno-oncology (i-o) therapy
KR20220016157A (ko) 2019-05-30 2022-02-08 브리스톨-마이어스 스큅 컴퍼니 세포 국재화 시그너쳐 및 조합 요법
CN114174538A (zh) 2019-05-30 2022-03-11 百时美施贵宝公司 适合于免疫肿瘤学疗法的多肿瘤基因特征
MX2021014932A (es) 2019-06-03 2022-04-06 Univ Chicago Métodos y composiciones para tratar cáncer con portadores de fármacos que se enlazan al colágeno.
US20220305135A1 (en) 2019-06-03 2022-09-29 The University Of Chicago Methods and compositions for treating cancer with cancer-targeted adjuvants
US20210038684A1 (en) 2019-06-11 2021-02-11 Alkermes Pharma Ireland Limited Compositions and Methods for Cancer Immunotherapy
KR20220020879A (ko) 2019-06-12 2022-02-21 에스크진 파마, 아이엔씨. 새로운 il-15 프로드럭 및 이를 사용하는 방법
CN114269715A (zh) 2019-06-12 2022-04-01 范德比尔特大学 作为氨基酸转运抑制剂的二苄基胺
JP2022536419A (ja) 2019-06-12 2022-08-16 ヴァンダービルト ユニバーシティー アミノ酸輸送阻害剤及びその使用
KR20220024495A (ko) 2019-06-14 2022-03-03 틸트 바이오세러퓨틱스 오이 종양용해성 아데노바이러스 및 체크포인트 억제제 조합 요법
JP2022536850A (ja) 2019-06-18 2022-08-19 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー Ｂ型肝炎ウイルス（ｈｂｖ）ワクチンおよび抗ｐｄ－１または抗ｐｄ－ｌ１抗体の組合せ
US20220233685A1 (en) 2019-06-18 2022-07-28 Janssen Sciences Ireland Unlimited Company Combination of hepatitis b virus (hbv) vaccines and anti-pd-1 antibody
WO2020263399A1 (en) 2019-06-26 2020-12-30 Massachusetts Institute Of Technology Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof
WO2020261097A1 (en) 2019-06-26 2020-12-30 Glaxosmithkline Intellectual Property Development Limited Il1rap binding proteins
US12485174B2 (en) 2019-06-27 2025-12-02 The George Washington University, A Congressionally Chartered Not-For-Profit Corporation HDAC6-activated macrophages, compositions, and uses thereof
EP3990635A1 (en) 2019-06-27 2022-05-04 Rigontec GmbH Design method for optimized rig-i ligands
WO2021003432A1 (en) 2019-07-02 2021-01-07 Fred Hutchinson Cancer Research Center Recombinant ad35 vectors and related gene therapy improvements
WO2021003417A1 (en) 2019-07-03 2021-01-07 Sumitomo Dainippon Pharma Oncology, Inc. Tyrosine kinase non-receptor 1 (tnk1) inhibitors and uses thereof
WO2021006199A1 (ja) 2019-07-05 2021-01-14 小野薬品工業株式会社 Ｐｄ－１／ｃｄ３二重特異性タンパク質による血液がん治療
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021005546A1 (en) 2019-07-09 2021-01-14 Cadila Healthcare Limited Antibodies to human programmed death receptor pd-1
UA130084C2 (uk) 2019-07-16 2025-11-05 Дзе Ріджентс Оф Дзе Юніверситі Оф Мічиган Імідазопіримідини як інгібітори eed і їх застосування
GB201910304D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
GB201910305D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
US11083705B2 (en) 2019-07-26 2021-08-10 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor
US12036204B2 (en) 2019-07-26 2024-07-16 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor
CA3147575A1 (en) 2019-07-29 2021-02-04 Yeda Research And Development Co. Ltd. Methods of treating and diagnosing lung cancer
CN112300280B (zh) * 2019-08-02 2022-10-11 正大天晴康方(上海)生物医药科技有限公司 一种抗pd-1抗体及其医药用途
MX2022001296A (es) 2019-08-02 2022-02-22 Amgen Inc Inhibidores de kif18a.
CA3147451A1 (en) 2019-08-02 2021-02-11 Amgen Inc. Kif18a inhibitors
MX2022001302A (es) 2019-08-02 2022-03-02 Amgen Inc Inhibidores de kif18a.
EP4007758A1 (en) 2019-08-02 2022-06-08 Mersana Therapeutics, Inc. Bis-[n-((5-carbamoyl)-1h-benzo[d]imidazol-2-yl)-pyrazol-5-carboxamide] derivatives and related compounds as sting (stimulator of interferon genes) agonists for the treatment of cancer
CN114514032A (zh) 2019-08-02 2022-05-17 兰提欧派普有限公司 用于治疗癌症的血管紧张素2型(at2)受体激动剂
ES3051917T3 (en) 2019-08-02 2025-12-30 Amgen Inc Kif18a inhibitors
CN114206386A (zh) 2019-08-05 2022-03-18 小野药品工业株式会社 免疫检查点抑制剂的有效性判定生物标记
WO2021024020A1 (en) 2019-08-06 2021-02-11 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
WO2021025140A1 (ja) 2019-08-08 2021-02-11 小野薬品工業株式会社 二重特異性タンパク質
CN114127121B (zh) 2019-08-12 2025-04-11 北京恩瑞尼生物科技股份有限公司 用于通过cd39表达细胞的adcc靶向促进和增强t细胞介导的免疫反应的方法和组合物
AU2020328025A1 (en) 2019-08-14 2022-03-03 Incyte Corporation Imidazolyl pyrimidinylamine compounds as CDK2 inhibitors
GB201912107D0 (en) 2019-08-22 2019-10-09 Amazentis Sa Combination
US20220388978A1 (en) 2019-08-27 2022-12-08 Regents Of The University Of Michigan Cereblon e3 ligase inhibitors
AU2020335928A1 (en) 2019-08-30 2022-02-17 Agenus Inc. Anti-CD96 antibodies and methods of use thereof
WO2021043961A1 (en) 2019-09-06 2021-03-11 Glaxosmithkline Intellectual Property Development Limited Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and chemotherapy
WO2021048292A1 (en) 2019-09-11 2021-03-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating melanoma
US12121565B2 (en) 2019-09-13 2024-10-22 Duke University Methods of treatment of specific cancers with NLRP3 inhibitors and anti-PD1/PD-L1 antibodies
TW202124444A (zh) 2019-09-16 2021-07-01 美商表面腫瘤學公司 抗ｃｄ３９抗體組合物及方法
WO2021055306A1 (en) 2019-09-16 2021-03-25 Bristol-Myers Squibb Company Dual capture method for analysis of antibody-drug conjugates
AU2020351178A1 (en) 2019-09-17 2022-03-17 Bial-R&D Investments, S.A. Substituted, saturated and unsaturated N-heterocyclic carboxamides and related compounds for their use in the treatment of medical disorders
CA3151022A1 (en) 2019-09-17 2021-03-25 Bial - R&D Investments, S.A. Substituted n-heterocyclic carboxamides as acid ceramidase inhibitors and their use as medicaments
BR112022004791A2 (pt) 2019-09-17 2022-06-21 Bial R&D Invest S A Carboxamidas de imidazol substituídas e seu uso no tratamento de distúrbios médicos
US12441807B2 (en) 2019-09-18 2025-10-14 Lamkap Bio Alpha AG Bispecific antibodies against CEACAM5 and CD3
CN114502590A (zh) 2019-09-18 2022-05-13 诺华股份有限公司 Entpd2抗体、组合疗法、以及使用这些抗体和组合疗法的方法
TW202124446A (zh) 2019-09-18 2021-07-01 瑞士商諾華公司 與ｅｎｔｐｄ２抗體之組合療法
AU2020347945B2 (en) 2019-09-18 2024-07-11 Novartis Ag NKG2D fusion proteins and uses thereof
CN110467675B (zh) * 2019-09-19 2020-08-14 合源生物科技(天津)有限公司 一种ctla-4单克隆抗体6f1及其用于抗肿瘤的用途
TW202124448A (zh) 2019-09-19 2021-07-01 美商必治妥美雅史谷比公司 於酸性pH結合VISTA之抗體
US20220380368A1 (en) 2019-09-19 2022-12-01 The Regents Of The University Of Michigan Spirocyclic androgen receptor protein degraders
JP2022549273A (ja) 2019-09-22 2022-11-24 ブリストル－マイヤーズ スクイブ カンパニー Ｌａｇ－３アンタゴニスト治療のための定量的空間プロファイリング
JP2022548791A (ja) * 2019-09-24 2022-11-21 ミラティ セラピューティクス， インコーポレイテッド 組み合わせ療法
TWI875823B (zh) 2019-09-25 2025-03-11 美商表面腫瘤學有限責任公司 抗ｉｌ-２７抗體及用途
CA3152263A1 (en) 2019-09-25 2021-04-01 Julia SANTUCCI PEREIRA DEL BUONO Composite biomarker for cancer therapy
WO2021062122A1 (en) 2019-09-25 2021-04-01 Seagen Inc. Combination anti-cd30 adc, anti-pd-1 and chemotherapeutic for treatment of hematopoietic cancers
EP4034537A1 (en) 2019-09-26 2022-08-03 Novartis AG Antiviral pyrazolopyridinone compounds
AU2020355614B2 (en) 2019-09-27 2024-12-05 Glaxosmithkline Intellectual Property Development Limited Antigen binding proteins
CN114401997B (zh) 2019-09-28 2025-05-16 奥美药业有限公司 细胞因子前药和双前药
AR120109A1 (es) 2019-09-30 2022-02-02 Incyte Corp Compuestos de pirido[3,2-d]pirimidina como inmunomoduladores
CA3151322A1 (en) 2019-10-01 2021-04-08 Silverback Therapeutics, Inc. Combination therapy with immune stimulatory conjugates
EP3800201A1 (en) 2019-10-01 2021-04-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Cd28h stimulation enhances nk cell killing activities
WO2021067374A1 (en) 2019-10-01 2021-04-08 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
AU2020358979A1 (en) 2019-10-03 2022-04-21 Xencor, Inc. Targeted IL-12 heterodimeric Fc-fusion proteins
EP4037714A1 (en) 2019-10-03 2022-08-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for modulating macrophages polarization
WO2021064184A1 (en) 2019-10-04 2021-04-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for the treatment of ovarian cancer, breast cancer or pancreatic cancer
TW202128757A (zh) 2019-10-11 2021-08-01 美商建南德克公司 具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白
GB201914747D0 (en) 2019-10-11 2019-11-27 Ultrahuman Eight Ltd PD1 and vegfr2 dual-binding agents
JOP20220087A1 (ar) 2019-10-11 2023-01-30 Incyte Corp أمينات ثنائية الحلقة كمثبطات لـ cdk2
US11607416B2 (en) 2019-10-14 2023-03-21 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US12380963B2 (en) 2019-10-14 2025-08-05 The Medical College Of Wisconsin, Inc. Gene expression signature of hyperprogressive disease (HPD) in patients after anti-PD-1 immunotherapy
US20240139193A1 (en) 2019-10-15 2024-05-02 Amgen Inc. Combination therapy of kras inhibitor and shp2 inhibitor for treatment of cancers
WO2021074683A1 (en) 2019-10-16 2021-04-22 Avacta Life Sciences Limited Bispecific anti-pd-l1 and anti-fcrn polypeptides
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
CA3157889A1 (en) 2019-10-17 2021-04-22 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods for diagnosing nasal intestinal type adenocarcinomas
CA3158298A1 (en) 2019-10-21 2021-04-29 Novartis Ag Combination therapies with venetoclax and tim-3 inhibitors
CA3157665A1 (en) 2019-10-21 2021-04-29 Novartis Ag Tim-3 inhibitors and uses thereof
US20220401539A1 (en) 2019-10-22 2022-12-22 Institut Curie Immunotherapy Targeting Tumor Neoantigenic Peptides
JP7707161B2 (ja) 2019-10-23 2025-07-14 チェックメイト ファーマシューティカルズ， インコーポレイテッド 合成ｒｉｇ－ｉ様受容体アゴニスト
US11459389B2 (en) 2019-10-24 2022-10-04 Massachusetts Institute Of Technology Monoclonal antibodies that bind human CD161
EP4048671A1 (en) 2019-10-24 2022-08-31 Amgen Inc. Pyridopyrimidine derivatives useful as kras g12c and kras g12d inhibitors in the treatment of cancer
EP4048295A1 (en) 2019-10-25 2022-08-31 Iovance Biotherapeutics, Inc. Gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
US20240190961A1 (en) 2019-10-25 2024-06-13 Daiichi Sankyo Company, Limited Combination of anti-garp antibody and immunomodulator
NL2024108B1 (en) 2019-10-26 2021-07-19 Vitroscan B V Methods and apparatus for measuring immune-cell mediated anti-tumoroid responses
CN114829357A (zh) 2019-10-28 2022-07-29 中国科学院上海药物研究所 五元杂环氧代羧酸类化合物及其医药用途
US20240122938A1 (en) 2019-10-29 2024-04-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating uveal melanoma
CN115023227B (zh) 2019-10-29 2024-06-18 卫材R&D管理有限公司 用于治疗癌症的PD-1拮抗剂、VEGFR/FGFR/RET酪氨酸激酶抑制剂和CBP/β-联蛋白抑制剂的组合
EP4051321A4 (en) 2019-10-30 2023-11-22 Duke University IMMUNOTHERAPY WITH COMBINATION THERAPY WITH AN IMMUNE TOXIN
WO2021087458A2 (en) 2019-11-02 2021-05-06 Board Of Regents, The University Of Texas System Targeting nonsense-mediated decay to activate p53 pathway for the treatment of cancer
EP4055153A4 (en) 2019-11-04 2024-02-14 Duke University TREATMENT OF PRIMARY AND METASTASIC CANCER
MX2022005357A (es) 2019-11-04 2022-06-02 Revolution Medicines Inc Inhibidores de ras.
JP2022553858A (ja) 2019-11-04 2022-12-26 レボリューション メディシンズ インコーポレイテッド Ｒａｓ阻害剤
CN119868377A (zh) 2019-11-04 2025-04-25 阿斯利康(瑞典)有限公司 用于治疗癌症的组合疗法
CN114867735A (zh) 2019-11-04 2022-08-05 锐新医药公司 Ras抑制剂
CN114901281A (zh) 2019-11-05 2022-08-12 细胞基因公司 与2-(4-氯苯基)-n-((2-(2,6-二氧代哌啶-3-基)-1-氧代异吲哚啉-5-基)甲基)-2,2-二氟乙酰胺的组合疗法
CN115298549A (zh) 2019-11-05 2022-11-04 百时美施贵宝公司 M蛋白测定及其用途
CN115066613A (zh) 2019-11-06 2022-09-16 基因泰克公司 用于治疗血液癌症的诊断和治疗方法
WO2021092220A1 (en) 2019-11-06 2021-05-14 Bristol-Myers Squibb Company Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy
WO2021092221A1 (en) 2019-11-06 2021-05-14 Bristol-Myers Squibb Company Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy
AU2020378280A1 (en) 2019-11-07 2022-04-07 Feng Biosciences, Ltd. Classification of tumor microenvironments
CA3160479A1 (en) 2019-11-08 2021-05-14 Bristol-Myers Squibb Company Lag-3 antagonist therapy for melanoma
KR20220100903A (ko) 2019-11-08 2022-07-18 레볼루션 메디슨즈, 인크. 이환식 헤테로아릴 화합물 및 이의 용도
CR20220237A (es) 2019-11-11 2022-08-05 Incyte Corp Sales y formas cristalinas de un inhibidor de pd-1/pd-l1
TWI895295B (zh) 2019-11-12 2025-09-01 美商方得生醫療公司 偵測編碼新生抗原之融合基因之方法
TW202130618A (zh) 2019-11-13 2021-08-16 美商建南德克公司 治療性化合物及使用方法
EP4058432A1 (en) 2019-11-14 2022-09-21 Amgen Inc. Improved synthesis of kras g12c inhibitor compound
CN114728960B (zh) 2019-11-14 2025-05-27 美国安进公司 Kras g12c抑制剂化合物的改善的合成
WO2021097256A1 (en) 2019-11-14 2021-05-20 Cohbar, Inc. Cxcr4 antagonist peptides
IL293118A (en) * 2019-11-21 2022-07-01 Beigene Ltd Methods of cancer treatment using anti-ox40 antibodies in combination with anti-tigit antibodies
EP3824954A1 (en) 2019-11-22 2021-05-26 Centre National de la Recherche Scientifique Device, apparatus and method for minibeam radiation therapy
WO2021102468A1 (en) 2019-11-22 2021-05-27 Theravance Biopharma R&D Ip, Llc Substituted 1,5-naphthyridines or quinolines as alk5 inhibitors
JP2023502264A (ja) 2019-11-22 2023-01-23 スミトモ ファーマ オンコロジー， インコーポレイテッド 固体用量医薬組成物
WO2021102624A1 (en) * 2019-11-25 2021-06-03 Hangzhou Branch Of Technical Institute Of Physics And Chemistry, Chinese Academy Of Sciences Covalent protein drugs developed via proximity-enabled reactive therapeutics (perx)
KR20220104217A (ko) 2019-11-26 2022-07-26 노파르티스 아게 Cd19 및 cd22 키메라 항원 수용체 및 이의 용도
WO2021108025A1 (en) 2019-11-26 2021-06-03 Massachusetts Institute Of Technology Cell-based cancer vaccines and cancer therapies
US20230032934A1 (en) 2019-11-27 2023-02-02 Myst Therapeutics, Llc Method of producing tumor-reactive t cell composition using modulatory agents
EP4065231A1 (en) 2019-11-27 2022-10-05 Revolution Medicines, Inc. Covalent ras inhibitors and uses thereof
WO2021106978A1 (ja) 2019-11-27 2021-06-03 サイトリミック株式会社 医薬組成物
CN110927389B (zh) * 2019-11-29 2021-07-16 中国科学院苏州生物医学工程技术研究所 一种癌症生物标志物、用途
EP3831849A1 (en) 2019-12-02 2021-06-09 LamKap Bio beta AG Bispecific antibodies against ceacam5 and cd47
US11897891B2 (en) 2019-12-04 2024-02-13 Incyte Corporation Tricyclic heterocycles as FGFR inhibitors
AU2020397956A1 (en) 2019-12-04 2022-07-07 Orna Therapeutics, Inc. Circular RNA compositions and methods
WO2021113462A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Derivatives of an fgfr inhibitor
WO2021113644A1 (en) 2019-12-05 2021-06-10 Multivir Inc. Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer
EP4069683A1 (en) 2019-12-06 2022-10-12 Mersana Therapeutics, Inc. Dimeric compounds as sting agonists
US11897950B2 (en) 2019-12-06 2024-02-13 Augusta University Research Institute, Inc. Osteopontin monoclonal antibodies
WO2021119105A1 (en) 2019-12-09 2021-06-17 Seagen Inc. Combination therapy with liv1-adc and pd-1 antagonist
GB201918230D0 (en) 2019-12-11 2020-01-22 Prec Therapeutics Ltd Antibodies and their uses
JP7749561B2 (ja) 2019-12-11 2025-10-06 アイオバンス バイオセラピューティクス，インコーポレイテッド 腫瘍浸潤リンパ球（ｔｉｌ）の産生のためのプロセス及びそれを使用する方法
US20230028414A1 (en) 2019-12-16 2023-01-26 Amgen Inc. Dosing regimen of kras g12c inhibitor
US20230084899A1 (en) 2019-12-16 2023-03-16 Bayer Aktiengesellschaft Combination of an ahr-inhibitor and an pd1-inhibitor antibody and its use in the treatment of cancer
AU2020406083A1 (en) 2019-12-17 2022-06-16 Boehringer Ingelheim International Gmbh Bifunctional molecules comprising an IL-7 variant
WO2021126725A1 (en) 2019-12-17 2021-06-24 Merck Sharp & Dohme Corp. Novel substituted 1,3,8-triazaspiro[4,5]decane-2,4-dione compounds as indoleamine 2,3-dioxygenase (ido) and/or tryptophan 2,3-dioxygenase (tdo) inhibitors
JP2023509359A (ja) 2019-12-17 2023-03-08 フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド 鉄依存性細胞分解の誘導物質との併用抗癌療法
US12415785B2 (en) 2019-12-18 2025-09-16 Ctxt Pty Ltd Compound modulators of sting
MX2022006932A (es) 2019-12-19 2022-07-11 Bristol Myers Squibb Co Combinaciones de inhibidores de diacilglicerol cinasas (dgk) y antagonistas de puntos de control.
US20230346901A1 (en) 2019-12-19 2023-11-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and vaccine compositions to treat cancers
BR112022011998A2 (pt) 2019-12-20 2022-08-30 Novartis Ag Usos de anticorpos anti-tgfss e inibidores de checkpoint para o tratamento de doenças proliferativas
EP4079763A4 (en) * 2019-12-20 2023-10-11 Guangdong Feipeng Pharmaceutical Co., Ltd MONOCLONAL ANTIBODY AGAINST HUMAN PROGRAMMED DEATH-1 (PD-1)
CN113024670A (zh) * 2019-12-25 2021-06-25 百奥泰生物制药股份有限公司 Ctla-4抗体及其制备方法
CN113045655A (zh) 2019-12-27 2021-06-29 高诚生物医药(香港)有限公司 抗ox40抗体及其用途
WO2021138407A2 (en) 2020-01-03 2021-07-08 Marengo Therapeutics, Inc. Multifunctional molecules that bind to cd33 and uses thereof
US20210205311A1 (en) 2020-01-03 2021-07-08 Incyte Corporation Combination Therapy Comprising A2A/A2B and PD-1/PD-L1 Inhibitors
AU2020416273A1 (en) 2020-01-03 2022-07-28 Marengo Therapeutics, Inc. Anti-TCR antibody molecules and uses thereof
TW202140011A (zh) 2020-01-07 2021-11-01 美商銳新醫藥公司 Shp2抑制劑給藥和治療癌症的方法
WO2021141977A1 (en) 2020-01-07 2021-07-15 Board Of Regents, The University Of Texas System Improved human methyl thioadenosine/adenosine depleting enzyme variants for cancer therapy
WO2021141751A1 (en) 2020-01-07 2021-07-15 Merck Sharp & Dohme Corp. Arginase inhibitors and methods of use
WO2021142237A1 (en) 2020-01-10 2021-07-15 Clovis Oncology, Inc. Methods for administering lucitanib and combinations thereof
CN115279400A (zh) 2020-01-10 2022-11-01 布里格姆妇女医院 用于跨血脑屏障递送免疫治疗剂以治疗脑癌的方法和组合物
CA3166509A1 (en) 2020-01-14 2021-07-22 Synthekine, Inc. Biased il2 muteins methods and compositions
WO2021146424A1 (en) 2020-01-15 2021-07-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
EP4090770A1 (en) 2020-01-17 2022-11-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating melanoma
JP2023510393A (ja) 2020-01-17 2023-03-13 ノバルティス アーゲー 骨髄異形成症候群または慢性骨髄単球性白血病の処置に使用するためのｔｉｍ－３阻害剤と低メチル化剤とを含む組合せ
CA3167689A1 (en) 2020-01-28 2021-08-05 Glaxosmithkline Intellectual Property Development Limited Combination treatments and uses and methods thereof
EP4097234A1 (en) 2020-01-28 2022-12-07 Université de Strasbourg Antisense oligonucleotide targeting linc00518 for treating melanoma
IL294944A (en) 2020-01-28 2022-09-01 Genentech Inc Il15/il15r alpha heterodimeric fc-fusion proteins for the treatment of cancer
JP2023513006A (ja) 2020-01-29 2023-03-30 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム Ｎｒｇ１融合体を有するがんの治療のためのｅｇｆｒ／ｈｅｒ２チロシンキナーゼインヒビターおよび／またはｈｅｒ２／ｈｅｒ３抗体の使用
WO2021154750A1 (en) 2020-01-29 2021-08-05 Corcept Therapeutics Incorporated TREATMENT OF ADRENOCORTICAL CARCINOMA WITH SELECTIVE GLUCOCORTICOID RECEPTOR MODULATORS (SGRMs) AND ANTIBODY CHECKPOINT INHIBITORS
EP4096789A4 (en) 2020-01-29 2023-10-11 Board of Regents, The University of Texas System USE OF POZIOTINIB TO TREAT CANCER WITH NRG1 FUSIONS
WO2021152400A1 (en) 2020-01-30 2021-08-05 Gnubiotics Sciences Sa Compositions comprising pig stomach mucins and uses thereof
CA3168923A1 (en) 2020-01-30 2021-08-05 ONA Therapeutics S.L. Combination therapy for treatment of cancer and cancer metastasis
MX2022009391A (es) 2020-01-31 2022-09-26 Genentech Inc Metodos para inducir linfocitos t especificos para neoepitopo con un antagonista de union al eje de pd-1 y una vacuna de arn.
EP4100126A1 (en) 2020-02-05 2022-12-14 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for discontinuing a treatment with a tyrosine kinase inhibitor (tki)
JP2023514152A (ja) 2020-02-06 2023-04-05 ブリストル－マイヤーズ スクイブ カンパニー Ｉｌ－１０およびその使用
CN113244385A (zh) * 2020-02-07 2021-08-13 上海君实生物医药科技股份有限公司 抗pd-1抗体在治疗恶性肿瘤中的用途
WO2021167908A1 (en) 2020-02-17 2021-08-26 Board Of Regents, The University Of Texas System Methods for expansion of tumor infiltrating lymphocytes and use thereof
WO2021168079A1 (en) 2020-02-21 2021-08-26 Pandion Operations, Inc. Tissue targeted immunotolerance with a cd39 effector
JP2023516195A (ja) 2020-02-26 2023-04-18 バイオグラフ ５５，インク． Ｃ１９ ｃ３８二特異性抗体
CA3172894A1 (en) 2020-02-27 2021-09-02 H. Lee Moffitt Cancer Center And Research Institute Inc. Tumor-infiltrating lymphocytes with enhanced tumor reactivity
KR20220158727A (ko) 2020-02-27 2022-12-01 미스트 쎄라퓨틱스, 엘엘씨 종양 반응성 t 세포의 생체외 농축 및 확장 방법 및 이의 관련 조성물
WO2021171264A1 (en) 2020-02-28 2021-09-02 Novartis Ag Dosing of a bispecific antibody that binds cd123 and cd3
WO2021170777A1 (en) 2020-02-28 2021-09-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosing, prognosing and managing treatment of breast cancer
AU2021225491A1 (en) 2020-02-28 2022-10-20 Novartis Ag A triple pharmaceutical combination comprising dabrafenib, an Erk inhibitor and a RAF inhibitor
AU2021357520A1 (en) 2020-03-05 2022-09-29 Neotx Therapeutics Ltd. Methods and compositions for treating cancer with immune cells
PH12022552347A1 (en) 2020-03-06 2024-01-29 Incyte Corp Combination therapy comprising axl/mer and pd-1/pd-l1 inhibitors
IL295979A (en) 2020-03-06 2022-10-01 Ona Therapeutics S L Anti-cd36 antibodies and their use for cancer treatment
US20230089536A1 (en) 2020-03-06 2023-03-23 Celgene Quanticel Research, Inc. Combination of an lsd-1 inhibitor and nivolumab for use in treating sclc or sqnsclc
WO2021177980A1 (en) 2020-03-06 2021-09-10 Genentech, Inc. Combination therapy for cancer comprising pd-1 axis binding antagonist and il6 antagonist
WO2021177822A1 (en) 2020-03-06 2021-09-10 Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Modulating anti-tumor immunity
EP3878446A1 (en) 2020-03-09 2021-09-15 Universite De Geneve Hsd11b1 inhibitors for use in immunotherapy and uses thereof
JP2023516459A (ja) 2020-03-09 2023-04-19 ブリストル－マイヤーズ スクイブ カンパニー 増強されたアゴニスト活性を有するｃｄ４０に対する抗体
US20230093147A1 (en) 2020-03-09 2023-03-23 President And Fellows Of Harvard College Methods and compositions relating to improved combination therapies
WO2021183973A1 (en) * 2020-03-13 2021-09-16 Research Development Foundation Methods for diagnosing and treating cancers
CA3172423A1 (en) 2020-03-20 2021-03-22 Alex WESSELHOEFT Circular rna compositions and methods
JP2023519254A (ja) 2020-03-23 2023-05-10 ブリストル－マイヤーズ スクイブ カンパニー がんを処置するための抗ｃｃｒ８抗体
CN115605268A (zh) * 2020-03-26 2023-01-13 康尔义明生物制药公司（Ca） 抗pd-1抗体及使用方法
US12522623B2 (en) 2020-03-26 2026-01-13 Regents Of The University Of Michigan Small molecule STAT protein degraders
JP2023519346A (ja) 2020-03-27 2023-05-10 メンドゥス・ベスローテン・フェンノートシャップ 養子細胞療法の有効性を増強するための白血病由来の改変細胞のエクスビボ（ｅｘ ｖｉｖｏ）使用
WO2021203131A1 (en) 2020-03-31 2021-10-07 Theravance Biopharma R&D Ip, Llc Substituted pyrimidines and methods of use
EP4218826A3 (en) 2020-04-02 2023-10-25 Mersana Therapeutics, Inc. Antibody drug conjugates comprising sting agonists
CN115698717A (zh) 2020-04-03 2023-02-03 基因泰克公司 癌症的治疗和诊断方法
WO2021205444A1 (en) 2020-04-06 2021-10-14 Yeda Research And Development Co. Ltd. Methods of diagnosing cancer and predicting responsiveness to therapy
WO2021205631A1 (ja) 2020-04-10 2021-10-14 小野薬品工業株式会社 Ｓｔｉｎｇ作動化合物
JP2023522857A (ja) 2020-04-10 2023-06-01 ジュノー セラピューティクス インコーポレイテッド Ｂ細胞成熟抗原を標的とするキメラ抗原受容体によって操作された細胞療法に関する方法および使用
TW202200136A (zh) 2020-04-10 2022-01-01 日商小野藥品工業股份有限公司 癌治療方法
CA3171557A1 (en) 2020-04-14 2021-10-21 Marc S. BALLAS Combination treatment for cancer involving anti-icos and anti-pd1 antibodies, optionally further involving anti-tim3 antibodies
CA3171597A1 (en) 2020-04-14 2021-10-21 Glaxosmithkline Intellectual Property Development Limited Combination treatment for cancer
MX2022012780A (es) 2020-04-16 2023-01-18 Incyte Corp Inhibidores de homologo de oncogen viral de sarcoma de rata kirsten (kras) triciclicos fusionados.
WO2021216572A1 (en) 2020-04-20 2021-10-28 Massachusetts Institute Of Technology Lipid compositions for delivery of sting agonist compounds and uses thereof
BR112022021105A2 (pt) 2020-04-21 2022-11-29 Novartis Ag Regime de dosagem para tratar uma doença modulada por csf-1r
US11834485B2 (en) 2020-04-21 2023-12-05 Regeneron Pharmaceuticals, Inc. IL-2 variants with reduced binding to IL-2 receptor alpha and uses thereof
AU2021258257A1 (en) 2020-04-22 2022-11-10 Iovance Biotherapeutics, Inc. Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy
KR20230004682A (ko) 2020-04-22 2023-01-06 머크 샤프 앤드 돔 엘엘씨 인터류킨-2 수용체 베타 감마c 이량체에 대해 편향되고 비펩티드성 수용성 중합체에 접합된 인간 인터류킨-2 접합체
TW202206100A (zh) 2020-04-27 2022-02-16 美商西健公司 癌症之治療
WO2021222167A1 (en) 2020-04-28 2021-11-04 Genentech, Inc. Methods and compositions for non-small cell lung cancer immunotherapy
US20230181756A1 (en) 2020-04-30 2023-06-15 Novartis Ag Ccr7 antibody drug conjugates for treating cancer
WO2021224186A1 (en) 2020-05-04 2021-11-11 Institut Curie New pyridine derivatives as radiosensitizers
MX2022013808A (es) * 2020-05-04 2023-02-09 Beyondspring Pharmaceuticals Inc Terapia de combinacion triple para mejorar la eliminacion de celulas cancerigenas en canceres con baja inmunogenicidad.
TW202208616A (zh) 2020-05-04 2022-03-01 美商艾歐凡斯生物治療公司 改良之腫瘤反應性ｔ細胞的選擇
CA3175491A1 (en) 2020-05-05 2021-11-11 David DILILLO Car comprising cd28 zeta and cd3 zeta
CN115835909A (zh) 2020-05-05 2023-03-21 泰昂治疗公司 大麻素受体2型（cb2）调节剂和其用途
US20230227917A1 (en) 2020-05-05 2023-07-20 Hoffmann-La Roche Inc. Predicting response to pd-1 axis inhibitors
EP4146644A1 (en) 2020-05-06 2023-03-15 Merck Sharp & Dohme LLC Il4i1 inhibitors and methods of use
CN115943312A (zh) 2020-05-07 2023-04-07 法国居里学院 免疫抑制性成纤维细胞群体的生物标志物antxr1及其在预测对免疫疗法的反应中的用途
WO2021231526A1 (en) 2020-05-13 2021-11-18 Incyte Corporation Fused pyrimidine compounds as kras inhibitors
IL298019A (en) 2020-05-13 2023-01-01 Massachusetts Inst Technology Compositions of polymeric microdevices and their use in cancer immunotherapy
US20230192867A1 (en) 2020-05-15 2023-06-22 Bristol-Myers Squibb Company Antibodies to garp
PE20230784A1 (es) 2020-05-19 2023-05-11 Boehringer Ingelheim Int Moleculas de fijacion para el tratamiento de cancer
US20230302050A1 (en) 2020-05-20 2023-09-28 Institut Curie Single Domain Antibodies and Their Use in Cancer Therapies
CN115803084A (zh) 2020-05-21 2023-03-14 得克萨斯大学体系董事会 具有vgll1特异性的t细胞受体和其用途
KR20230015954A (ko) 2020-05-26 2023-01-31 리제너론 파마슈티칼스 인코포레이티드 Pd-1 억제제의 투여에 의한 자궁경부암의 치료 방법
KR102871588B1 (ko) 2020-05-26 2025-10-17 베링거 인겔하임 인터내셔날 게엠베하 항-pd-1 항체
CA3185040A1 (en) 2020-05-26 2021-12-02 Truebinding, Inc. Methods of treating inflammatory diseases by blocking galectin-3
WO2021239838A2 (en) 2020-05-26 2021-12-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Severe acute respiratory syndrome coronavirus 2 (sars-cov-2) polypeptides and uses thereof for vaccine purposes
EP4157319A1 (en) 2020-05-28 2023-04-05 Modernatx, Inc. Use of mrnas encoding ox40l, il-23 and il-36gamma for treating cancer
EP4157923A2 (en) 2020-05-29 2023-04-05 President And Fellows Of Harvard College Living cells engineered with polyphenol-functionalized biologically active nanocomplexes
WO2021247836A1 (en) 2020-06-03 2021-12-09 Board Of Regents, The University Of Texas System Methods for targeting shp-2 to overcome resistance
WO2021245111A1 (en) 2020-06-03 2021-12-09 Boehringer Ingelheim International Gmbh Recombinant rhabdovirus encoding for a cd80 extracellular domain fc-fusion protein
US11767353B2 (en) 2020-06-05 2023-09-26 Theraly Fibrosis, Inc. Trail compositions with reduced immunogenicity
WO2021253041A1 (en) 2020-06-10 2021-12-16 Theravance Biopharma R&D Ip, Llc Naphthyridine derivatives useful as alk5 inhibitors
WO2021252920A1 (en) 2020-06-11 2021-12-16 Novartis Ag Zbtb32 inhibitors and uses thereof
JP2023529206A (ja) 2020-06-12 2023-07-07 ジェネンテック， インコーポレイテッド がん免疫療法のための方法及び組成物
KR20230025691A (ko) 2020-06-16 2023-02-22 제넨테크, 인크. 삼중 음성 유방암을 치료하기 위한 방법과 조성물
BR112022025550A2 (pt) 2020-06-18 2023-03-07 Revolution Medicines Inc Métodos para retardar, prevenir e tratar resistência adquirida aos inibidores de ras
CA3153085A1 (en) 2020-06-19 2021-12-23 F. Hoffmann-La Roche Ag Antibodies binding to cd3 and cd19
TW202214857A (zh) 2020-06-19 2022-04-16 法商昂席歐公司 新型結合核酸分子及其用途
EP4168007A1 (en) 2020-06-23 2023-04-26 Novartis AG Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
WO2021260675A1 (en) 2020-06-24 2021-12-30 Yeda Research And Development Co. Ltd. Agents for sensitizing solid tumors to treatment
WO2021262969A1 (en) 2020-06-24 2021-12-30 The General Hospital Corporation Materials and methods of treating cancer
WO2021260443A1 (en) 2020-06-24 2021-12-30 Bayer Aktiengesellschaft Combinations of 2,3-dihydroimidazo[1,2-c]quinazolines
CN115916191A (zh) 2020-06-25 2023-04-04 新基公司 用组合疗法治疗癌症的方法
WO2021263167A2 (en) 2020-06-26 2021-12-30 Amgen Inc. Il-10 muteins and fusion proteins thereof
CN116209677A (zh) * 2020-06-26 2023-06-02 索伦托药业有限公司 抗pd1抗体及其用途
CN116096906A (zh) 2020-06-29 2023-05-09 旗舰创业创新五公司 工程化以促进萨诺传递的病毒及其在治疗癌症中的用途
EP4171617A1 (en) 2020-06-30 2023-05-03 Mendus B.V. Use of leukemia-derived cells in ovarian cancer vaccines
EP4172628A1 (en) 2020-06-30 2023-05-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the risk of recurrence and/or death of patients suffering from a solid cancer after preoperative adjuvant therapy and radical surgery
CN115997123A (zh) 2020-06-30 2023-04-21 国家医疗保健研究所 用于预测实体癌患者在术前辅助治疗后复发和/或死亡风险的方法
US12472176B2 (en) 2020-07-07 2025-11-18 Celgene Corporation Pharmaceutical compositions comprising (S)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile and methods of using the same
CA3182579A1 (en) 2020-07-07 2022-01-13 Ugur Sahin Therapeutic rna for hpv-positive cancer
WO2022011204A1 (en) 2020-07-10 2022-01-13 The Regents Of The University Of Michigan Small molecule androgen receptor protein degraders
US20230233690A1 (en) 2020-07-10 2023-07-27 The Regents Of The University Of Michigan Androgen receptor protein degraders
WO2022009157A1 (en) 2020-07-10 2022-01-13 Novartis Ag Lhc165 and spartalizumab combinations for treating solid tumors
WO2022015716A2 (en) * 2020-07-13 2022-01-20 The Children's Medical Center Corporation Novel anti-pd1 antibodies for inhibiting t-cell activity
TW202216778A (zh) 2020-07-15 2022-05-01 美商安進公司 Ｔｉｇｉｔ及ｃｄ１１２ｒ阻斷
US11787775B2 (en) 2020-07-24 2023-10-17 Genentech, Inc. Therapeutic compounds and methods of use
KR20230042038A (ko) * 2020-07-27 2023-03-27 마크로제닉스, 인크. PD-1 x CTLA-4 이중특이적 분자의 사용 방법
WO2022023379A1 (en) 2020-07-28 2022-02-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for preventing and treating a cancer
CN116406274A (zh) * 2020-07-30 2023-07-07 迪赞纳生命科学公开有限公司 用于治疗冠状病毒的cd3抗体
TW202221031A (zh) 2020-07-30 2022-06-01 英商阿法克塔生命科學有限公司 血清半衰期延長之pd-l1抑制多肽
EP4188549A1 (en) 2020-08-03 2023-06-07 Novartis AG Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
EP4192852A4 (en) 2020-08-05 2025-07-23 Synthekine Inc IL10RA-BINDING MOLECULES AND METHODS OF USE
BR112023001723A2 (pt) 2020-08-05 2023-05-02 Synthekine Inc Moléculas de ligação à gp130 e métodos de uso
CA3190415A1 (en) 2020-08-05 2022-02-10 Synthekine, Inc. Il2rb/il2rg synthetic cytokines
AU2021321525A1 (en) 2020-08-05 2023-03-30 Synthekine, Inc. IL10 receptor binding molecules and methods of use
AU2021320327A1 (en) 2020-08-05 2023-03-23 Synthekine, Inc. IL10Rb binding molecules and methods of use
WO2022036146A1 (en) 2020-08-12 2022-02-17 Genentech, Inc. Diagnostic and therapeutic methods for cancer
JP7788447B2 (ja) 2020-08-13 2025-12-18 ブリストル－マイヤーズ スクイブ カンパニー 目的の細胞を標的とするためのｉｌ－２の向け直し方法
CN116157513A (zh) 2020-08-18 2023-05-23 昂希莱斯制药公司 经修饰的猪胰腺弹性蛋白酶蛋白
CN116761818A (zh) 2020-08-26 2023-09-15 马伦戈治疗公司 检测trbc1或trbc2的方法
MX2023002123A (es) 2020-08-26 2023-03-15 Regeneron Pharma Metodos de tratamiento de cancer mediante la administracion de un inhibidor de pd-1.
CN111944052B (zh) * 2020-08-26 2022-02-11 中国药科大学 抗TNF-α/PD-1双特异性抗体及其应用
EP4204095A1 (en) 2020-08-28 2023-07-05 Bristol-Myers Squibb Company Lag-3 antagonist therapy for hepatocellular carcinoma
US11999752B2 (en) 2020-08-28 2024-06-04 Incyte Corporation Vinyl imidazole compounds as inhibitors of KRAS
EP4204454A4 (en) * 2020-08-31 2024-07-24 Biosion, Inc. PD-1 BINDING ANTIBODIES AND THEIR USES
KR20230061430A (ko) 2020-08-31 2023-05-08 브리스톨-마이어스 스큅 컴퍼니 세포 국재화 시그너쳐 및 면역요법
CN111808196B (zh) * 2020-08-31 2020-12-29 北京百奥赛图基因生物技术有限公司 抗pd-1抗体及其用途
KR20230087451A (ko) 2020-09-02 2023-06-16 주식회사 파멥신 암 환자를 치료하기 위한 pd-1 길항제 및 vegfr-2에 대한 길항제의 조합 요법
KR20230081726A (ko) 2020-09-03 2023-06-07 레볼루션 메디슨즈, 인크. Shp2 돌연변이가 있는 악성 종양을 치료하기 위한 sos1 억제제의 용도
AU2021337650A1 (en) 2020-09-03 2023-05-04 Regeneron Pharmaceuticals, Inc. Methods of treating cancer pain by administering a pd-1 inhibitor
CA3188236A1 (en) 2020-09-14 2022-03-17 Boehringer Ingelheim International Gmbh Heterologous prime boost vaccine
TW202227460A (zh) 2020-09-15 2022-07-16 美商銳新醫藥公司 Ｒａｓ抑制劑
KR20230082038A (ko) 2020-10-02 2023-06-08 리제너론 파마슈티칼스 인코포레이티드 사이토카인 방출 증후군을 저하하는 암 치료용 항체 조합
WO2022072783A1 (en) 2020-10-02 2022-04-07 Incyte Corporation Bicyclic dione compounds as inhibitors of kras
JP2023548745A (ja) 2020-10-02 2023-11-21 ドラセン ファーマシューティカルズ インコーポレイテッド 皮下投与のための（ｓ）－イソプロピル２－（（ｓ）－２－アセトアミド－３－（１ｈ－インドール－３－イル）プロパンアミド）－６－ジアゾ－５－オキソヘキサノエートを含む凍結乾燥組成物およびその使用
CN116406369A (zh) 2020-10-05 2023-07-07 百时美施贵宝公司 用于浓缩蛋白质的方法
JP2023546359A (ja) 2020-10-06 2023-11-02 アイオバンス バイオセラピューティクス，インコーポレイテッド 腫瘍浸潤リンパ球療法によるｎｓｃｌｃ患者の治療
WO2022076606A1 (en) 2020-10-06 2022-04-14 Iovance Biotherapeutics, Inc. Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
US20230364127A1 (en) 2020-10-06 2023-11-16 Codiak Biosciences, Inc. Extracellular vesicle-aso constructs targeting stat6
KR20230084476A (ko) 2020-10-08 2023-06-13 타르그이뮨 테라퓨틱스 아게 암의 치료를 위한 면역요법
EP4226377A1 (en) 2020-10-09 2023-08-16 Worldwide Innovative Network Novel prediction method and gene signatures for the treatment of cancer
US20240002511A1 (en) * 2020-10-11 2024-01-04 Bio-Thera Solutions, Ltd. Use of anti-pd-1 antibody in combination therapy
EP4228610A1 (en) 2020-10-13 2023-08-23 Kriya Therapeutics, Inc. Viral vector constructs for delivery of nucleic acids encoding cytokines and uses thereof for treating cancer
EP4229090A1 (en) 2020-10-16 2023-08-23 Université d'Aix-Marseille Anti-gpc4 single domain antibodies
EP4232040A1 (en) 2020-10-20 2023-08-30 F. Hoffmann-La Roche AG Combination therapy of pd-1 axis binding antagonists and lrrk2 inhitibors
WO2022086957A1 (en) 2020-10-20 2022-04-28 Genentech, Inc. Peg-conjugated anti-mertk antibodies and methods of use
EP4232453A1 (en) 2020-10-20 2023-08-30 Institut Curie Metallic trans-(n-heterocyclic carbene)-amine-platinum complexes and uses thereof for treating cancer
WO2022084531A1 (en) 2020-10-23 2022-04-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating glioma
KR20230093282A (ko) 2020-10-23 2023-06-27 브리스톨-마이어스 스큅 컴퍼니 폐암에 대한 lag-3 길항제 요법
US20240148740A1 (en) 2020-10-28 2024-05-09 Ikena Oncology, Inc. Combination of an ahr inhibitor with a pdx inhibitor or doxorubicine
WO2022093981A1 (en) 2020-10-28 2022-05-05 Genentech, Inc. Combination therapy comprising ptpn22 inhibitors and pd-l1 binding antagonists
WO2022092085A1 (ja) 2020-10-28 2022-05-05 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍治療用医薬組成物
TWI838660B (zh) 2020-11-04 2024-04-11 美商建南德克公司 以抗cd20/抗cd3雙特異性抗體和抗cd79b抗體藥物結合物治療的給藥方法
MX2023005192A (es) 2020-11-04 2023-05-15 Heidelberg Pharma Res Gmbh Composicion que comprende una combinacion de inhibidor de punto de control inmunitario y conjugado de anticuerpo-amatoxina para uso en la terapia del cancer.
TWI888665B (zh) 2020-11-04 2025-07-01 美商建南德克公司 抗cd20/抗cd3雙特異性抗體之皮下給藥
IL302396A (en) 2020-11-04 2023-06-01 Genentech Inc Dosage for treatment with bispecific anti-CD20/anti-CD3 antibodies
WO2022098845A1 (en) 2020-11-05 2022-05-12 Board Of Regents, The University Of Texas System Engineered t cell receptors targeting egfr antigens and methods of use
MX2023005353A (es) 2020-11-06 2023-05-22 Novartis Ag Moleculas de union a cd19 y usos de las mismas.
IL302590A (en) 2020-11-06 2023-07-01 Incyte Corp Process for preparing PD-1/PD-L1 inhibitor and salts and crystalline forms thereof
TW202233615A (zh) 2020-11-06 2022-09-01 美商英塞特公司 Ｐｄ—１／ｐｄ—ｌ１抑制劑之結晶形式
WO2022099018A1 (en) 2020-11-06 2022-05-12 Incyte Corporation Process of preparing a pd-1/pd-l1 inhibitor
MX2023004941A (es) 2020-11-08 2023-07-12 Seagen Inc Conjugado de anticuerpo y fármaco para terapia de combinación con inhibidor de células inmunitarias.
WO2022101302A1 (en) 2020-11-12 2022-05-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies conjugated or fused to the receptor-binding domain of the sars-cov-2 spike protein and uses thereof for vaccine purposes
KR20230107228A (ko) 2020-11-13 2023-07-14 오노 야꾸힝 고교 가부시키가이샤 Ep4 길항약과 면역 체크포인트 저해 물질의 병용에 의한 암 치료
EP4243839A1 (en) 2020-11-13 2023-09-20 Catamaran Bio, Inc. Genetically modified natural killer cells and methods of use thereof
WO2022101484A1 (en) 2020-11-16 2022-05-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for predicting and treating uveal melanoma
EP4244391A1 (en) 2020-11-16 2023-09-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for predicting and treating uveal melanoma
WO2022101463A1 (en) 2020-11-16 2022-05-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of the last c-terminal residues m31/41 of zikv m ectodomain for triggering apoptotic cell death
CN117580859A (zh) 2020-11-17 2024-02-20 思进股份有限公司 用图卡替尼和抗pd-1/抗pd-l1抗体的组合治疗癌症的方法
EP4247352A1 (en) 2020-11-18 2023-09-27 Institut Curie Dimers of biguanidines and their therapeutic uses
WO2022112198A1 (en) 2020-11-24 2022-06-02 Worldwide Innovative Network Method to select the optimal immune checkpoint therapies
WO2022115611A1 (en) 2020-11-25 2022-06-02 Catamaran Bio, Inc. Cellular therapeutics engineered with signal modulators and methods of use thereof
TWI877433B (zh) 2020-11-30 2025-03-21 大陸商杭州阿諾生物醫藥科技有限公司 用於治療ｐｉｋ３ｃａ突變癌症的組合療法
IL303256A (en) 2020-12-02 2023-07-01 Genentech Inc Methods and compositions for the treatment of neoadjuvant and adjuvant carcinoma of the urinary tract
WO2022120179A1 (en) 2020-12-03 2022-06-09 Bristol-Myers Squibb Company Multi-tumor gene signatures and uses thereof
PH12023500013A1 (en) 2020-12-04 2024-03-11 Tidal Therapeutics Inc Ionizable cationic lipids and lipi nanoparticles, and methods of synthesis and use thereof
WO2022125497A1 (en) 2020-12-08 2022-06-16 Infinity Pharmaceuticals, Inc. Eganelisib for use in the treatment of pd-l1 negative cancer
TW202237119A (zh) 2020-12-10 2022-10-01 美商住友製藥腫瘤公司 Ａｌｋ﹘５抑制劑和彼之用途
WO2022130206A1 (en) 2020-12-16 2022-06-23 Pfizer Inc. TGFβr1 INHIBITOR COMBINATION THERAPIES
MX2023007301A (es) 2020-12-17 2023-07-04 Ose Immunotherapeutics Moleculas bifuncionales anti-pd1/il-7.
WO2022130348A1 (en) 2020-12-18 2022-06-23 Lamkap Bio Beta Ag Bispecific antibodies against ceacam5 and cd47
WO2022135666A1 (en) 2020-12-21 2022-06-30 BioNTech SE Treatment schedule for cytokine proteins
TW202245808A (zh) 2020-12-21 2022-12-01 德商拜恩迪克公司 用於治療癌症之治療性ｒｎａ
WO2022135667A1 (en) 2020-12-21 2022-06-30 BioNTech SE Therapeutic rna for treating cancer
TW202241885A (zh) 2020-12-22 2022-11-01 大陸商上海齊魯銳格醫藥研發有限公司 Ｓｏｓ１抑制劑及其用途
EP4267172A1 (en) 2020-12-28 2023-11-01 Bristol-Myers Squibb Company Subcutaneous administration of pd1/pd-l1 antibodies
AU2021411486A1 (en) 2020-12-28 2023-06-29 Bristol-Myers Squibb Company Antibody compositions and methods of use thereof
TW202241441A (zh) 2020-12-29 2022-11-01 美商英塞特公司 包含ａ２ａ／ａ２ｂ抑制劑、ｐｄ－１／ｐｄ－ｌ１抑制劑及抗ｃｄ７３抗體之組合療法
CA3203382A1 (en) 2020-12-31 2022-07-07 Adrian Emanual Wells Devices and processes for automated production of tumor infiltrating lymphocytes
WO2022148781A1 (en) 2021-01-05 2022-07-14 Institut Curie Combination of mcoln activators and immune checkpoint inhibitors
CA3207090A1 (en) 2021-01-06 2022-07-14 F. Hoffmann-La Roche Ag Combination therapy employing a pd1-lag3 bispecific antibody and a cd20 t cell bispecific antibody
EP4274850A1 (en) 2021-01-08 2023-11-15 Bristol-Myers Squibb Company Combination therapy using an anti-fucosyl-gm1 antibody
JP2024504923A (ja) 2021-01-11 2024-02-02 シンセカイン インコーポレイテッド 受容体ペア形成に関する組成物および方法
WO2022155541A1 (en) 2021-01-14 2022-07-21 AskGene Pharma, Inc. Interferon prodrugs and methods of making and using the same
JP2024505428A (ja) 2021-01-14 2024-02-06 アンスティテュ キュリー Ｈｅｒ２単一ドメイン抗体バリアントおよびそのｃａｒ
US20240299568A1 (en) 2021-01-19 2024-09-12 William Marsh Rice University Bone-specific delivery of polypeptides
AU2022211682A1 (en) 2021-01-22 2023-08-03 Mendus B.V. Methods of tumor vaccination
EP4284510A1 (en) 2021-01-29 2023-12-06 Novartis AG Dosage regimes for anti-cd73 and anti-entpd2 antibodies and uses thereof
US20240384350A1 (en) 2021-01-29 2024-11-21 Board Of Regents, The University Of Texas System Methods of treating cancer with kinase inhibitors
US20240423972A1 (en) 2021-02-01 2024-12-26 Yale University Chemotherapeutic bioadhesive particles with immunostimulatory molecules for cancer treatment
KR20230152032A (ko) 2021-02-03 2023-11-02 모차르트 쎄라퓨틱스 인코포레이티드 결합제 및 이를 사용하는 방법
CN117222413A (zh) 2021-02-10 2023-12-12 同润生物医药(上海)有限公司 治疗肿瘤的方法和组合
TW202302148A (zh) 2021-02-12 2023-01-16 美商欣爍克斯公司 使用ｉｌ－２接合物和抗ｐｄ－１抗體或其抗原結合片段的肺癌組合療法
CN117337304A (zh) * 2021-02-18 2024-01-02 齐鲁普吉湾生物治疗公司 抗pd1抗体和抗ctla4抗体的联合
BR112023016717A2 (pt) 2021-02-19 2023-10-31 Seoul Nat Univ R&Db Foundation Anticorpo biespecífico que se liga biespecificamente ao ligante 1 de morte programada e agrupamento de diferenciação 47, molécula de ácido nucleico, e, uso do anticorpo biespecífico que se liga biespecificamente ao ligante 1 de morte programada e agrupamento de diferenciação 47
EP4296283A4 (en) 2021-02-19 2025-03-05 SHAPERON Inc. SINGLE DOMAIN ANTIBODIES AGAINST PD-L1 AND USE THEREOF
CN116917273A (zh) 2021-03-02 2023-10-20 葛兰素史克知识产权发展有限公司 作为dnmt1抑制剂的经取代的吡啶
US20240190874A1 (en) 2021-03-03 2024-06-13 The Regents Of The University Of Michigan Small molecule degraders of androgen receptor
US20240166647A1 (en) 2021-03-03 2024-05-23 The Regents Of The University Of Michigan Cereblon Ligands
CN117279506A (zh) 2021-03-05 2023-12-22 艾欧凡斯生物治疗公司 肿瘤储存及细胞培养组合物
CN117677634A (zh) 2021-03-05 2024-03-08 利达提斯有限公司 三聚体多肽及其在治疗癌症中的用途
EP4304633A1 (en) 2021-03-12 2024-01-17 Mendus B.V. Methods of vaccination and use of cd47 blockade
WO2022189618A1 (en) 2021-03-12 2022-09-15 Institut Curie Nitrogen-containing heterocycles as radiosensitizers
EP4308118A1 (en) 2021-03-17 2024-01-24 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods and compositions for treating melanoma
EP4308935A1 (en) 2021-03-18 2024-01-24 Novartis AG Biomarkers for cancer and methods of use thereof
EP4308169A2 (en) 2021-03-19 2024-01-24 Heidelberg Pharma Research GmbH B-lymphocyte specific amatoxin antibody conjugates
BR112023018950A2 (pt) 2021-03-19 2024-02-27 Icahn School Med Mount Sinai Composto, composições nanobiológica e farmacêutica, métodos para tratar um distúrbio de proliferação celular, para tratar sepse e para ativar um receptor nod2, processo para fabricação de uma composição nanobiológica e kit
CA3170902A1 (en) 2021-03-23 2022-09-23 Jigar Desai Methods of treating cancer in immunosuppressed or immunocompromised patients by administering a pd-1 inhibitor
TW202304506A (zh) 2021-03-25 2023-02-01 日商安斯泰來製藥公司 涉及抗claudin 18.2抗體的組合治療以治療癌症
WO2022204438A1 (en) 2021-03-25 2022-09-29 Oncxerna Therapeutics, Inc. Targeted therapies in cancer
IL307262A (en) 2021-03-29 2023-11-01 Juno Therapeutics Inc METHODS FOR DOSAGE AND THERAPY IN COMBINATION OF CHECKPOINT INHIBITOR AND CAR T CELL THERAPY
EP4314060A1 (en) 2021-03-31 2024-02-07 GlaxoSmithKline Intellectual Property Development Limited Antigen binding proteins and combinations thereof
KR20230165276A (ko) 2021-03-31 2023-12-05 플래그쉽 파이어니어링 이노베이션스 브이, 인크. 타노트랜스미션 폴리펩티드 및 암의 치료에서의 이의 용도
IL307316A (en) * 2021-03-31 2023-11-01 Merus Nv New binding regions for PD-1
US20240376224A1 (en) 2021-04-02 2024-11-14 The Regents Of The University Of California Antibodies against cleaved cdcp1 and uses thereof
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
EP4319739A2 (en) 2021-04-08 2024-02-14 Nurix Therapeutics, Inc. Combination therapies with cbl-b inhibitor compounds
TW202305009A (zh) 2021-04-08 2023-02-01 美商默沙東有限責任公司 以皮下投予抗pd1抗體治療癌症之方法
AU2022255506A1 (en) 2021-04-08 2023-11-09 Marengo Therapeutics, Inc. Multifunctional molecules binding to tcr and uses thereof
WO2022216979A1 (en) 2021-04-08 2022-10-13 Board Of Regents, The University Of Texas System Compounds and methods for theranostic targeting of parp activity
AU2022254727A1 (en) 2021-04-09 2023-10-12 Seagen Inc. Methods of treating cancer with anti-tigit antibodies
KR20230167097A (ko) 2021-04-09 2023-12-07 제넨테크, 인크. Raf 억제제와 pd-1 축 억제제를 사용한 병용 요법
EP4320156A1 (en) 2021-04-09 2024-02-14 Ose Immunotherapeutics Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains
KR20240006541A (ko) 2021-04-09 2024-01-15 셀덱스 쎄라퓨틱스, 인크. Ilt4에 대한 항체, 이중특이적 항-ilt4/pd-l1 항체 및 이의 용도
KR20240005741A (ko) 2021-04-09 2024-01-12 오제 이뮈노테라프틱스 특성이 향상된 이작용성 분자용 신규한 스캐폴드
US20240197723A1 (en) 2021-04-09 2024-06-20 Beyondspring Pharmaceuticals, Inc. Therapeutic compositions and methods for treating tumors
CA3215903A1 (en) 2021-04-12 2022-10-20 Incyte Corporation Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
PE20240327A1 (es) 2021-04-13 2024-02-22 Nuvalent Inc Heterociclos con sustitucion amino para tratar canceres con mutaciones de egfr
EP4322938A1 (en) 2021-04-14 2024-02-21 Institut National de la Santé et de la Recherche Médicale (INSERM) New method to improve nk cells cytotoxicity
BR112023021475A2 (pt) 2021-04-16 2023-12-19 Novartis Ag Conjugados anticorpo-fármaco e métodos para produzir os mesmos
AU2022262600A1 (en) 2021-04-20 2023-10-05 Seagen Inc. Modulation of antibody-dependent cellular cytotoxicity
EP4326903A1 (en) 2021-04-23 2024-02-28 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and compositions for treating cell senescence accumulation related disease
US12472148B2 (en) 2021-04-26 2025-11-18 Celanese Eva Performance Polymers Llc Implantable device for sustained release of a macromolecular drug compound
JP2024518302A (ja) 2021-04-29 2024-05-01 イェダ リサーチ アンド デベロップメント カンパニー リミテッド Ｒａｓ誘導性再発性ネオアンチゲンに対するｔ細胞受容体およびそれらを同定するための方法
EP4330436A1 (en) 2021-04-30 2024-03-06 Genentech, Inc. Therapeutic and diagnostic methods and compositions for cancer
WO2022227015A1 (en) 2021-04-30 2022-11-03 Merck Sharp & Dohme Corp. Il4i1 inhibitors and methods of use
WO2022228705A1 (en) 2021-04-30 2022-11-03 F. Hoffmann-La Roche Ag Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
US12252497B2 (en) 2021-05-05 2025-03-18 Revolution Medicines, Inc. Ras inhibitors
JP2024516450A (ja) 2021-05-05 2024-04-15 レボリューション メディシンズ インコーポレイテッド 共有結合性ｒａｓ阻害剤及びその使用
MX2023013085A (es) 2021-05-05 2023-11-16 Revolution Medicines Inc Inhibidores de ras.
WO2022236134A1 (en) 2021-05-07 2022-11-10 Surface Oncology, Inc. Anti-il-27 antibodies and uses thereof
US20240269282A1 (en) 2021-05-10 2024-08-15 Institut Curie Methods for the Treatment of Cancer, Inflammatory Diseases and Autoimmune Diseases
JP2024519029A (ja) 2021-05-17 2024-05-08 アイオバンス バイオセラピューティクス，インコーポレイテッド Ｐｄ－１遺伝子編集された腫瘍浸潤リンパ球及び免疫療法におけるその使用
AR125874A1 (es) 2021-05-18 2023-08-23 Novartis Ag Terapias de combinación
EP4342492A4 (en) 2021-05-21 2025-01-15 Tianjin Lipogen Technology Co., Ltd PHARMACEUTICAL COMBINATION AND ITS USE
CN113030475B (zh) * 2021-05-25 2021-08-10 泛肽生物科技(浙江)有限公司 一种基于细胞线粒体质量评估的t细胞pd-1检测方法
WO2022251359A1 (en) 2021-05-26 2022-12-01 Theravance Biopharma R&D Ip, Llc Bicyclic inhibitors of alk5 and methods of use
US20240173392A1 (en) 2021-05-26 2024-05-30 Centro De Inmunolggia Molecular Use of therapeutic compositions for the treatment of patients with tumors of epithelial origin
EP4349362A4 (en) 2021-05-28 2025-05-14 Nippon Kayaku Kabushiki Kaisha COMBINED USE OF UBENIMEX AND IMMUNE CHECKPOINT INHIBITORS
WO2022254337A1 (en) 2021-06-01 2022-12-08 Novartis Ag Cd19 and cd22 chimeric antigen receptors and uses thereof
TW202313117A (zh) 2021-06-03 2023-04-01 美商欣爍克斯公司 包含il-2接合物及西妥昔單抗(cetuximab)之頭頸癌組合療法
GB202107994D0 (en) 2021-06-04 2021-07-21 Kymab Ltd Treatment of cancer
CA3218590A1 (en) 2021-06-07 2022-12-15 Providence Health & Services - Oregon Cxcr5, pd-1, and icos expressing tumor reactive cd4 t cells and their use
JP2024522188A (ja) 2021-06-09 2024-06-11 インサイト・コーポレイション Ｆｇｆｒ阻害剤としての三環式ヘテロ環
US11939331B2 (en) 2021-06-09 2024-03-26 Incyte Corporation Tricyclic heterocycles as FGFR inhibitors
AU2022289317A1 (en) 2021-06-10 2023-12-14 Ono Pharmaceutical Co., Ltd. Method for treating cancer through combination of cd47 inhibitor, immune checkpoint inhibitor, and standard therapy
TW202317623A (zh) 2021-06-14 2023-05-01 美商再生元醫藥公司 基於il2之治療劑及其使用方法
WO2022263632A1 (en) 2021-06-18 2022-12-22 Alligator Bioscience Ab Novel combination therapies and uses thereof
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
AU2022303363A1 (en) 2021-06-29 2024-01-18 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
MX2023015416A (es) 2021-07-02 2024-04-30 Genentech Inc Procedimientos y composiciones para tratar el cancer.
US20240316005A1 (en) 2021-07-05 2024-09-26 Institut National de la Santé et de la Recherche Médicale Gene signatures for predicting survival time in patients suffering from renal cell carcinoma
JP2024527567A (ja) 2021-07-07 2024-07-25 インサイト・コーポレイション Ｋｒａｓの阻害剤としての三環式化合物
EP4370552A1 (en) 2021-07-13 2024-05-22 BioNTech SE Multispecific binding agents against cd40 and cd137 in combination therapy for cancer
CA3224841A1 (en) 2021-07-14 2023-01-19 Zhenwu Li Tricyclic compounds as inhibitors of kras
US20250288666A1 (en) 2021-07-14 2025-09-18 Synthekine, Inc. Methods and compositions for use in cell therapy of neoplastic disease
US20230139492A1 (en) 2021-07-19 2023-05-04 Regeneron Pharmaceuticals, Inc. Combination of checkpoint inhibitors and an oncolytic virus for treating cancer
WO2023010094A2 (en) 2021-07-28 2023-02-02 Genentech, Inc. Methods and compositions for treating cancer
AU2022317820A1 (en) 2021-07-28 2023-12-14 F. Hoffmann-La Roche Ag Methods and compositions for treating cancer
CN118488964A (zh) 2021-07-30 2024-08-13 Ona疗法有限公司 抗cd36抗体及其治疗癌症的用途
US20250009877A1 (en) 2021-07-30 2025-01-09 Seagen Inc. Treatment for cancer
EP4380980A1 (en) 2021-08-03 2024-06-12 F. Hoffmann-La Roche AG Bispecific antibodies and methods of use
EP4380967A1 (en) 2021-08-04 2024-06-12 The Regents of the University of Colorado, a body corporate Lat activating chimeric antigen receptor t cells and methods of use thereof
EP4380596A1 (en) 2021-08-04 2024-06-12 Genentech, Inc. Il15/il15r alpha heterodimeric fc-fusion proteins for the expansion of nk cells in the treatment of solid tumours
WO2023011879A1 (en) 2021-08-05 2023-02-09 Institut Curie Scanning dynamic device for minibeams production
EP4392451A1 (en) 2021-08-23 2024-07-03 Immunitas Therapeutics, Inc. Anti-cd161 antibodies and uses thereof
WO2023034290A1 (en) 2021-08-31 2023-03-09 Incyte Corporation Naphthyridine compounds as inhibitors of kras
WO2023034530A1 (en) 2021-09-02 2023-03-09 Teon Therapeutics, Inc. Methods of improving growth and function of immune cells
EP4396229A1 (en) 2021-09-02 2024-07-10 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Anti-cecam6 antibodies with reduced side-effects
TW202328090A (zh) 2021-09-08 2023-07-16 美商雷度納製藥公司 Ｐａｐｄ５及／或ｐａｐｄ７抑制劑
US12410252B2 (en) * 2021-09-10 2025-09-09 Trustees Of Tufts College Anti-PD-1 immunoglobulin polypeptides and uses thereof
JP2024535811A (ja) 2021-09-13 2024-10-02 プランティバディーズ 組換えタンパク質作製のための遺伝子改変された生物
WO2023041744A1 (en) 2021-09-17 2023-03-23 Institut Curie Bet inhibitors for treating pab1 deficient cancer
US12030883B2 (en) 2021-09-21 2024-07-09 Incyte Corporation Hetero-tricyclic compounds as inhibitors of KRAS
WO2023051926A1 (en) 2021-09-30 2023-04-06 BioNTech SE Treatment involving non-immunogenic rna for antigen vaccination and pd-1 axis binding antagonists
WO2023056403A1 (en) 2021-09-30 2023-04-06 Genentech, Inc. Methods for treatment of hematologic cancers using anti-tigit antibodies, anti-cd38 antibodies, and pd-1 axis binding antagonists
US12030884B2 (en) 2021-10-01 2024-07-09 Incyte Corporation Pyrazoloquinoline KRAS inhibitors
IL311790A (en) 2021-10-05 2024-05-01 Chang Hao Ming Natural killer cells and methods of use thereof
TW202327595A (zh) 2021-10-05 2023-07-16 美商輝瑞大藥廠 用於治療癌症之氮雜內醯胺化合物的組合
IL311771A (en) 2021-10-06 2024-05-01 BioNTech SE Multispecific binding agents against pd-l1 and cd137 in combination
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras
TW202333802A (zh) 2021-10-11 2023-09-01 德商拜恩迪克公司 用於肺癌之治療性rna(二)
CR20240197A (es) 2021-10-14 2024-08-07 Incyte Corp Compuestos de quinolina como inhibidores de kras
EP4419561A2 (en) 2021-10-20 2024-08-28 Takeda Pharmaceutical Company Limited Compositions targeting bcma and methods of use thereof
WO2023070056A2 (en) 2021-10-20 2023-04-27 Synthekine, Inc. Heterodimeric fc cytokines and uses thereof
WO2023076880A1 (en) 2021-10-25 2023-05-04 Board Of Regents, The University Of Texas System Foxo1-targeted therapy for the treatment of cancer
JP2024540106A (ja) 2021-10-28 2024-10-31 ライエル・イミュノファーマ・インコーポレイテッド 免疫細胞を培養するための方法
IL309227A (en) 2021-10-29 2024-02-01 Bristol Myers Squibb Co LAG-3 antagonist therapy for hematological cancer
WO2023081730A1 (en) 2021-11-03 2023-05-11 Teon Therapeutics, Inc. 4-hydroxy-2-oxo-1,2-dihydro-1,8-naphthyridine-3-carboxamide derivatives as cannabinoid cb2 receptor modulators for the treatment of cancer
US20240426823A1 (en) 2021-11-03 2024-12-26 Institut National de la Santé et de la Recherche Médicale Methods and compositions for treating triple negative breast cancer (tnbc)
WO2023079428A1 (en) 2021-11-03 2023-05-11 Pfizer Inc. Combination therapies using tlr7/8 agonist
WO2023080900A1 (en) 2021-11-05 2023-05-11 Genentech, Inc. Methods and compositions for classifying and treating kidney cancer
WO2023083439A1 (en) 2021-11-09 2023-05-19 BioNTech SE Tlr7 agonist and combinations for cancer treatment
US20230272082A1 (en) 2021-11-09 2023-08-31 Sensei Biotherapeutics, Inc. Anti-vista antibodies and uses thereof
US20250009916A1 (en) 2021-11-12 2025-01-09 Novartis Ag Combination therapy for treating lung cancer
JP2024539432A (ja) 2021-11-15 2024-10-28 中国科学院生物物理研究所 インターロイキン１５を有効成分とする融合タンパク質構築物およびその使用
MX2024006003A (es) 2021-11-17 2024-08-06 Inst Nat Sante Rech Med Vacunas universales contra el sarbecovirus.
EP4433089A1 (en) 2021-11-19 2024-09-25 Institut Curie Methods for the treatment of hrd cancer and brca-associated cancer
IL312886A (en) 2021-11-22 2024-07-01 Incyte Corp Combined treatment that includes a Pegfer inhibitor and a Kras inhibitor
EP4436969A2 (en) 2021-11-24 2024-10-02 Genentech, Inc. Bicyclic therapeutic compounds and methods of use in the treatment of cancer
WO2023097211A1 (en) 2021-11-24 2023-06-01 The University Of Southern California Methods for enhancing immune checkpoint inhibitor therapy
EP4436957A1 (en) 2021-11-24 2024-10-02 Genentech, Inc. Therapeutic indazole compounds and methods of use in the treatment of cancer
WO2023099763A1 (en) 2021-12-03 2023-06-08 Institut Curie Sirt6 inhibitors for use in treating resistant hrd cancer
US20230203010A1 (en) 2021-12-03 2023-06-29 Incyte Corporation Bicyclic amine cdk12 inhibitors
TW202328438A (zh) 2021-12-08 2023-07-16 新加坡商泰莎治療有限公司 淋巴瘤之治療
US12084453B2 (en) 2021-12-10 2024-09-10 Incyte Corporation Bicyclic amines as CDK12 inhibitors
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors
IL313439A (en) 2021-12-16 2024-08-01 Valerio Therapeutics New conjugated nucleic acid molecules and their uses
WO2023114954A1 (en) 2021-12-17 2023-06-22 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
US20250302950A1 (en) 2021-12-20 2025-10-02 Synthorx, Inc. Head and neck cancer combination therapy comprising an il-2 conjugate and pembrolizumab
US20250041261A1 (en) 2021-12-21 2025-02-06 Institut National de la Santé et de la Recherche Médicale Methods and compositions for treating melanoma
JP2025500466A (ja) 2021-12-22 2025-01-09 インサイト・コーポレイション Ｆｇｆｒ阻害剤の塩及び固体の形態ならびにその調製方法
WO2023129438A1 (en) 2021-12-28 2023-07-06 Wisconsin Alumni Research Foundation Hydrogel compositions for use for depletion of tumor associated macrophages
EP4456907A1 (en) 2021-12-30 2024-11-06 NeoImmuneTech, Inc. Method of treating a tumor with a combination of il-7 protein and vegf antagonist
IL313864A (en) 2022-01-07 2024-08-01 Regeneron Pharma Methods for treating recurrent ovarian cancer using bispecific antibodies against MUC16 and against CD3 alone or in combination with antibodies against PD-1
EP4469477A1 (en) 2022-01-26 2024-12-04 Bristol-Myers Squibb Company Combination therapy for hepatocellular carcinoma
CA3243281A1 (en) 2022-01-28 2023-08-03 Georgiamune Inc. ANTIBODIES DIRECTED AGAINST PROGRAMMED CELL DEATH PROTEIN 1 PD-1 AGONISTS
US20250170090A1 (en) 2022-01-28 2025-05-29 Onquality Pharmaceuticals China Ltd. Method for preventing or treating disease or disorder associated with antineoplastic agent
EP4227307A1 (en) 2022-02-11 2023-08-16 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
JP2025507378A (ja) 2022-02-14 2025-03-18 ギリアード サイエンシーズ， インコーポレイテッド 抗ウイルスナフチリジノン化合物
WO2023154799A1 (en) 2022-02-14 2023-08-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Combination immunotherapy for treating cancer
US12074641B2 (en) 2022-02-15 2024-08-27 Bank Of America Corporation System and method for secured data transmission using LiFi and holochain network
US12052261B2 (en) 2022-02-15 2024-07-30 Bank Of America Corporation System and method for authenticating the receiving end of data transmission via LiFi and holochain network
WO2023159102A1 (en) 2022-02-17 2023-08-24 Regeneron Pharmaceuticals, Inc. Combinations of checkpoint inhibitors and oncolytic virus for treating cancer
CN118715226A (zh) 2022-02-21 2024-09-27 上海岸阔医药科技有限公司 化合物及其用途
EP4482947A1 (en) 2022-02-24 2025-01-01 Amazentis SA Uses of urolithins
AU2023226078A1 (en) 2022-02-25 2024-08-22 Bristol-Myers Squibb Company Combination therapy for colorectal carcinoma.
WO2023168404A1 (en) 2022-03-04 2023-09-07 Bristol-Myers Squibb Company Methods of treating a tumor
MX2024010828A (es) 2022-03-07 2024-09-17 Amgen Inc Procedimiento para preparar 4-metil-2-propan-2-il-piridin-3-carbon itrilo.
US20230279004A1 (en) 2022-03-07 2023-09-07 Incyte Corporation Solid forms, salts, and processes of preparation of a cdk2 inhibitor
MX2024009994A (es) 2022-03-07 2024-08-22 Mabxience Res S L Formulaciones estables para anticuerpos.
CN119156403A (zh) 2022-03-08 2024-12-17 阿伦蒂斯治疗股份公司 抗紧密连接蛋白-1抗体增加t细胞可用性的用途
JP2025510572A (ja) 2022-03-08 2025-04-15 レボリューション メディシンズ インコーポレイテッド 免疫不応性肺癌を治療するための方法
JP2025509401A (ja) 2022-03-10 2025-04-11 ジェネクシン・インコーポレイテッド 頭頸部がん治療のための三重複合薬物投与療法
CN119031932A (zh) 2022-03-16 2024-11-26 第一三共株式会社 多特异性分子和免疫检查点抑制剂的组合
CN119677534A (zh) 2022-03-17 2025-03-21 瑞泽恩制药公司 使用双特异性抗muc16×抗cd3抗体单独或与抗pd-1抗体组合来治疗复发性上皮样肉瘤的方法
US20250206775A1 (en) 2022-03-18 2025-06-26 Bristol-Myers Squibb Company Methods of isolating polypeptides
CA3254182A1 (en) 2022-03-24 2023-09-28 Universite Paris Cite Immunotherapy targeting neoantigenic peptides derived from a tumor-specific transposable element in a glioblastoma
EP4499677A1 (en) 2022-03-31 2025-02-05 Institut Curie Modified rela protein for inducing interferon expression and engineered immune cells with improved interferon expression
CN115028726B (zh) * 2022-03-31 2024-01-09 浙江特瑞思药业股份有限公司 一种抗pd-1纳米抗体及其应用
WO2023192478A1 (en) 2022-04-01 2023-10-05 Bristol-Myers Squibb Company Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer
CA3246312A1 (en) 2022-04-01 2023-10-05 Genentech, Inc. DOSAGE FOR TREATMENT WITH BISOPECIFIC ANTI-FCRH5/ANTI-CD3 ANTIBODIES
EP4504220A1 (en) 2022-04-06 2025-02-12 Iovance Biotherapeutics, Inc. Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
EP4504244A1 (en) 2022-04-07 2025-02-12 Institut Curie Myeloid cells modified by chimeric antigen receptor with cd40 and uses thereof for anti-cancer therapy
WO2023196988A1 (en) 2022-04-07 2023-10-12 Modernatx, Inc. Methods of use of mrnas encoding il-12
WO2023196987A1 (en) 2022-04-07 2023-10-12 Bristol-Myers Squibb Company Methods of treating tumor
US20250241949A1 (en) 2022-04-07 2025-07-31 Institut Curie Myeloid cells modified by chimeric antigen receptor and uses thereof for anti-cancer therapy
JP2025517869A (ja) 2022-04-08 2025-06-12 ブリストル－マイヤーズ スクイブ カンパニー 三次リンパ組織様構造の機械学習識別、分類、及び定量化
KR20250004768A (ko) 2022-04-13 2025-01-08 제넨테크, 인크. 치료 단백질의 약학적 조성물 및 사용 방법
KR20250004727A (ko) 2022-04-13 2025-01-08 제넨테크, 인크. 모수네투주맙의 약학적 조성물 및 사용 방법
CA3248034A1 (en) 2022-04-15 2023-10-19 Iovance Biotherapeutics, Inc. METHODS FOR EXPANSION OF TIL CELLS BY MEANS OF SPECIFIC CYTOKINE COMBINATIONS AND/OR AKT INHIBITOR TREATMENT
US20250235478A1 (en) 2022-04-28 2025-07-24 Musc Foundation For Research Development Chimeric antigen receptor modified regulatory t cells for treating cancer
WO2023213764A1 (en) 2022-05-02 2023-11-09 Transgene Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf
WO2023213763A1 (en) 2022-05-02 2023-11-09 Transgene Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab
WO2023214325A1 (en) 2022-05-05 2023-11-09 Novartis Ag Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
EP4522653A1 (en) 2022-05-11 2025-03-19 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
TW202413412A (zh) 2022-05-12 2024-04-01 丹麥商珍美寶股份有限公司 在組合療法中能夠結合到ｃｄ２７之結合劑
KR20250010677A (ko) 2022-05-16 2025-01-21 리제너론 파아마슈티컬스, 인크. 이중특이적 항-PSMA x 항-CD3 항체를 단독으로 또는 항-PD-1 항체와 병용으로 전이성 거세 저항성 전립선암을 치료하는 방법
JP2025521122A (ja) 2022-05-19 2025-07-08 シャペロン インク． Ｐｄ－ｌ１およびｃｄ４７に対する二重特異性ヒト化単一ドメイン抗体およびその使用
KR20250012631A (ko) 2022-05-24 2025-01-24 다이이찌 산쿄 가부시키가이샤 항-cdh6 항체-약물 접합체의 투약
WO2023230554A1 (en) 2022-05-25 2023-11-30 Pfizer Inc. Combination of a braf inhibitor, an egfr inhibitor, and a pd-1 antagonist for the treatment of braf v600e-mutant, msi-h/dmmr colorectal cancer
TW202410916A (zh) 2022-05-27 2024-03-16 日商武田藥品工業股份有限公司 Ｃｄ３８結合融合蛋白之給藥
AR129423A1 (es) 2022-05-27 2024-08-21 Viiv Healthcare Co Compuestos útiles en la terapia contra el hiv
WO2023235847A1 (en) 2022-06-02 2023-12-07 Bristol-Myers Squibb Company Antibody compositions and methods of use thereof
WO2023240058A2 (en) 2022-06-07 2023-12-14 Genentech, Inc. Prognostic and therapeutic methods for cancer
TW202402279A (zh) 2022-06-08 2024-01-16 美商英塞特公司 作為ｄｇｋ抑制劑之三環三唑并化合物
AU2023285094A1 (en) 2022-06-08 2025-01-23 Tidal Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles, and methods of synthesis and use thereof
AU2023285116A1 (en) 2022-06-10 2024-12-19 Revolution Medicines, Inc. Macrocyclic ras inhibitors
CA3248576A1 (en) 2022-06-16 2023-12-21 Lamkap Bio Beta Ltd POLYTHERAPY OF BISPECIFIC ANTIBODY AGAINST CEACAM5 AND CD47, AND BISPECIFIC ANTIBODY AGAINST CEACAM5 AND CD3
WO2023245097A2 (en) 2022-06-16 2023-12-21 Cephalon Llc Anti-pd-1 antibody-attenuated il-2 immunoconjugates and uses thereof
JP2025521543A (ja) 2022-06-22 2025-07-10 ジュノー セラピューティクス インコーポレイテッド Ｃｄ１９標的ｃａｒ ｔ細胞のセカンドライン治療のための処置方法
AR129675A1 (es) 2022-06-22 2024-09-18 Incyte Corp Inhibidores de cdk12 de aminas biciclicas
GB202209518D0 (en) 2022-06-29 2022-08-10 Snipr Biome Aps Treating & preventing E coli infections
CN119654339A (zh) 2022-07-01 2025-03-18 特兰斯吉恩股份有限公司 包含表面活性蛋白-d和tnfsf成员的融合蛋白
WO2024003360A1 (en) 2022-07-01 2024-01-04 Institut Curie Biomarkers and uses thereof for the treatment of neuroblastoma
US20260008990A1 (en) 2022-07-06 2026-01-08 Iovance Biotherapeutics, Inc. Devices and processes for automated production of tumor infiltrating lymphocytes
WO2024015731A1 (en) 2022-07-11 2024-01-18 Incyte Corporation Fused tricyclic compounds as inhibitors of kras g12v mutants
JP2025523057A (ja) 2022-07-12 2025-07-17 ホットスポット セラピューティクス インコーポレイテッド がん処置における使用のためのｃｂｌ－ｂ阻害剤及び抗ｐｄ１／抗ｐｄ－ｌ１
WO2024015372A1 (en) 2022-07-14 2024-01-18 Teon Therapeutics, Inc. Adenosine receptor antagonists and uses thereof
CN119836305A (zh) 2022-07-15 2025-04-15 费恩治疗有限公司 抗体-药物缀合物
EP4558524A1 (en) 2022-07-19 2025-05-28 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
EP4310197A1 (en) 2022-07-21 2024-01-24 Fundación para la Investigación Biomédica del Hospital Universitario Puerta de Hierro Majadahonda Method for identifying lung cancer patients for a combination treatment of immuno- and chemotherapy
WO2024023740A1 (en) 2022-07-27 2024-02-01 Astrazeneca Ab Combinations of recombinant virus expressing interleukin-12 with pd-1/pd-l1 inhibitors
IL318586A (en) 2022-07-28 2025-03-01 Astrazeneca Uk Ltd Combination of antibody-drug conjugate and bispecific checkpoint inhibitor
EP4565612A1 (en) 2022-08-02 2025-06-11 Regeneron Pharmaceuticals, Inc. Methods of treating metastatic castration-resistant prostate cancer with bispecific anti-psma x anti-cd28 antibodies in combination with anti-pd-1 antibodies
WO2024028386A1 (en) 2022-08-02 2024-02-08 Ose Immunotherapeutics Multifunctional molecule directed against cd28
WO2024028794A1 (en) 2022-08-02 2024-02-08 Temple Therapeutics BV Methods for treating endometrial and ovarian hyperproliferative disorders
AU2023320568A1 (en) 2022-08-05 2025-02-06 Juno Therapeutics, Inc. Chimeric antigen receptors specific for gprc5d and bcma
EP4568670A1 (en) 2022-08-10 2025-06-18 Institut National de la Santé et de la Recherche Médicale Sigmar1 ligand for the treatment of pancreatic cancer
WO2024033400A1 (en) 2022-08-10 2024-02-15 Institut National de la Santé et de la Recherche Médicale Sk2 inhibitor for the treatment of pancreatic cancer
WO2024040175A1 (en) 2022-08-18 2024-02-22 Pulmatrix Operating Company, Inc. Methods for treating cancer using inhaled angiogenesis inhibitor
WO2024040264A1 (en) 2022-08-19 2024-02-22 Massachusetts Institute Of Technology Compositions and methods for targeting dendritic cell lectins
JPWO2024043227A1 (show.php) 2022-08-23 2024-02-29
TW202416953A (zh) 2022-08-26 2024-05-01 日商衛材R&D企管股份有限公司 抗體藥物複合物
CN120153254A (zh) 2022-09-01 2025-06-13 基因泰克公司 膀胱癌的治疗和诊断方法
EP4583860A1 (en) 2022-09-06 2025-07-16 Institut National de la Santé et de la Recherche Médicale Inhibitors of the ceramide metabolic pathway for overcoming immunotherapy resistance in cancer
WO2024056716A1 (en) 2022-09-14 2024-03-21 Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical compositions for the treatment of dilated cardiomyopathy
WO2024068617A1 (en) 2022-09-26 2024-04-04 Institut Curie Myeloid cells expressing il-2 and uses thereof for quick anticancer therapy
EP4593961A1 (en) 2022-09-30 2025-08-06 Alentis Therapeutics AG Treatment of drug-resistant hepatocellular carcinoma
AU2023356866A1 (en) 2022-10-03 2025-04-17 Regeneron Pharmaceuticals, Inc. Methods of treating cancer with bispecific egfr x cd28 antibodies alone or in combination with anti-pd-1 antibodies
WO2024077191A1 (en) 2022-10-05 2024-04-11 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
WO2024077166A1 (en) 2022-10-05 2024-04-11 Genentech, Inc. Methods and compositions for classifying and treating lung cancer
WO2024077095A1 (en) 2022-10-05 2024-04-11 Genentech, Inc. Methods and compositions for classifying and treating bladder cancer
JP2025536260A (ja) 2022-10-11 2025-11-05 イェール ユニバーシティー 細胞透過性抗体の組成物および使用方法
CR20250141A (es) 2022-10-14 2025-05-26 Black Diamond Therapeutics Inc Métodos de tratamiento del cáncer usando derivados de isoquinolina o 6-aza-quinolina
KR20250089513A (ko) 2022-10-19 2025-06-18 아스텔라스세이야쿠 가부시키가이샤 암 치료에 있어서의 pd-1 시그널 저해제와의 조합에 의한 항cldn4-항cd137 이중특이성 항체의 사용
WO2024086827A2 (en) 2022-10-20 2024-04-25 Repertoire Immune Medicines, Inc. Cd8 t cell targeted il2
JP2025536252A (ja) 2022-10-20 2025-11-05 アンセルム（アンスティチュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル） 癌治療のための併用療法
WO2024086739A1 (en) 2022-10-20 2024-04-25 Synthekine, Inc. Methods and compositions of il12 muteins and il2 muteins
WO2024084034A1 (en) 2022-10-21 2024-04-25 Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical compositions for the treatment of osteoarthritis
WO2024089417A1 (en) 2022-10-24 2024-05-02 Memorial Sloan-Kettering Cancer Center Tumour stratification for responsiveness to an immune checkpoint inhibitor
EP4608390A1 (en) 2022-10-24 2025-09-03 Cancer Research Technology Limited Tumour sensitisation to checkpoint inhibitors with redox status modifier
TW202426505A (zh) 2022-10-25 2024-07-01 美商建南德克公司 癌症之治療及診斷方法
IL320168A (en) 2022-11-01 2025-06-01 Heidelberg Pharma Res Gmbh Anti-gucy2c antibody and uses thereof
KR20250089492A (ko) 2022-11-07 2025-06-18 네오이뮨텍, 인코퍼레이티드 비메틸화된 mgmt 프로모터를 갖는 종양의 치료 방법
CN120202222A (zh) 2022-11-16 2025-06-24 勃林格殷格翰国际有限公司 抗SIRPa抗体的疗效预测性生物标志物
WO2024107477A1 (en) * 2022-11-18 2024-05-23 Massachusetts Institute Of Technology Compositions and methods for antibody mediated delivery of antigen to b cell follicles
US20240217989A1 (en) 2022-11-18 2024-07-04 Incyte Corporation Heteroaryl Fluoroalkenes As DGK Inhibitors
CN120584182A (zh) 2022-11-21 2025-09-02 艾欧凡斯生物治疗公司 肿瘤浸润淋巴细胞扩增的二维过程及其疗法
WO2024112867A1 (en) 2022-11-23 2024-05-30 University Of Georgia Research Foundation, Inc. Compositions and methods of use thereof for increasing immune responses
AR131143A1 (es) 2022-11-24 2025-02-19 Beigene Switzerland Gmbh Conjugados anticuerpo-fármaco anti-cea y métodos de uso
WO2024118836A1 (en) 2022-11-30 2024-06-06 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes with shortened rep step
TW202440157A (zh) 2022-12-01 2024-10-16 英商梅迪繆思有限公司 用於治療癌症的組合療法
AU2023401158A1 (en) 2022-12-01 2025-05-29 BioNTech SE Multispecific antibody against cd40 and cd137 in combination therapy with anti-pd1 ab and chemotherapy
KR20250112761A (ko) 2022-12-01 2025-07-24 이나뜨 파르마 에스.에이. 항-cd39 항체를 포함하는 암의 신보조 치료를 위한 조성물 및 방법
WO2024119193A2 (en) 2022-12-02 2024-06-06 AskGene Pharma, Inc. Mutant il-2 polypeptides and il-2 prodrugs
US20240226298A1 (en) 2022-12-13 2024-07-11 Juno Therapeutics, Inc. Chimeric antigen receptors specific for baff-r and cd19 and methods and uses thereof
KR20250120305A (ko) 2022-12-14 2025-08-08 아스텔라스 파마 유럽 비.브이. Cldn18.2 및 cd3에 결합하는 2중 특이성 결합제와 면역 체크포인트 저해제를 수반한 조합 요법
WO2024129555A1 (en) * 2022-12-15 2024-06-20 Merck Sharp & Dohme Llc Lyospheres containing programmed death receptor 1 (pd-1) antibodies and methods of use thereof
TW202440154A (zh) 2022-12-20 2024-10-16 美商建南德克公司 用ｐｄ－１軸結合拮抗劑及ｒｎａ疫苗治療胰臟癌之方法
US20260000757A1 (en) 2022-12-21 2026-01-01 Bristol-Myers Squibb Company Combination therapy for lung cancer
WO2024148241A1 (en) 2023-01-06 2024-07-11 Lassen Therapeutics 1, Inc. Anti-il-18bp antibodies
KR20250133728A (ko) 2023-01-06 2025-09-08 라센 테라퓨틱스, 인코포레이티드 항-il-18bp 항체
WO2024151687A1 (en) 2023-01-09 2024-07-18 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer
WO2024150177A1 (en) 2023-01-11 2024-07-18 Advesya Treatment methods for solid tumors
AR131101A1 (es) 2023-01-12 2025-02-19 Incyte Corp Heteroarilfluoroalquenos como inhibidores de dgk
WO2024150017A1 (en) 2023-01-13 2024-07-18 Akrivia Biomedics Limited Method of profiling diseases
WO2024151885A1 (en) 2023-01-13 2024-07-18 Iovance Biotherapeutics, Inc. Use of til as maintenance therapy for nsclc patients who achieved pr/cr after prior therapy
AU2024209475A1 (en) 2023-01-19 2025-09-04 Beone Medicines I Gmbh Anti-cmet antibodies and methods of use
KR20250136390A (ko) 2023-01-20 2025-09-16 베링거 인겔하임 인터내셔날 게엠베하 IL-12 Fc 융합 단백질
WO2024160721A1 (en) 2023-01-30 2024-08-08 Kymab Limited Antibodies
WO2024163477A1 (en) 2023-01-31 2024-08-08 University Of Rochester Immune checkpoint blockade therapy for treating staphylococcus aureus infections
WO2024184811A1 (en) 2023-03-06 2024-09-12 Beigene Switzerland Gmbh Anti-cd3 multispecific antibodies and methods of use
AR132063A1 (es) 2023-03-06 2025-05-21 Beigene Switzerland Gmbh Anticuerpos multiespecíficos anti-cldn6 y anti-cd3 y métodos de uso
AR132064A1 (es) 2023-03-06 2025-05-21 Beigene Switzerland Gmbh Anticuerpos anti-cldn6 y métodos de uso
CN116218786B (zh) * 2023-03-09 2024-01-23 山东大学齐鲁医院 一种多重基因编辑的通用型巨噬细胞及在制备抗肿瘤药物中的应用
EP4680635A1 (en) 2023-03-13 2026-01-21 F. Hoffmann-La Roche AG Combination therapy employing a pd1-lag3 bispecific antibody and an hla-g t cell bispecific antibody
EP4680269A1 (en) 2023-03-13 2026-01-21 H. Lee Moffitt Cancer Center And Research Institute, Inc. Composition of selected tumor infiltrating lymphocytes and related methods of producing and using the same
KR20250152101A (ko) 2023-03-13 2025-10-22 하이델베르크 파마 리서치 게엠베하 암 치료에의 사용을 위한 피하 투여 항체-약물 접합체
WO2024192033A1 (en) 2023-03-13 2024-09-19 Regeneron Pharmaceuticals, Inc. Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating melanoma
WO2024196952A1 (en) 2023-03-20 2024-09-26 Bristol-Myers Squibb Company Tumor subtype assessment for cancer therapy
WO2024194673A1 (en) 2023-03-21 2024-09-26 Institut Curie Methods for the treatment of dedifferentiated liposarcoma
WO2024194401A1 (en) 2023-03-21 2024-09-26 Institut Curie Vps4b inhibitor for use in methods for the treatment of hrd cancer
US12173081B2 (en) 2023-03-21 2024-12-24 Biograph 55, Inc. CD19/CD38 multispecific antibodies
WO2024194402A1 (en) 2023-03-21 2024-09-26 Institut Curie Farnesyl transferase inhibitor for use in methods for the treatment of hrd cancer
WO2024206155A1 (en) 2023-03-24 2024-10-03 Cornell University Utilizing t cells derived from tumor draining lymph nodes for chimeric antigen receptor (car) t cell therapy for the treatment of cancer
WO2024200571A1 (en) 2023-03-28 2024-10-03 Institut National de la Santé et de la Recherche Médicale Method for discriminating mono-immunotherapy from combined immunotherapy in cancers
WO2024206357A1 (en) 2023-03-29 2024-10-03 Merck Sharp & Dohme Llc Il4i1 inhibitors and methods of use
IL320593A (en) 2023-03-29 2025-07-01 Daiichi Sankyo Co Ltd Anti-CD25 antibody and anti-CD25 antibody conjugate
WO2024200826A1 (en) 2023-03-30 2024-10-03 Ose Immunotherapeutics Lipid-based nanoparticle targeted at activated immune cells for the expression of immune cell inhibiting molecule and use thereof
WO2024206858A1 (en) 2023-03-30 2024-10-03 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof
WO2024200823A1 (en) 2023-03-30 2024-10-03 Ose Immunotherapeutics Lipid-based nanoparticle targeted at activated immune cells for the expression of immune cell enhancing molecule and use thereof
WO2024209072A1 (en) 2023-04-06 2024-10-10 Genmab A/S Multispecific binding agents against pd-l1 and cd137 for treating cancer
AU2024252845A1 (en) 2023-04-06 2025-10-16 Glaxosmithkline Intellectual Property (No.4) Limited Methods for treating and monitoring cancer
WO2024211663A1 (en) 2023-04-07 2024-10-10 Revolution Medicines, Inc. Condensed macrocyclic compounds as ras inhibitors
WO2024211712A1 (en) 2023-04-07 2024-10-10 Revolution Medicines, Inc. Condensed macrocyclic compounds as ras inhibitors
WO2024216028A1 (en) 2023-04-12 2024-10-17 Agenus Inc. Methods of treating cancer using an anti-ctla4 antibody and an enpp1 inhibitor
WO2024213782A1 (en) 2023-04-13 2024-10-17 Institut Curie Methods for the treatment of t-cell acute lymphoblastic leukemia
WO2024213533A1 (en) 2023-04-13 2024-10-17 Alligator Bioscience Ab Combination therapies
TW202448897A (zh) 2023-04-14 2024-12-16 美商銳新醫藥公司 Ｒａｓ抑制劑之結晶形式、含有其之組合物及其使用方法
WO2024216016A1 (en) 2023-04-14 2024-10-17 Revolution Medicines, Inc. Crystalline forms of a ras inhibitor
WO2024213767A1 (en) 2023-04-14 2024-10-17 Institut National de la Santé et de la Recherche Médicale Engraftment of mesenchymal stromal cells engineered to stimulate immune infiltration in tumors
US20240390340A1 (en) 2023-04-18 2024-11-28 Incyte Corporation Pyrrolidine kras inhibitors
WO2024223299A2 (en) 2023-04-26 2024-10-31 Isa Pharmaceuticals B.V. Methods of treating cancer by administering immunogenic compositions and a pd-1 inhibitor
WO2024228167A1 (en) 2023-05-03 2024-11-07 Iox Therapeutics Inc. Inkt cell modulator liposomal compositions and methods of use
AU2024265613A1 (en) 2023-05-04 2025-09-25 Novasenta, Inc. Anti-cd161 antibodies and methods of use thereof
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
WO2024233341A1 (en) 2023-05-05 2024-11-14 Genentech, Inc. Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
WO2024231384A1 (en) 2023-05-10 2024-11-14 Institut National de la Santé et de la Recherche Médicale Compositions for treating senescence related disease
WO2024233646A1 (en) 2023-05-10 2024-11-14 Genentech, Inc. Methods and compositions for treating cancer
US12410258B2 (en) 2023-05-12 2025-09-09 Ganmab A/S Antibodies capable of binding to OX40, variants thereof and uses thereof
WO2024245951A1 (en) 2023-05-26 2024-12-05 Institut National de la Santé et de la Recherche Médicale Combination of slc8a1 inhibitor and mitochondria-targeted antioxidant for treating melanoma
EP4470542A1 (en) 2023-05-31 2024-12-04 Fundación Miguel Servet Oleuropein in the management of cancer
WO2024254245A1 (en) 2023-06-09 2024-12-12 Incyte Corporation Bicyclic amines as cdk2 inhibitors
WO2024256635A1 (en) 2023-06-15 2024-12-19 Institut National de la Santé et de la Recherche Médicale Dpm1 inhibitor for treating cancer
WO2024261302A1 (en) 2023-06-22 2024-12-26 Institut National de la Santé et de la Recherche Médicale Nlrp3 inhibitors, pak1/2 inhibitors and/or caspase 1 inhibitors for use in the treatment of rac2 monogenic disorders
WO2024261239A1 (en) 2023-06-23 2024-12-26 Imcheck Therapeutics Bispecific antibodies targeting btn3a and the pd-1/pd-l1 inhibitory axis
WO2024263195A1 (en) 2023-06-23 2024-12-26 Genentech, Inc. Methods for treatment of liver cancer
WO2024263904A1 (en) 2023-06-23 2024-12-26 Genentech, Inc. Methods for treatment of liver cancer
WO2025003193A1 (en) 2023-06-26 2025-01-02 Institut National de la Santé et de la Recherche Médicale Sertraline and indatraline for disrupting intracellular cholesterol trafficking and subsequently inducing lysosomal damage and anti-tumor immunity
WO2025006811A1 (en) 2023-06-27 2025-01-02 Lyell Immunopharma, Inc. Methods for culturing immune cells
WO2025002264A1 (zh) 2023-06-30 2025-01-02 默沙东有限责任公司 包含偶联物的药物组合的治疗方法和用途
WO2025002263A1 (zh) 2023-06-30 2025-01-02 默沙东有限责任公司 治疗组合及其用途和治疗方法
WO2025012620A1 (en) 2023-07-07 2025-01-16 Mestag Therapeutics Ltd Binding constructs
WO2025012417A1 (en) 2023-07-13 2025-01-16 Institut National de la Santé et de la Recherche Médicale Anti-neurotensin long fragment and anti-neuromedin n long fragment antibodies and uses thereof
WO2025024257A1 (en) 2023-07-21 2025-01-30 Genentech, Inc. Diagnostic and therapeutic methods for cancer
IL304887A (en) 2023-07-31 2025-02-01 Yeda Res & Dev T-cell receptor directed against RAS neoantigen
WO2025030041A1 (en) 2023-08-02 2025-02-06 Regeneron Pharmaceuticals, Inc. Methods of treating metastatic castration-resistant prostate cancer with bispecific anti-psma x anti-cd28 antibodies
WO2025030044A1 (en) 2023-08-02 2025-02-06 Regeneron Pharmaceuticals, Inc. Methods of treating clear cell renal cell carcinoma with bispecific anti-psma x anti-cd28 antibodies
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025034883A1 (en) 2023-08-08 2025-02-13 Quanta Therapeutics, Inc. Combination therapies with kras modulators
WO2025038763A1 (en) 2023-08-15 2025-02-20 Bristol-Myers Squibb Company Ceramic hydroxyapatite chromatography flow through method
WO2025038770A1 (en) 2023-08-15 2025-02-20 Gilead Sciences, Inc. Treatment of non-small cell lung cancer using sacituzumab govitecan and an anti-pd-1 antibody or antigen binding fragment thereof
WO2025042742A1 (en) 2023-08-18 2025-02-27 Bristol-Myers Squibb Company Compositions comprising antibodies that bind bcma and cd3 and methods of treatment
TW202517247A (zh) 2023-08-24 2025-05-01 美商英塞特公司 雙環ｄｇｋ抑制劑
TW202515614A (zh) 2023-08-25 2025-04-16 美商建南德克公司 治療非小細胞肺癌之方法及組成物
WO2025049858A1 (en) 2023-09-01 2025-03-06 Amgen Inc. Molecules for treatment of cancer
WO2025050009A2 (en) 2023-09-01 2025-03-06 Children's Hospital Medical Center Identification of targets for immunotherapy in melanoma using splicing-derived neoantigens
WO2025051895A1 (en) 2023-09-06 2025-03-13 Novimmune Sa Combination therapy with a cea x cd28 bispecific antibody and blocking anti-pd-1 antibodies for enhanced in vivo anti-tumor activity
WO2025056180A1 (en) 2023-09-15 2025-03-20 BioNTech SE Methods of treatment using agents binding to epcam and cd137 in combination with pd-1 axis binding antagonists
WO2025068393A1 (en) 2023-09-27 2025-04-03 Institut Curie Methods for the treatment of fibrotic related diseases
WO2025068452A1 (en) 2023-09-29 2025-04-03 Negio Therapeutics Guanfacine derivatives and their use in treating cancer
WO2025068461A1 (en) 2023-09-29 2025-04-03 Negio Therapeutics Guanfacine derivatives and their use in treating cancer
WO2025073765A1 (en) 2023-10-03 2025-04-10 Institut National de la Santé et de la Recherche Médicale Methods of prognosis and treatment of patients suffering from melanoma
WO2025080538A1 (en) 2023-10-09 2025-04-17 Regeneron Pharmaceuticals, Inc. Methods of treating cancer with a combination of a pd1 inhibitor and a targeted immunocytokine
US20250114346A1 (en) 2023-10-09 2025-04-10 Incyte Corporation Combination therapy using a kras g12d inhibitor and pd-1 inhibitor or pd-l1 inhibitor
WO2025080865A1 (en) 2023-10-11 2025-04-17 Turnstone Biologics Corp. Combination of tumor infiltrating lymphocytes (til) and low dose radiation
TW202515903A (zh) 2023-10-12 2025-04-16 瑞士商百濟神州瑞士有限責任公司 手術前後基於抗ｐｄ－１之治療
WO2025078632A1 (en) 2023-10-12 2025-04-17 Institut National de la Santé et de la Recherche Médicale Methods of prognosis and treatment of patients suffering from cancer
WO2025080946A2 (en) 2023-10-12 2025-04-17 Revolution Medicines, Inc. Ras inhibitors
WO2025081075A1 (en) 2023-10-13 2025-04-17 Gilead Sciences, Inc. Combination therapies for treating cancers
WO2025085404A1 (en) 2023-10-16 2025-04-24 Genentech, Inc. Diagnostic and therapeutic methods for treating lung cancer
TW202532440A (zh) 2023-10-19 2025-08-16 美商建南德克公司 用於治療ＨＥＲ２陽性癌症的ＩＬ１５／ＩＬ１５Ｒα異二聚體ＦＣ融合蛋白及ＨＥＲ２ｘＣＤ３雙特異性抗體之組合
WO2025096638A2 (en) 2023-10-30 2025-05-08 Turnstone Biologics Corp. Genetically modified tumor infilitrating lymphocytes and methods of producing and using the same
US20250163079A1 (en) 2023-11-01 2025-05-22 Incyte Corporation Kras inhibitors
WO2025093824A1 (en) 2023-11-02 2025-05-08 Tilt Biotherapeutics Oy Oncolytic adenovirus, immune checkpoint inhibitor and chemoterapeutic agent combination therapy of cancer
WO2025096843A1 (en) 2023-11-03 2025-05-08 Amgen Inc. Bispecific molecules
WO2025101484A1 (en) 2023-11-06 2025-05-15 Iovance Biotherapeutics, Inc. Treatment of endometrial cancers with tumor infiltrating lymphocyte therapies
WO2025106736A2 (en) 2023-11-15 2025-05-22 Regeneron Pharmaceuticals, Inc. Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating lung cancer
WO2025106905A1 (en) 2023-11-17 2025-05-22 Quanta Therapeutics, Inc. Combination therapies with a kras modulator and an immunomodulator inhibitor
WO2025109597A1 (en) 2023-11-22 2025-05-30 Yeda Research And Development Co. Ltd. T cell receptors directed against androgen receptor mutation
CN117756915B (zh) * 2023-11-24 2025-05-30 河南省肿瘤医院 一组阻断抗pd-1抗体与细胞表面pd-1分子结合的pd-1分子及其突变体和用途
TW202539732A (zh) 2023-11-29 2025-10-16 美商再生元醫藥公司 以雙特異性抗muc16×抗cd28抗體與抗pd-1抗體之組合或與雙特異性抗muc16×抗cd3抗體之組合治療復發性卵巢癌及子宮內膜癌之方法
WO2025114541A1 (en) 2023-11-30 2025-06-05 Genmab A/S Antibodies capable of binding to ox40 in combination therapy
US20250179083A1 (en) 2023-12-05 2025-06-05 Incyte Corporation Tricyclic triazolo compounds as dgk inhibitors
US20250186450A1 (en) 2023-12-06 2025-06-12 Incyte Corporation COMBINATION THERAPY COMPRISING DGK INHIBITORS and PD-1/PD-L1 INHIBITORS
WO2025120867A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies
WO2025120866A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
WO2025121445A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
WO2025128652A1 (en) 2023-12-12 2025-06-19 Regeneron Pharmaceuticals, Inc. Methods of treating endometrial cancer with bispecific anti-muc16 x anti-cd3 antibodies alone or in combination with anti-pd-1 antibodies
US20250195536A1 (en) 2023-12-13 2025-06-19 Incyte Corporation Bicyclooctane kras inhibitors
WO2025132479A1 (en) 2023-12-18 2025-06-26 Institut National de la Santé et de la Recherche Médicale Flt3 inhibitor for modulating macrophages polarization
WO2025132831A1 (en) 2023-12-19 2025-06-26 Universite D'aix-Marseille N-heteroaryl derivatives and uses thereof for treating cancer
WO2025132695A1 (en) 2023-12-19 2025-06-26 Boehringer Ingelheim International Gmbh Recombinant rhabdovirus encoding for a gasdermin
WO2025137093A1 (en) 2023-12-19 2025-06-26 Cephalon Llc Uses for attenuated il-2 immunoconjugates
EP4574165A1 (en) 2023-12-21 2025-06-25 Egle Therapeutics Immunocytokine for cancer treatment
WO2025133115A1 (en) 2023-12-21 2025-06-26 Ose Immunotherapeutics Lipid-based nanoparticles comprising il-35
WO2025133175A1 (en) 2023-12-21 2025-06-26 Egle Therapeutics Immunocytokine for cancer treatment
WO2025137507A1 (en) 2023-12-22 2025-06-26 Regor Pharmaceuticals, Inc. Sos1 inhibitors and uses thereof
WO2025132770A1 (en) 2023-12-22 2025-06-26 Institut National de la Santé et de la Recherche Médicale Affitins for the treatment of cancer
WO2025145207A1 (en) 2023-12-29 2025-07-03 Bristol-Myers Squibb Company Combination therapy of kras inhibitor and treg-depleting agent
US20250222125A1 (en) 2024-01-05 2025-07-10 Beigene, Ltd. Anti-FGFR2b Antibodies, Conjugates and Methods of Use
WO2025151487A2 (en) 2024-01-08 2025-07-17 Regents Of The University Of Michigan Small-molecule inhibitors of adar1
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
WO2025155607A1 (en) 2024-01-16 2025-07-24 Genentech, Inc. Methods of treating urothelial carcinoma with a pd-1 axis binding antagonist and an rna vaccine
WO2025153834A1 (en) 2024-01-19 2025-07-24 Institut National de la Santé et de la Recherche Médicale Methods of predicting the risk of recurrence and/or death of patients suffering from a hepatocellular carcinoma (hcc)
WO2025158077A1 (en) 2024-01-26 2025-07-31 Institut Curie Lipid degraders to trigger ferroptosis in cancer
WO2025163468A1 (en) 2024-01-30 2025-08-07 Seagen Inc. Anti-pd-l1 antibodies and antibody-drug conjugates and their use in the treatment of cancer
WO2025174825A2 (en) 2024-02-12 2025-08-21 Aera Therapeutics, Inc. Delivery compositions
WO2025174933A1 (en) 2024-02-14 2025-08-21 Genentech, Inc. Methods for treatment of pancreatic cancer with anti-pd-l1 ab, anti-tigit ab, gemcitabine and nab-placlitaxel
WO2025184208A1 (en) 2024-02-27 2025-09-04 Bristol-Myers Squibb Company Anti-ceacam5 antibodies and uses thereof
EP4658320A1 (en) 2024-02-27 2025-12-10 Bristol-Myers Squibb Company Anti-ceacam5 antibody drug conjugates
WO2025188693A1 (en) 2024-03-05 2025-09-12 Bristol-Myers Squibb Company Bicyclic tlr7 agonists and uses thereof
WO2025188694A1 (en) 2024-03-05 2025-09-12 Bristol-Myers Squibb Company Tricyclic tlr7 agonists and uses thereof
WO2025191529A1 (en) 2024-03-14 2025-09-18 Biohaven Therapeutics Ltd. Next generation riluzole prodrugs
WO2025202213A1 (en) 2024-03-26 2025-10-02 Institut National de la Santé et de la Recherche Médicale Lipid nanoparticle loaded with antitumoral agent and functionnalized to target immosuppressive cells
WO2025207705A1 (en) 2024-03-26 2025-10-02 Amgen Inc. Cancer treatments using mta-cooperative prmt5 inhibitors
WO2025202450A1 (en) 2024-03-28 2025-10-02 Institut Curie Myeloid cells modified by cytokine chimeric receptor and uses thereof
EP4624494A1 (en) 2024-03-29 2025-10-01 Institut Curie Her2 single domain antibody and uses thereof
WO2025210123A1 (en) 2024-04-03 2025-10-09 Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical composition for treating cancers
WO2025210175A1 (en) 2024-04-04 2025-10-09 Centre National De La Recherche Scientifique Mutant csf-1r extracellular domain fusion molecules and therapeutic uses thereof
WO2025210252A1 (en) 2024-04-05 2025-10-09 Institut Curie Modulators of fam118b protein for use in therapy
WO2025213154A1 (en) 2024-04-05 2025-10-09 Amgen Inc. Gastrointestinal cancer treatments using mta-cooperative prmt5 inhibitors
WO2025216894A1 (en) 2024-04-09 2025-10-16 Sensei Biotherapeutics, Inc. Bispecific anti-vista and anti-cd28 binding proteins and uses thereof
WO2025219330A1 (en) 2024-04-15 2025-10-23 Institut National de la Santé et de la Recherche Médicale Detection of ppix for use in methods for melanoma ferroptosis sensitivity and targeted therapy resistance prediction
WO2025219595A1 (en) 2024-04-19 2025-10-23 Biper Therapeutics Method for combination treatments using alkynylbenzenesulphonamides for cancer therapy
WO2025223372A1 (en) 2024-04-22 2025-10-30 Fujian Haixi Pharmaceuticals Co., Ltd. Combination comprising a pd-1 inhibitor and a pyridine compound for use in treating solid tumors
WO2025228998A1 (en) 2024-04-30 2025-11-06 Institut National de la Santé et de la Recherche Médicale Use of hdac4 inhibitors for the treatment of melanoma
WO2025232879A1 (en) 2024-05-10 2025-11-13 Cytocares (Shanghai) Inc. Anti-lilrb2 monospecific and bispecific antibody constructs and uses thereof
WO2025240670A2 (en) 2024-05-15 2025-11-20 Abalytics Oncology, Inc. Anti-pd-1 antibodies and related binding molecules and methods and uses thereof
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025242836A1 (en) 2024-05-22 2025-11-27 Ose Immunotherapeutics Molecules comprising masking linkers and uses thereof for the treatment of auto-immune or inflammatory diseases and disorders
WO2025242835A1 (en) 2024-05-22 2025-11-27 Ose Immunotherapeutics Molecules comprising masking linkers and uses thereof for the treatment of cancer
WO2025245489A1 (en) 2024-05-24 2025-11-27 Bristol-Myers Squibb Company Treatment of tumors in subjects having fgl-1 positive samples
WO2025247829A1 (en) 2024-05-27 2025-12-04 Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical composition for treating prostate cancer
NL2037811B1 (en) 2024-05-29 2025-12-12 Univ Oslo Treatment for Cancer
WO2025248505A1 (en) 2024-05-31 2025-12-04 Wayne State University Methods for treating endometrial and ovarian hyperproliferative disorders
WO2025252857A1 (en) 2024-06-05 2025-12-11 Institut National de la Santé et de la Recherche Médicale Il-15 muteins with ph-dependent binding for il-15ralpha
WO2025252855A1 (en) 2024-06-05 2025-12-11 Institut National de la Santé et de la Recherche Médicale IL-15 MUTEINS WITH PH-DEPENDENT BINDING FOR IL-15Rbeta
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025257588A1 (en) 2024-06-10 2025-12-18 Affimed Gmbh Cd16a/tumor antigen polyspecific binder for use in the treatment of immune checkpoint inhibitor resistance
WO2025257220A1 (en) 2024-06-10 2025-12-18 Merck Patent Gmbh Muc-1 conditional cd40 agonists
GB202408360D0 (en) 2024-06-11 2024-07-24 Cancer Research Tech Ltd Tumour sensitisation
WO2025259515A2 (en) 2024-06-11 2025-12-18 Amgen Inc. Combination treatment
WO2025262641A1 (en) 2024-06-19 2025-12-26 Pheon Therapeutics Ltd Antibody drug conjugates that bind cdcp1 and uses thereof
WO2025262250A1 (en) 2024-06-20 2025-12-26 Negio Therapeutics Guanfacine derivatives and their uses
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026003224A2 (en) 2024-06-26 2026-01-02 Iomx Therapeutics Ag Bispecific antigen binding proteins (abp) targeting immune checkpoint molecules and both leukocyte immunoglobulin-like receptor subfamily b1 (lilrb1) and lilrb2; combinations and uses thereof
WO2026006604A1 (en) 2024-06-26 2026-01-02 Lyell Immunopharma, Inc. Feeder cell replacement
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (158)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4954617A (en) 1986-07-07 1990-09-04 Trustees Of Dartmouth College Monoclonal antibodies to FC receptors for immunoglobulin G on human mononuclear phagocytes
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US5013653A (en) 1987-03-20 1991-05-07 Creative Biomolecules, Inc. Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
WO1988009344A1 (en) 1987-05-21 1988-12-01 Creative Biomolecules, Inc. Targeted multifunctional proteins
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US5476996A (en) 1988-06-14 1995-12-19 Lidak Pharmaceuticals Human immune system in non-human animal
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
DE68925966T2 (de) 1988-12-22 1996-08-29 Kirin Amgen Inc Chemisch modifizierte granulocytenkolonie erregender faktor
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
JP3068180B2 (ja) 1990-01-12 2000-07-24 アブジェニックス インコーポレイテッド 異種抗体の生成
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1992003918A1 (en) 1990-08-29 1992-03-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
DK1024191T3 (da) 1991-12-02 2008-12-08 Medical Res Council Fremstilling af autoantistoffer fremvist på fag-overflader ud fra antistofsegmentbiblioteker
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
CA2118508A1 (en) 1992-04-24 1993-11-11 Elizabeth S. Ward Recombinant production of immunoglobulin-like domains in prokaryotic cells
US5260074A (en) 1992-06-22 1993-11-09 Digestive Care Inc. Compositions of digestive enzymes and salts of bile acids and process for preparation thereof
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
GB9223377D0 (en) 1992-11-04 1992-12-23 Medarex Inc Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes
AU6819494A (en) 1993-04-26 1994-11-21 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1994029351A2 (en) 1993-06-16 1994-12-22 Celltech Limited Antibodies
US5625825A (en) 1993-10-21 1997-04-29 Lsi Logic Corporation Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network
IL108501A (en) 1994-01-31 1998-10-30 Mor Research Applic Ltd Antibodies and pharmaceutical compositions containing them
JPH07291996A (ja) * 1994-03-01 1995-11-07 Yuu Honshiyo ヒトにおけるプログラムされた細胞死に関連したポリペプチド、それをコードするｄｎａ、そのｄｎａからなるベクター、そのベクターで形質転換された宿主細胞、そのポリペプチドの抗体、およびそのポリペプチドまたはその抗体を含有する薬学的組成物
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US6410690B1 (en) 1995-06-07 2002-06-25 Medarex, Inc. Therapeutic compounds comprised of anti-Fc receptor antibodies
US5855887A (en) 1995-07-25 1999-01-05 The Regents Of The University Of California Blockade of lymphocyte down-regulation associated with CTLA-4 signaling
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US6632976B1 (en) * 1995-08-29 2003-10-14 Kirin Beer Kabushiki Kaisha Chimeric mice that are produced by microcell mediated chromosome transfer and that retain a human antibody gene
KR100308764B1 (ko) * 1995-08-29 2001-12-17 마나배게이사꾸 키메라동물및그의제작법
US5922845A (en) 1996-07-11 1999-07-13 Medarex, Inc. Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
EP1007090B1 (en) * 1996-11-08 2009-12-30 Biogen Idec Inc. Identification of unique binding interactions between certain antibodies and the human b7.1 (cd80) and b7.2 (cd28) co-stimulatory antigens
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
JP2001523958A (ja) 1997-03-21 2001-11-27 ブライハム アンド ウィミンズ ホスピタル，インコーポレイテッド 免疫療法のｃｔｌａ−４結合ペプチド
JPH10291996A (ja) 1997-04-22 1998-11-04 Mitsubishi Chem Corp ロジウム錯体溶液の調製方法
EP0983303B1 (en) 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
WO2004087163A2 (ja) * 1998-12-02 2004-10-14 Masato Kusunoki 薬物動態修飾化学療法
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
DK2180007T4 (da) 1998-04-20 2017-11-27 Roche Glycart Ag Glycosyleringsteknik for antistoffer til forbedring af antistofafhængig cellecytotoxicitet
ES2308857T3 (es) 1998-12-03 2008-12-01 The Regents Of The University Of California Estimulacion de celulas t contra autoantigenos mediante el uso de agentes bloqueadores de ctla-4.
SG143018A1 (en) 1998-12-23 2008-06-27 Pfizer Human monoclonal antibodies to ctla-4
US7041474B2 (en) * 1998-12-30 2006-05-09 Millennium Pharmaceuticals, Inc. Nucleic acid encoding human tango 509
PL220113B1 (pl) 1999-01-15 2015-08-31 Genentech Inc Wariant macierzystego polipeptydu zawierającego region Fc, polipeptyd zawierający wariant regionu Fc o zmienionym powinowactwie wiązania receptora Fc gamma (FcγR), polipeptyd zawierający wariant regionu Fc o zmienionym powinowactwie wiązania noworodkowego receptora Fc (FcRn), kompozycja, wyizolowany kwas nukleinowy, wektor, komórka gospodarza, sposób otrzymywania wariantu polipeptydu, zastosowanie wariantu polipeptydu i sposób otrzymywania wariantu regionu Fc
ES2571230T3 (es) 1999-04-09 2016-05-24 Kyowa Hakko Kirin Co Ltd Procedimiento para controlar la actividad de una molécula inmunofuncional
US6316462B1 (en) * 1999-04-09 2001-11-13 Schering Corporation Methods of inducing cancer cell death and tumor regression
FR2794025A1 (fr) 1999-05-25 2000-12-01 Transgene Sa Composition destinee a la mise en oeuvre d'un traitement antitumoral ou antiviral chez un mammifere
ES2277683T3 (es) 1999-07-23 2007-07-16 Glaxo Group Limited Combinacion de anticuerpo anti-ep-cam con un agente quimioterapeutico.
NZ517372A (en) 1999-07-29 2004-04-30 Medarex Inc Human monoclonal antibodies to HER2/neu
CA2383424C (en) * 1999-08-23 2011-02-15 Gordon Freeman Novel b7-4 molecules and uses therefor
AU7072700A (en) * 1999-08-23 2001-03-19 Dana-Farber Cancer Institute, Inc. Pd-1, a receptor for b7-4, and uses therefor
KR20020047132A (ko) * 1999-08-24 2002-06-21 메다렉스, 인코포레이티드 인간 씨티엘에이-4 항체 및 그의 용도
US6803192B1 (en) * 1999-11-30 2004-10-12 Mayo Foundation For Medical Education And Research B7-H1, a novel immunoregulatory molecule
ES2629683T3 (es) 1999-11-30 2017-08-14 Mayo Foundation For Medical Education And Research B7-H1, una nueva molécula inmunorreguladora
AU2001233027A1 (en) 2000-01-27 2001-08-07 Genetics Institute, Llc Antibodies against ctla4 (cd152), conjugates comprising same, and uses thereof
EP1265635A1 (en) 2000-03-22 2002-12-18 Glaxo Group Limited Pharmaceutical comprising an agent that blocks the cell cycle and an antibody
US7030219B2 (en) 2000-04-28 2006-04-18 Johns Hopkins University B7-DC, Dendritic cell co-stimulatory molecules
EP1297135B1 (en) 2000-06-28 2013-01-09 Genetics Institute, LLC Pd-l2 molecules: novel pd-1 ligands and uses therefor
CA2418117A1 (en) * 2000-07-31 2003-01-30 The Nisshin Oillio, Ltd. Antitumor agent
US7132109B1 (en) 2000-10-20 2006-11-07 University Of Connecticut Health Center Using heat shock proteins to increase immune response
AU2002225990B2 (en) 2000-10-20 2007-07-19 Tsuneya Ohno Fusion cells and cytokine compositions for treatment of disease
US7041870B2 (en) 2000-11-30 2006-05-09 Medarex, Inc. Transgenic transchromosomal rodents for making human antibodies
JP2002194491A (ja) 2000-12-27 2002-07-10 Daido Steel Co Ltd ばね用鋼材
AR036993A1 (es) 2001-04-02 2004-10-20 Wyeth Corp Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas
AU2002338272B2 (en) * 2001-04-02 2007-10-11 Dana-Farber Cancer Institute, Inc. PD-1, a receptor for B7-4, and uses therefor
US7794710B2 (en) 2001-04-20 2010-09-14 Mayo Foundation For Medical Education And Research Methods of enhancing T cell responsiveness
US6727072B2 (en) 2001-05-01 2004-04-27 Dako Corporation EGF-r detection kit
EP1421203A4 (en) 2001-05-17 2005-06-01 Diversa Corp NEW ANTIGEN-BINDING MOLECULES FOR THERAPEUTIC, DIAGNOSTIC, PROPHYLACTIC, ENZYMATIC, INDUSTRIAL AND AGRICULTURAL APPLICATIONS AND METHOD FOR THE PRODUCTION AND SCREENING THEREOF
IL149701A0 (en) * 2001-05-23 2002-11-10 Pfizer Prod Inc Use of anti-ctla-4 antibodies
US6592849B2 (en) 2001-06-21 2003-07-15 Colgate Palmolive Company Chewing gum to control malodorous breath
JP2003029846A (ja) 2001-07-11 2003-01-31 Sanyo Electric Co Ltd 流量調整器および流量調整器を備えた飲料供給装置
WO2003006636A1 (de) 2001-07-12 2003-01-23 Genethor Gmbh Reduktion der stimulationsfähigkeit von antigen präsentierenden zellen
WO2003011911A1 (fr) 2001-07-31 2003-02-13 Ono Pharmaceutical Co., Ltd. Substance specifique pour pd-1
IL145926A0 (en) * 2001-10-15 2002-07-25 Mor Research Applic Ltd Peptide epitopes of mimotopes useful in immunomodulation
ES2326964T3 (es) 2001-10-25 2009-10-22 Genentech, Inc. Composiciones de glicoproteina.
WO2003042402A2 (en) * 2001-11-13 2003-05-22 Dana-Farber Cancer Institute, Inc. Agents that modulate immune cell activation and methods of use thereof
AU2003224604B2 (en) * 2002-01-28 2007-06-14 Medarex, Inc. Human monoclonal antibodies to prostate specific membrane antigen (PSMA)
WO2003074679A2 (en) 2002-03-01 2003-09-12 Xencor Antibody optimization
EA200401325A1 (ru) 2002-04-09 2005-04-28 Киова Хакко Когио Ко., Лтд. Клетки с модифицированным геномом
IL149820A0 (en) * 2002-05-23 2002-11-10 Curetech Ltd Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
CA2489803A1 (en) * 2002-06-20 2003-12-31 The Regents Of The University Of California Compositions and methods for modulating lymphocyte activity
DE10161767T1 (de) 2002-07-03 2018-06-07 Honjo Tasuku Immunopotenzierende Zusammensetzungen, die einen Anti-PD-L1 Antikörper enthalten
AR040778A1 (es) 2002-08-06 2005-04-20 Glaxo Group Ltd Anticuerpos alterados o fragmentos funcionales que se unen a mag (glicoproteina asociada a mielina).
EP1576014B1 (en) * 2002-12-23 2011-06-29 Wyeth LLC Antibodies against pd-1 and uses thereof
ES2729974T3 (es) * 2003-01-23 2019-11-07 Ono Pharmaceutical Co Anticuerpo específico de PD-1 y CD3 humanas
US7465446B2 (en) * 2003-05-30 2008-12-16 Medarex, Inc. Surrogate therapeutic endpoint for anti-CTLA4-based immunotherapy of disease
US20060275253A1 (en) * 2003-09-01 2006-12-07 Kazunari Ushida Beta hydroxy short to medium chain fatty acid polymer
EP1673630A4 (en) * 2003-10-16 2009-04-29 Inst Virology MN / CA IX AND CANCER PROGNOSIS
WO2006021955A2 (en) 2004-08-23 2006-03-02 Mor Research Applications Ltd. Use of bat monoclonal antibody for immunotherapy
HUE070155T2 (hu) 2004-10-06 2025-05-28 Mayo Found Medical Education & Res B7-H10 és PD-1 vesesejtes karcinóma kezelésében
US7423128B2 (en) 2004-11-03 2008-09-09 Amgen Fremont Inc. Anti-properdin antibodies, and methods for making and using same
JP4005080B2 (ja) * 2004-11-25 2007-11-07 オリンパス株式会社 内視鏡装置
EP2161336B2 (en) * 2005-05-09 2017-03-29 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
WO2006124269A2 (en) * 2005-05-16 2006-11-23 Amgen Fremont Inc. Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders
AU2006265108C1 (en) 2005-07-01 2013-01-17 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to programmed death ligand 1 (PD-L1)
WO2010027423A2 (en) * 2008-08-25 2010-03-11 Amplimmune, Inc. Compositions of pd-1 antagonists and methods of use
KR20240135058A (ko) 2012-05-15 2024-09-10 브리스톨-마이어스 스큅 컴퍼니 Pd-1/pd-l1 신호전달을 방해하는 것에 의한 암 면역요법
UY34887A (es) * 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
EP3192517A4 (en) * 2014-08-19 2018-04-25 National University Corporation Okayama University Method for enhancing immune cell function and method for assessing immune cell multifunctionality
WO2017038997A1 (ja) * 2015-09-03 2017-03-09 小野薬品工業株式会社 Ａｌｌｅｒｇｉｎ－１アンタゴニストによるがん免疫増強剤
US20190054090A1 (en) * 2015-10-01 2019-02-21 Gilead Sciences, Inc. Combination of a btk inhibitor and a checkpoint inhibitor for treating cancers
JP7159007B2 (ja) * 2017-11-01 2022-10-24 小野薬品工業株式会社 脳腫瘍の治療のための医薬
KR20200109339A (ko) * 2018-01-16 2020-09-22 브리스톨-마이어스 스큅 컴퍼니 Tim3에 대한 항체를 사용하여 암을 치료하는 방법
CN111919119A (zh) * 2018-03-27 2020-11-10 国立大学法人京都大学 辅助免疫检查点抑制剂的奏效性的判定的方法、试剂盒、装置及计算机程序
WO2019195452A1 (en) * 2018-04-04 2019-10-10 Bristol-Myers Squibb Company Anti-cd27 antibodies and uses thereof
MX2020012939A (es) * 2018-05-31 2021-02-15 Ono Pharmaceutical Co Biomarcadores para determinar la eficacia de los inhibidores de puntos de control inmunitarios.
MY205758A (en) * 2018-11-16 2024-11-12 Bristol Myers Squibb Co Anti-nkg2a antibodies and uses thereof
TWI818120B (zh) * 2018-11-27 2023-10-11 日商小野藥品工業股份有限公司 藉由免疫檢查點阻礙藥與ｆｏｌｆｉｒｉｎｏｘ療法之併用的癌症治療
US12036204B2 (en) * 2019-07-26 2024-07-16 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor

Also Published As

Publication number Publication date
JP2009155338A (ja) 2009-07-16
US8779105B2 (en) 2014-07-15
US9358289B2 (en) 2016-06-07
EP2439272A3 (en) 2013-07-31
US20170088615A1 (en) 2017-03-30
JP5028700B2 (ja) 2012-09-19
AU2006244885A1 (en) 2006-11-16
HUE044719T2 (hu) 2019-11-28
BE2015C074I2 (show.php) 2025-12-10
NO20231166A1 (no) 2008-02-11
DK2439273T3 (da) 2019-06-03
NO341219B1 (no) 2017-09-18
EP2439272A2 (en) 2012-04-11
JP2016033135A (ja) 2016-03-10
FR15C0087I2 (fr) 2017-01-06
EP2439273A3 (en) 2012-10-03
KR20130032908A (ko) 2013-04-02
US20140328833A1 (en) 2014-11-06
US20090217401A1 (en) 2009-08-27
US20140348743A1 (en) 2014-11-27
LTPA2015052I1 (lt) 2016-01-25
JP2012158605A (ja) 2012-08-23
KR20130114226A (ko) 2013-10-16
EP2418278A3 (en) 2012-07-04
CA2970873A1 (en) 2006-11-16
US20130133091A1 (en) 2013-05-23
JP2006340714A (ja) 2006-12-21
US20200138945A1 (en) 2020-05-07
RU2494107C2 (ru) 2013-09-27
EP2439273B1 (en) 2019-02-27
IL187108A (en) 2011-06-30
JP5872377B2 (ja) 2016-03-01
EP1896582A4 (en) 2009-04-08
LTC2161336I2 (lt) 2017-07-10
EP1896582A1 (en) 2008-03-12
IL208642A0 (en) 2010-12-30
CA2607147C (en) 2018-07-17
LU92904I2 (fr) 2016-02-10
NO2023031I1 (no) 2023-08-23
RU2599417C2 (ru) 2016-10-10
RU2016133899A (ru) 2018-02-22
US20150165025A1 (en) 2015-06-18
TWI379898B (en) 2012-12-21
CN101213297B (zh) 2013-02-13
US20140294852A1 (en) 2014-10-02
NZ563193A (en) 2010-05-28
PL2439273T3 (pl) 2019-08-30
RU2732924C2 (ru) 2020-09-24
CA2970873C (en) 2022-05-17
SI2439273T1 (sl) 2019-05-31
US9084776B2 (en) 2015-07-21
NL300782I2 (show.php) 2016-05-18
SI2161336T1 (sl) 2013-11-29
TW200716743A (en) 2007-05-01
BRPI0610235B8 (pt) 2021-05-25
ES2720160T3 (es) 2019-07-18
LT2439273T (lt) 2019-05-10
US9492540B2 (en) 2016-11-15
CY1121648T1 (el) 2020-07-31
HUS1500067I1 (hu) 2016-02-29
EP3530736A3 (en) 2019-11-06
RU2016133899A3 (show.php) 2020-01-17
CN101213297A (zh) 2008-07-02
FR15C0087I1 (show.php) 2016-01-22
RU2013133714A (ru) 2015-01-27
US9387247B2 (en) 2016-07-12
PT2161336E (pt) 2013-10-03
JP2017052784A (ja) 2017-03-16
EP2418278A2 (en) 2012-02-15
NO20200470A1 (no) 2008-02-11
JP2019103504A (ja) 2019-06-27
DK2161336T3 (da) 2013-10-28
PT2439273T (pt) 2019-05-13
KR20080011428A (ko) 2008-02-04
CA2607147A1 (en) 2006-11-16
KR101498834B1 (ko) 2015-03-05
NO20170138A1 (no) 2008-02-11
JP6185971B2 (ja) 2017-08-23
US20230272079A1 (en) 2023-08-31
RU2010135087A (ru) 2012-02-27
EP2161336B1 (en) 2013-07-31
PL2161336T3 (pl) 2014-01-31
CY2015057I1 (el) 2016-06-22
CA3151350A1 (en) 2006-11-16
WO2006121168A1 (en) 2006-11-16
PL2161336T5 (pl) 2017-10-31
BRPI0610235B1 (pt) 2020-05-05
JP2014077015A (ja) 2014-05-01
JP2024023539A (ja) 2024-02-21
CN105315373A (zh) 2016-02-10
IL187108A0 (en) 2008-02-09
KR101318469B1 (ko) 2013-10-23
NO2018008I2 (no) 2018-02-14
IL208642A (en) 2012-08-30
CN109485727A (zh) 2019-03-19
EP2161336A1 (en) 2010-03-10
NO344818B1 (no) 2020-05-04
RU2406760C3 (ru) 2017-11-28
NO20075697L (no) 2008-02-11
CN105315373B (zh) 2018-11-09
KR101339628B1 (ko) 2013-12-09
JP6975733B2 (ja) 2021-12-01
RU2406760C2 (ru) 2010-12-20
EP2439273A2 (en) 2012-04-11
BRPI0610235A2 (pt) 2010-06-08
CN117534755A (zh) 2024-02-09
EP2161336B2 (en) 2017-03-29
US9492539B2 (en) 2016-11-15
RU2599417C3 (ru) 2017-11-28
CN103059138B (zh) 2015-10-28
AU2006244885B2 (en) 2011-03-31
EP3530736A2 (en) 2019-08-28
NO2018008I1 (no) 2018-02-14
US10441655B2 (en) 2019-10-15
US20140212422A1 (en) 2014-07-31
MX2007013978A (es) 2008-02-22
CY2015057I2 (el) 2016-06-22
RU2007145419A (ru) 2009-06-20
US8008449B2 (en) 2011-08-30
HK1140793A1 (en) 2010-10-22
CN103059138A (zh) 2013-04-24
ES2427646T5 (es) 2017-08-22
DK2161336T4 (en) 2017-04-24
ES2427646T3 (es) 2013-10-31
JP2021191793A (ja) 2021-12-16
JP7443302B2 (ja) 2024-03-05

Similar Documents

Publication Publication Date Title
JP7443302B2 (ja) Ｐｒｏｇｒａｍｍｅｄ Ｄｅａｔｈ １（ＰＤ－１）に対するヒトモノクローナル抗体および抗ＰＤ－１抗体単独または他の免疫療法と併用した癌治療方法
AU2011203119B2 (en) Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060810

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20061102

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20061120

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20061102

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090310

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090310

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090331

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20090331

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20090428

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090630

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090709

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20090804

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20090812

R150 Certificate of patent or registration of utility model

Ref document number: 4361545

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120821

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120821

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130821

Year of fee payment: 4

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313115

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313111

R360 Written notification for declining of transfer of rights

Free format text: JAPANESE INTERMEDIATE CODE: R360

R360 Written notification for declining of transfer of rights

Free format text: JAPANESE INTERMEDIATE CODE: R360

R371 Transfer withdrawn

Free format text: JAPANESE INTERMEDIATE CODE: R371

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313115

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153